

Saturday, 16 September 2023

ESOT SCIENCE DAY

09:00 - 10:30
MC 2

ESOT Science Day: Translational and clinical cell therapy

*Chairs: Nina Pilat - Vienna Austria
Klearchos Papas - Tucson United States*

In this session, the latest insight into clinical cell therapy in solid organ transplantation is discussed. What do we learn from the clinical studies on cellular therapy, how do we monitor our patients and what are the obstacles and opportunities to move this field?

In addition, we will focus on monitoring aspects, how can we identify tolerant patients?

- 09:00 ILC cell therapy Alternative: Translational and clinical cell therapy in solid organ transplantation
Katja Kotsch – Berlin, Germany
- 09:20 Translational and clinical cell therapy in VCA
Fadi Issa – Oxford, United Kingdom
- 09:40 Monitoring: How can we identify tolerant patients?
Sophie Brouard – Nantes, France
- 10:00 Panel discussion

11:00 - 12:30
MC 2

ESOT Science Day: Cheating death

*Chairs: Fadi Issa – Oxford, United Kingdom
Marlies Reinders – Rotterdam, The Netherlands*

In this session, participants will learn about the most novel and exciting approaches to organ transplantation. Supercooling of organs could revolutionize organ allocation, the use of extracellular vesicles could overcome some hurdles of cellular therapy and we learn about the role of mitochondria could be the key to preventing ischemia-reperfusion injury.

- 11:00 Supercooling / hybernation
Gerald Brandacher – Baltimore, United States
- 11:20 Cell derived EV as a replacement of living cell therapy
Marcella Franquesa – Badalona, Spain
- 11:40 Mitochondria in the spotlight
Andras Meszaros – Innsbruck, Austria
- 12:00 Panel discussion

13:30 - 15:00
MC 2

ESOT Science Day: Spatial Omics

*Chairs: Annemarie Weissenbacher – Innsbruck, Austria
Sandra Lindstedt – Lund, Sweden*

Spatial Omics is an exciting new field, technical advances allow for the simultaneous assessment of multiple modalities as well as spatial organization, providing new opportunities in the discovery of new cell types, cellular differentiation trajectories and communication networks across cells and tissues. This session is designed to provide an overview of how spatial omics can be implemented in your research and will guide the discovery of novel biomarkers and a better understanding of rejection and tolerance mechanisms.

13:30 A practical guide to start tomorrow
Benedikt Kessler – Oxford, United Kingdom

14:00 t-SNE and clustering for starters
Sören Lukassen – Berlin, Germany

14:30 Uncharting the hidden dimensions of transplantation with single cell and spatial omics
Jasper Callemeyn - Korbeek-Lo, Belgium

15:30 - 17:10
MC 2

ESOT Science Day: Organ Manipulation and bioengineering: Repair or replace?

*Chairs: Cees van Kooten – Leiden, The Netherlands
Jan Czogalla – Hamburg, Germany
Franka Messner – Innsbruck, Austria*

Organ manipulation and bioengineering are exciting fields in transplantation. We will focus on bile duct repair on the pump and generating bile ducts from stem cells. What is the current state of these innovations and should we repair or replace organs? The pros and cons will be discussed in a lively discussion. The session will end with an exciting scientific pub quiz organized by BSC, ECTORS and VCA. Who knows the most about these fields and will win the trophy?

15:30 Bile duct repair (on the pump)
Stuart Forbes – Edinburgh, United Kingdom

15:50 Bile duct generation from stem cells
Fotios Sampaziotis – Cambridge, United Kingdom

16:10 Pro-con discussion: Repair or replace?
*Fotios Sampaziotis – Cambridge, United Kingdom
Stuart Forbes – Edinburgh, United Kingdom*

16:40 Quiz
*Jan Czogalla – Hamburg, Germany; Franka Messner – Innsbruck, Austria
; Cees van Kooten – Leiden, The Netherlands*

ESOT EDUCATION COURSE

Saturday, 16 September 2023

09:20 - 10:30
MC 3

ESOT Education Course: Immunosuppression: a critical step in the transplantation journey - Session 1: The fundamentals of immunosuppression (part I) - Transplant immunology

*Chairs: Maria Kaisar - Oxford, United Kingdom
Luca Toti – Rome, Italy*

In the area of Immunosuppression, we identified five hot topics that will be at the centre of this one-day course:

- **Transplant immunology:** gain insights into the fascinating field of transplant immunology, understanding the intricate mechanisms behind immune responses in transplantation
- **IS management:** learn about the latest advances in immunosuppressive therapy and discover effective strategies to optimise patient outcomes
- **Post-transplant infections:** explore the challenges posed by post-transplant infections, including prevention, diagnosis, and treatment approaches, ensuring comprehensive care for transplant recipients
- **The patient experience:** understand the transplant journey from the perspective of patients, emphasising the importance of patient-centred care and enhancing patient outcomes
- **Tolerance:** explore emerging concepts and research on tolerance induction in transplantation, paving the way for future breakthroughs in the field

The course combines dynamic lectures, interactive group discussions, and engaging roundtables to foster a collaborative and enriching learning environment. By actively participating, you can exchange ideas, learn from leading experts, and network with peers who share a passion for improving transplant outcomes.

09:20

Welcome and Introduction
Luca Toti – Rome, Italy

09:30

A refresher on the basic mechanisms underlying rejection(s)
Sushma Shankar – Oxford, United Kingdom

09:45

Pharmacodynamic of the main immunosuppressive drugs
Pierre Marquet – Limoges, France

10:00

Emerging concepts in transplant immunology: innate rejection
Olivier Thaunat – Lyon, France

10:15

Q&A

11:00 - 12:30
MC 3

ESOT Education Course: Immunosuppression: a critical step in the transplantation journey - Session 1: The fundamentals of immunosuppression (part II) - The management of immunosuppression

*Chairs: Jelena Stojanovic – London, United Kingdom
Luca Toti – Rome, Italy*

11:00

Kidney and pancreas
Raj Thuraisingham – London, United Kingdom

- 11:15 Heart and lung
Luciano Potena – Bologna, Italy
- 11:30 Liver and intestine
Tommaso Manzia – Rome, Italy
- 11:45 Management of immunosuppression in paediatric patients
Jelena Stojanovic – London, United Kingdom
- 12:00 Q&A and guided group discussion "Managing the side effects of immunosuppression"
Luciano Potena - Bologna, Italy; Jelena Stojanovic - London, United Kingdom; Raj Thuraisingham - London, United Kingdom; Luca Toti - Rome, Italy
- 13:30 - 15:00**
MC 3 **ESOT Education Course: Immunosuppression: a critical step in the transplantation journey - Session 2: Living with immunosuppression: clinical practice (part I) - Balancing the risk of rejection: infections et al.**
*Chairs: Luciano Potena – Bologna, Italy
Luca Toti – Rome, Italy*
- 13:30 Prophylaxis and treatment of post-transplant infections: CMV and other opportunistic bugs
Paolo Grossi – Varese, Italy
- 13:45 Prevention and management of anti-microbial resistance
Sophie Alain – Limoges, France
- 14:00 Long-term adverse effects of immunosuppression: renal insufficiency and malignancies
Martijn van den Hoogen – Rotterdam, The Netherlands
- 14:15 Infections and immune monitoring: quantiferon, TTV et al.
Gregor Bond – Vienna, Austria
- 14:30 *Q&A and group discussion*
- 15:30 - 17:00**
MC 3 **ESOT Education Course: Immunosuppression: a critical step in the transplantation journey - Session 2: Living with immunosuppression: clinical practice (part II) - Centering the patient perspective**
*Chairs: Anna Forsberg - Lund Sweden
Luca Toti - Rome Italy*
- 15:30 Risk management of peculiar immunological conditions
Martijn van den Hoogen – Rotterdam, The Netherlands
- 15:45 Fertility and pregnancy while on immunosuppression
Marleen van Buren – Rotterdam, The Netherlands
- 16:00 The person with an organ - not the organ in the person. What matters to the organ recipient and how it can be evaluated
Anna Forsberg – Lund, Sweden

- 16:15 Q&A
- 16:30 Integrating the patient perspective: patient-reported outcomes
Pisana Ferrari - Udine, Italy; Anna Forsberg – Lund, Sweden; Marleen van Buren - Rotterdam, The Netherlands; Martijn van den Hoogen - Rotterdam, The Netherlands; Luca Toti - Rome, Italy
- 17:10 - 18:00**
MC 3 **ESOT Education Course: Immunosuppression: a critical step in the transplantation journey - Session 3: Future perspectives of immunosuppression**
*Chairs: Nina Pilat - Vienna Austria
Luca Toti - Rome Italy*
- 17:10 Tolerance in solid organ transplantation: the holy grail or a foreseeable reality?
Nina Pilat - Vienna Austria
- 17:25 Round table: Tolerance in solid organ transplantation - can we get rid of immunosuppressive drugs in all solid organ transplant?
Sophie Brouard - Nantes, France; Olivier Thaumat - Lyon, France; Nina Pilat - Vienna, Austria
- 17:55 Wrap up and conclusion
Luca Toti - Rome Italy

Sunday, 17 September 2023

SPECIALTY UPDATE SYMPOSIA

09:00 - 10:30
Trianti

EKITA SUS: Reaching consensus among experts when evidence lacks

*Chairs: David Cucchiari – Barcelona, Spain
Lorna Marson – Edinburgh, United Kingdom*

The session has been envisioned to report on and to disseminate the activities in which EKITA contributed during TLJ 3.0 and the consensus/guideline development in the field of kidney transplantation.

09:00

ENGAGE Consensus project: European guidelines for the management of Graft Recipients

Lucrezia Furian – Padua, Italy

09:20

The value of monitoring (subclinical) DSAs for kidney transplant outcomes

Aiko De Vries – Amsterdam, The Netherlands

09:40

Histopathological analysis of pre-implantation donor kidney biopsy: Redefining the Role in the Process of Graft Assessment

Gianluigi Zaza – Verona, Italy

10:00

Novel antidiabetic treatments in kidney transplant recipients

Adnan Sharif – Birmingham, United Kingdom

10:20

Discussion

11:00 - 12:30
Trianti

EKITA SUS: Comorbidities management post- kidney transplantation: specialists in the arena:

*Chairs: Robert Langer – Vienna, Austria
Dimitrios Moutzouris – London, United Kingdom*

The second part of the session has been designed to address the topic of long-term management of kidney transplant recipients including not only transplant specialists but also vascular surgeons and endocrinologist and paediatricians. In this latter part there will be a pros and cons discussion and a “talk show” format, where different point of views in the treatment of bone disease post-transplantation will be presented by four speakers

11:00

Pros and Cons: Management of vascular access after kidney transplantation

Emin Baris Akin - Istanbul Turkey; Joris Rotmans - Leiden, The Netherlands

11:30

Renal bone disease in kidney transplant recipients: are we speaking the same language?

Dimitrios Moutzouris - London United Kingdom; Hanne Skou Jorgensen - Skoedstrup, Denmark; Marc Vervloet - Amsterdam, The Netherlands

11:55 Complexities of pediatric kidney transplantation in the 21st century
Jelena Stojanovic – London, United Kingdom

12:20 Discussion

09:00 - 10:30
Banquet Hall

ELITA SUS: Non-tumoral portal vein thrombosis in liver transplant candidates

Chairs: Constantino Fondevila – Madrid, Spain
Hermien Hartog – Groningen, The Netherlands

Once a contraindication to liver transplantation, now even candidates with extensive portal vein thrombosis are increasingly undergoing the procedure. This SUS updates the classification of PVT and optimal strategies for its management at different stages and highlights the results of recent collaborative studies.

09:00 New insights of Pathophysiology of Portal Vein Thrombosis (PVT)
Ton Lisman – Groningen, The Netherlands

09:10 Evaluation and classification of PVT in Liver Transplant (LT) candidates
Prashant Bhangui - Gurgaon Haryana, India

09:20 Discussion

09:25 Update on medical management of PVT on cirrhotics and LT candidates
Sarwa Darwish Murad – Rotterdam, The Netherlands

09:35 Outcomes and limitations of TIPS and portal recanalization in LT candidates
Marco Senzolo – Padua, Italy

09:45 Surgical Treatment before LT: still a place for shunt surgery?
Pal-Dag Line – Asker, Norway

09:55 Discussion

10:00 Management of complex PVT: technical considerations during LT
Daniel Azoulay – Villejuif, France

10:10 Management of complex PVT: when to consider multivisceral transplantation?
Jacques Pirenne – Leuven, Belgium

10:20 Update on RP4LT Collaborative Study
Amelia Hessheimer – Madrid, Spain

10:25 Discussion

11:00 - 12:30
Banquet Hall

ELITA: Controversies and emerging issues in liver transplant candidates

Chairs: Marina Berenguer – Valencia, Spain
Giacomo Germani – Padua, Italy

- 11:00 Active drinkers in urgent need of a liver transplant
Luca Belli – Milan, Italy
- 11:15 The stigma of alcohol-related liver disease and its impact on liver transplantation
Patrizia Burra – Padua, Italy
- 11:30 Discussion
- 11:45 Cardiovascular risk assessment of liver transplant candidates
Gonzalo Crespo – Barcelona, Spain
- 12:00 Frailty and liver transplantation: a practical approach
Matthew Armstrong – Birmingham, United Kingdom
- 12:15 Discussion and wrap-up

09:00 - 10:30
Skalkotas

ELPAT,ETAHP, EDTCO in conjunction with ETPO: Patient Pioneers – Those who dare to go first

*Chairs: Nichon Jansen – Leiden, The Netherlands
Hannah Maple – London, United Kingdom*

The aim of this Speciality Update Symposium is to discuss the vital role of patients and their loved ones in the progression of transplantation. We will hear from 'patient pioneers' - those who are brave enough to pursue new treatments and techniques as part of their transplant journey. We will discuss the ethical, legal and psychosocial aspects of establishing new practices, and the role of patients and the transplant multidisciplinary team. This collaborative symposium will unite ELPAT, ETAHP, EDTCO and ETPO, enabling a fruitful conversation between a wide group of transplant professionals and persons with transplants. Attendees can expect to hear inspirational stories and interesting perspectives and will have the opportunity to actively engage in what will undoubtedly be a forum for fascinating discussion.

- 09:00 Welcome and introduction
Hannah Maple – London, United Kingdom
- 09:05 My journey to new hands
Corinne Hutton – Paisley, United Kingdom; Simon Kay – Leeds, United Kingdom
- 09:20 Early days of Unspecified Kidney Donation in the UK
Kay Mason – Hertfordshire, United Kingdom; Jan Shorrocks – Lancaster, United Kingdom
- 09:35 DCD Heart Transplantation in Children
TBC
- 09:50 Deceased Donor family experience
Alison Moore – Huntingdon, United Kingdom

- 10:05 Panel discussion
Anna Forsberg - Lund, Sweden; Nichon Jansen - Leiden, The Netherlands; Hannah Maple – London, United Kingdom
- 10:25 Closing remarks for Part I
Nichon Jansen – Leiden, The Netherlands
- 11:00 - 12:30**
Skalkotas
- ELPAT,ETAHP, EDTCO in conjunction with ETPO: Patient Pioneers – Those who dare to go first**
*Chairs: Anna Forsberg – Lund, Sweden
Marleen van Buren – Rotterdam, The Netherlands*
- 11:00 Welcome and introduction to part 2 Patient Pioneers – advocacy and the role of the Multi Disciplinary Team
Anna Forsberg – Lund, Sweden
- 11:05 What does a successful transplant look like to you? The importance of patient expectations in pre-transplant decision making
Christian Falck, Sweden ; Guðmundur Felix Grétarsson - Lyon, France
- 11:25 Group discussion with the audience
Anna Forsberg - Lund, Sweden
- 11:40 Shared decision making, what is the team approach? Special focus on the role of the patient, nurses, and allied healthcare professionals
Chiara Cavalli - Padua, Italy; Christian Falck, Sweden; Guðmundur Felix Grétarsson – Lyon, France; Asia Imedi - London, United Kingdom; Yvette Meuleman - Leiden, The Netherlands
- 12:00 Group discussion with the audience
Coby Annema - Groningen, The Netherlands
- 12:15 Transplant Care Management Award
Anna Forsberg - Lund Sweden; Marleen van Buren - Rotterdam, The Netherlands
- 12:25 Closing remarks
Christina Papachristou – Thessaloniki, Greece
- 09:00 - 10:30**
MC 3
- ECTTA: Pushing the boundaries of heart and lung donation and preservation**
*Chairs: Irene Bello – Barcelona, Spain
Stephan Ensminger – Lübeck, Germany*
- The session will deal with the realistic possibilities of expanding the donor pool of thoracic donors with new innovative solutions. The envision of reshaping the field of organ donation moving from the centre's direct retrieval toward organ banks will be explored and discussed. The final objective is to enlarge the armamentarium of each transplant centre with different solutions aimed at improving the extraction of organs and reducing the incidence of primary graft failure
- 09:00 Some like it hot: Normothermic, Subnormothermic or Cold?
Marius Berman – Cambridge, United Kingdom
- 09:15 In-situ evaluation of DCD heart donors: the value of NRP
Elena Sandoval – Barcelona, Spain

- 09:30 The road from direct retrieval toward organ repair centres and organ banks.
Where are we now?
Marcelo Cypel – Toronto, Canada
- 09:45 Darwin and transplants: the Australian experience with Non-Ischemic Heart Preservation
David McGiffin – Melbourne, Australia
- 10:00 Preserving without freezing the lung: working for a standard of care in organ preservation.
Laurens Ceulemans – Tremelo, Belgium
- 10:15 DCD heart with 20 minutes of no-touch, is it feasible?
Massimo Boffini – Turin, Italy
- 10:20 Open discussion
- 11:00 - 12:30**
MC 3 **ECTTA: Preserving the organs and the recipients in the long-term**
Chairs: David Gomez-de-Antonio – Majadahonda, Spain
Martin Schweiger – Zurich, Switzerland
- The session will deal with the realistic possibilities of improving QOL and long term survival after thoracic transplantation. Multiple and different dimensions of the problem will be highlighted to clarify the need for multidisciplinary teams to provide extended survival to recipients. Questions and answers with patients' representatives will be welcome
- 11:00 ERAS in thoracic transplantation.
Irene Bello – Barcelona, Spain
- 11:15 Prehabilitation and rehabilitation in thoracic transplantation
Maria Simonenko - Saint-Petersburg, Russian Federation
- 11:30 Novel biomarkers to evaluate organ preservation and rejection in thoracic transplantation (focus on dd-cfDNA)
Luciano Potena – Bologna, Italy
- 11:45 Management of thoracic transplant candidates with preformed DSA antibodies
Antoine Roux – Suresnes, France
- 12:00 Prevention and treatment of chronic lung allograft dysfunction: new kids on the block?
Robin Vos – Leuven, Belgium
- 12:15 Cardiac allograft vasculopathy: what's new?
Andreas Zuckermann – Vienna, Austria

09:00 - 10:30
MC 2

EPITA SUS: Predicting success of beta cell replacement therapy

Chair: Andrew Sutherland – Edinburgh, United Kingdom

09:00

Welcome and Introductions
Julie Kerr-Conte – Lille, France

09:05

Update in perfusion technology do we have a consensus?
Joana Ferrer-Fàbrega – Barcelona, Spain

09:20

Donor factors predicting success after pancreas transplantation
Fabio Vistoli – Pisa, Italy

09:35

Pancreas and islet allocation scores-any room for improvement
Steve White - Newcastle upon Tyne, United Kingdom

09:50

Does donor HbA1C matter for islet transplantation
Julie Kerr-Conte – Lille, France

10:05

Factors predicting success during islet isolation
Paul Johnson – Oxford, United Kingdom

11:00 - 12:30
MC 2

EPITA: Alternatives to simultaneous transplants

*Chairs: Ekaterine Berishvili – Geneva, Switzerland
Peter Girman – Prague, Czech Republic*

11:00

Pancreas after kidney or islet after kidney: who should get what?
Michiel Nijhoff – Leiden, The Netherlands

11:15

Top scoring abstract EPITA: Islet after kidney vs kidney Transplant alone: A French nationwide study on behalf of the TREPID group
Mehdi Maanaoui – Lille, France

11:30

Hypoimmune stem cell derived islets for transplantation without immunosuppression.
Valeria Sordi – Milan, Italy

11:45

Conclusions

TV-STUDIO

Sunday, 17 September 2023

10:30 - 11:00
Muses Foyer

The small print: update on Science and Education

Host: Jacqui Thornton – Winchester, United Kingdom

Guests: Nina Pilat – Vienna, Austria, Marlies Reinders – Rotterdam, The Netherlands; Raj Thuraisingham – London, United Kingdom; Luca Toti – Rome, Italy; Annemarie Weissenbacher – Innsbruck, Austria

STORYTELLING

Sunday, 17 September 2023

11:00 - 12:45
MC 3.2

Diversity, inclusion and equality in medical training

*Chairs: Stan Benjamens – Groningen, The Netherlands
Caroline Dudreuilh – London, United Kingdom*

11:00

Introduction & welcome
Caroline Dudreuilh – London, United Kingdom

11:05

DIE (diversity, inclusion, equality) in medical training
Ginny Bowbrick – Dartford, United Kingdom

11:50

The untrainable trainee- unconscious bias
Gillian Hardman – Bristol, United Kingdom

12:15

Discussion
Dilan Dabare - Birmingham, United Kingdom ; Hannah Esser – Innsbruck, Austria

GENERAL ASSEMBLY

Sunday, 17 September 2023

12:30 - 14:00
Mitropoulos

ESOT General Assembly

ESOT General Assembly is reserved exclusively for ESOT members in good standing.

SOLUTION ROOM

Sunday, 17 September 2023

14:00 - 15:30
Mitropoulos

What if we make regenerative medicine available for everyone

*Chairs: Pedro Miguel Baptista – Zaragoza, Spain
Ekaterine Berishvili – Geneva, Switzerland*

This session will bring together ethicists and regulators to discuss challenges that lie ahead for the progression of regenerative medicine therapy products toward the clinic.

14:00

Introduction
Pedro Miguel Baptista - Zaragoza, Spain; Ekaterine Berishvili – Geneva, Switzerland

- 14:05 How can we avoid the 'valley of death' between first-in-human advanced therapy trials and adopted standard of care, equitably available to all
James Shaw - Newcastle upon Tyne, United Kingdom
- 14:15 Navigating an ATMP through the Regulatory Maze to the Clinic
Antonia Cronin – London, United Kingdom
- 14:25 Impediments and Ethical-Legal Challenges on the Road of Clinical Translation
Timothy Caulfield – Edmonton, Canada
- 14:35 Discussion Panel with audience
Fiona Loud - Alton, United Kingdom

FISHBOWL

Sunday, 17 September 2023

14:00 - 15:30
Conference Suite 1

How far can we really push the envelope in organ donation

Chairs: *Chloe Balleste – Barcelona, Spain*
Frank Dor – London, United Kingdom

During this session we intend for the participants to understand the current challenges regarding organ donation in Europe and the main measures to improve the situation; the need of improving organ quality during maintenance, the use of normothermic regional perfusion techniques in DCD, the indications for ex-situ perfusion machines, and strategies for cold ischemia time's shortening from professionals and patient's perspectives. The session will be conducted by a moderator that will present a clinic case and in each phase, the speakers related to the procedure will debate with the participants the options and decisions that can be taken based on evidence and experiences.

- 14:00 The safe haven of DBD
Julien Charpentier – Paris, France
- 14:15 The ying & yang of DCD
Beatriz Dominguez-Gil – Madrid, Spain
- 14:30 Fighting the ischemic clock: virtual cross match
Corinne Antoine - Paris, France
- 14:45 Who can they be? The donors
David Paredes-Zapata – Barcelona, Spain
- 15:00 Audience debate and discussion
Chloe Balleste – Barcelona, Spain; Frank Dor - London, United Kingdom

STORYTELLING

Sunday, 17 September 2023

14:00 - 15:30

MC 3.2

Future Leaders on Stage

*Chairs: Luca Toti – Rome, Italy
Liset Pengel – Rotterdam, The Netherlands*

14:00

ESOT Grants programme 2024 launch
Umberto Cillo – Padua, Italy

14:02

Introduction
Liset Pengel- Rotterdam The Netherlands; Luca Toti - Rome, Italy

14:05

Anders Andreasson (ESOT Transplant Fellowship recipient 2021)
Anders Andreasson - Newcastle upon Tyne, United Kingdom

14:17

Emilio Canovai (ESOT Transplant Fellowship recipient 2021)
Emilio Canovai – Oxford, United Kingdom

14:29

Tess Van Meerhaeghe (ESOT Transplant Fellowship recipient 2022)
Tess Van Meerhaeghe – Brussels, Belgium

14:41

Daniele Pievani (ESOT Transplant Fellowship recipient 2022)
Daniele Pievani – Paris, France

14:53

ECP Immunomodulation award (Mallinckrodt) ceremony
Liset Pengel- Rotterdam The Netherlands; Luca Toti - Rome, Italy

14:56

Introduction to the ESOT mentorship programme
Liset Pengel- Rotterdam The Netherlands; Luca Toti - Rome, Italy

14:58

Our mentorship experience: lessons learned from mentors and mentees: Part I
*Mentee: Mindaugas Kvietkauskas - Vilnius Lithuania
Mentor: Stephen Clark - Newcastle upon Tyne, United Kingdom*

15:06

Our mentorship experience: lessons learned from mentors and mentees: Part II
*Mentee: Lucia Ramona - Barcelona Spain
Mentor: Lorna Marson - Edinburgh, United Kingdom*

15:14

Discussion with all mentors and mentees

15:26

Launch of the 2024 ESOT Mentorship programme and concluding remarks
Liset Pengel- Rotterdam The Netherlands; Luca Toti - Rome, Italy

FOCUS GROUP

Sunday, 17 September 2023

14:00 - 15:30

Do we need incompatible kidney transplant

- MC 3.4** *Chairs:* *Lucrezia Furian – Padua, Italy*
Oriol Bestard – Barcelona, Spain
- 14:00 IS UNSPECIFIED (NON-DIRECTED) KIDNEY DONATION JUSTIFIED?
RESULTS FROM A PROSPECTIVE STUDY OF 837 DONORS
Hannah Maple – London, United Kingdom
- 14:10 THE IMPACT OF NON-DIRECTED ALTRUISTIC DONORS (NDAD) IN LIVING
KIDNEY EXCHANGE IN THE UK
L Matthew Robb – Bristol, United Kingdom
- 14:20 COMPARING OUTCOMES OF KIDNEY EXCHANGE PROGRAMMES WITH
DIRECT LIVING DONOR KIDNEY TRANSPLANTATION IN A COUNTRY WITH
HIGH LIVING DONATION RATES
Stijn van de Laar – Rotterdam, The Netherlands
- 14:30 EARLY OUTCOMES OF A MULTIMODALITY DESENSITIZATION-INDUCTION
SCHEME WITH ECULIZUMAB AND OBINUTUZUMAB IN HIGH-RISK
DECEASED-DONOR KIDNEY TRANSPLANTATION
Evaldo Favi – Milan, Italy
- 14:40 DESENSITIZATION AND IMMUNOMODULATION IN SENSITIZED KIDNEY
TRANSPLANT RECIPIENTS: A DELPHI METHOD CONSENSUS FROM THE
ENGAGE WORKING GROUP OF ESOT
Lucrezia Furian – Padua, Italy
- 14:50 CLINICAL OUTCOMES OF ABO- AND HLA-INCOMPATIBLE LIVING DONOR
KIDNEY TRANSPLANTATION: A NATIONWIDE STUDY
Ara Cho - Seoul, Republic of South Korea
- 15:00 CLINICAL OUTCOMES IN ABO MISMATCHING KIDNEY TRANSPLANTATION
IN PATIENTS WITH HIGH BASELINE ANTI-A/B ANTIBODY TITER
Seok Joon Shin - Seoul, Republic of South Korea
- 15:10 ENZYMATIC CONVERSION OF HUMAN BLOOD GROUP A KIDNEYS TO
UNIVERSAL BLOOD GROUP O
Serena MacMillan – Cambridge, United Kingdom

TV-STUDIO

Sunday, 17 September 2023

14:00 - 14:30
Muses Foyer

The next step: Moving forward now with patient inclusion
Host: *Jacqui Thornton – Winchester, United Kingdom*

Guests: *Pisana Ferrari – Udine, Italy*
Nichon Jansen – Leiden, The Netherlands

FULL ORAL

Sunday, 17 September 2023

14:00 - 15:30

Trianti

Kidney medical complications

Chairs: *Eleni Kapsia – Athens, Greece*
Fernanda Ortiz – Helsinki, Finland

- 14:00 AUSTRALIAN AND NEW ZEALAND CANCER RELATIVE SURVIVAL IN END-STAGE RENAL KIDNEY PATIENTS: A RETROSPECTIVE COHORT STUDY
Laia Oliveras - L'Hospitalet de Llobregat, Spain
- 14:10 SHIGATOXIN-PRODUCING ESCHERICHIA COLI-ASSOCIATED HEMOLYTIC UREMIC SYNDROME IN ADULT KIDNEY TRANSPLANT RECIPIENTS
Manal Mazloum – Paris, France
- 14:20 CAUSES OF DEATH IN KIDNEY TRANSPLANTATION, A PARADIGM SHIFT?
Thomas Beaudrey – Strasbourg, France
- 14:30 CURRENT STATUS OF PREGNANCY AND DELIVERY AFTER RENAL TRANSPLANTATION IN JAPAN
Yuki Nakagawa – Tokyo, Japan
- 14:40 CANCER INCIDENCE AMONG ITALIAN KIDNEY TRANSPLANT RECIPIENTS OVER A 25-YEAR PERIOD
Pierluca Piselli – Rome, Italy
- 14:50 VOLUMETRIC BONE MINERAL DENSITY, BONE MICRO-ARCHITECTURE EVOLUTION AFTER KIDNEY TRANSPLANTATION: A 1-YEAR RESULTS OF A PROSPECTIVE COHORT STUDY
Antoine Bouquegneau – Liège, Belgium
- 15:00 ALLOGENEIC IMMUNITY HELPS SUSTAIN EFFECTIVE BK-VIRUS IMMUNE RESPONSES AND PREVENTS BK VIRUS-ASSOCIATED NEPHROPATHY
Manon Dekeyser – Villejuif, France
- 15:10 TIME-DEPENDENT VARIATIONS IN BK POLYOMAVIRUS GENOME FROM KIDNEY TRANSPLANT RECIPIENTS WITH PERSISTENT VIREMIA
Olga Mineeva-Sangwo – Leuven, Belgium

FULL ORAL

Sunday, 17 September 2023

14:00 - 15:30
Banquet Hall

Biomarkers in Liver transplantation

*Chairs: Ina Jochmans – Leuven, Belgium
Paulo Martins - Boston, United States*

- 14:00 LIVER IMMUNOSUPPRESSION FREE TRIAL (LIFT): OUTCOMES OF THE FIRST BIOMARKER-GUIDED IMMUNOSUPPRESSION WITHDRAWAL TRIAL IN LIVER TRANSPLANT RECIPIENTS
Julien Vionnet – Lausanne, Switzerland
- 14:10 MOLECULAR SIGNATURES OF REJECTION IN LIVER TRANSPLANT BIOPSIES USING THE BANFF HUMAN ORGAN TRANSPLANT GENE PANEL
Zeynep Demir – Paris, France
- 14:20 EX SITU REPERFUSION INJURY//INFLAMMATION: IMMUNO-MOLECULAR PROFILING OF HUMAN LIVERS DURING NORMOTHERMIC MACHINE PERFUSION.
Fungai Dengu – Oxford, United Kingdom
- 14:30 BILE PROTEOME REVEALS BILIARY REGENERATION DURING NORMOTHERMIC PRESERVATION OF HUMAN LIVERS
Adam M. Thorne – Groningen, The Netherlands
- 14:40 MMP9 CORRELATES TO WORSE ISCHEMIA REPERFUSION INJURY AND IS PARTIALLY AMELIORATED BY NORMOTHERMIC MACHINE PERFUSION IN LIVER TRANSPLANTATION
Abraham Den Dekker – Leiden, The Netherlands
- 14:50 GRAFT-DERIVED CFDNA MONITORING IN PLASMA & BILE DURING EX-VIVO NORMOTHERMIC MACHINE PERFUSION IN LIVER TRANSPLANTATION: A PROMISING OBJECTIVE TOOL
Daniel Cox – Melbourne, Australia
- 15:00 BILE ACID ANALYSIS DURING NORMOTHERMIC MACHINE PERFUSION CAN REFINE LIVER GRAFT ASSESSMENT PRIOR TO TRANSPLANTATION: A PROOF-OF-CONCEPT STUDY
Guillaume Rossignol – Lyon, France
- 15:10 ANALYSIS OF THE BILE METABOLOME TO SEARCH FOR POTENTIAL BIOMARKERS OF QUALITY OF THE LIVER WITH PARTICULAR EMPHASIS ON BILE ACIDS
Kamil Łuczykowski – Bydgoszcz, Poland

FULL ORAL

Sunday, 17 September 2023

14:00 - 15:30

Translational immunology of rejection

Skalkotas	Chairs: <i>William E Scott III - Newcastle upon Tyne, United Kingdom Nina Pilat – Vienna, Austria</i>
14:00	TOWARDS DECIPHERING HLA IMMUNOGENICITY - ONE STEP FORWARD <i>Anat Tambur – Chicago, United States</i>
14:10	SOLVENT-ACCESSIBLE AMINO ACID MISMATCHES ON DONOR HLA ARE ASSOCIATED WITH KIDNEY GRAFT OUTCOMES; A STEP TOWARDS PERSONALIZING POST-TRANSPLANT CARE? <i>Soufian Meziyeh – Leiden, The Netherlands</i>
14:20	DIRECT PROFILING OF CLINICALLY RELEVANT HUMORAL IMMUNITY IN TRANSPLANTATION AND BEYOND <i>Ashley Priddey – Cambridge, United Kingdom</i>
14:30	ADOPTIVE CELLULAR IMMUNOTHERAPY FOR THE CONTROL OF HLA CLASS II ANTIBODY- MEDIATED REJECTION IN TRANSPLANTATION <i>Carolt Arana – Barcelona, Spain</i>
14:40	TCL1A PROTEIN INVOLVEMENT IN B CELLS AND TOLERANCE IN KYDNEY TRANSPLANTATION <i>François Brinas – Nantes, France</i>
14:50	CHARACTERIZATION OF EXTRACELLULAR VESICLES PRODUCED BY REGULATORY B CELLS IN KIDNEY TRANSPLANTATION <i>Amandine Dupuy – Nantes, France</i>
15:00	CHARACTERISTICS AND FUNCTION OF DONOR AND RECIPIENT TISSUE RESIDENT LYMPHOCYTES IN KIDNEY TRANSPLANTS <i>Daphne Hullegie-Peelen – Rotterdam, The Netherlands</i>
15:10	TARGETING INTRAGRAFT CELL-CELL COMMUNICATIONS DURING KIDNEY TRANSPLANT REJECTION <i>Baptiste Lamarthée – Leuven, Belgium</i>

FULL ORAL

Sunday, 17 September 2023

14:00 - 15:30 MC 3	Molecular monitoring of lung allograft rejection Chairs: <i>Robin Vos – Leuven, Belgium Saskia Bos - Newcastle upon Tyne, United Kingdom</i>
14:00	UTILITY OF THE BANFF HUMAN ORGAN TRANSPLANT PANEL IN DIAGNOSING ANTIBODY-MEDIATED REJECTION IN LUNG TRANSPLANT BIOPSIES <i>Marta Sablik – Paris, France</i>

- 14:10 USING PREDICTED INDIRECTLY RECOGNIZABLE HLA EPITOPES TO INVESTIGATE FORMATION OF DE NOVO DONOR-SPECIFIC HLA-ANTIBODIES AFTER LUNG TRANSPLANTATION
Maximilian Vorstandlechner – Munich, Germany
- 14:20 TRANSCRIPTIONAL CO-ACTIVATOR BOB1 AS THE KEY REGULATOR OF PATHOGENIC LYMPHOCYTIC RESPONSES IN CHRONIC LUNG ALLOGRAFT DYSFUNCTION
Nataliya Yeremenko – Nantes, France
- 14:30 VALIDATION OF A BLOOD GENE SIGNATURE TO PREDICT CHRONIC ALLOGRAFT DYSFUNCTION IN LUNG TRANSPLANTATION
Richard Danger – Nantes, France
- 14:40 UNSUPERVISED ANALYSIS OF LUNG TRANSPLANT PHENOTYPES USING GENE EXPRESSION DATA
Marta Sablik – Paris, France
- 14:50 ROLE OF DONOR-DERIVED CELL-FREE DNA IN CHRONIC LUNG ALLOGRAFT DYSFUNCTION. A LONGITUDINAL STUDY.
Susana Gomez-Olles – Barcelona, Spain
- 15:00 DONOR-DERIVED CELL-FREE DNA AND CELL-FREE RNA LEVELS USING A COST-EFFECTIVE LIQUID BIOPSY TECHNIQUE MONITORING LUNG ALLOGRAFT REJECTION.
Owais Tisekar – Secunderabad, India
- 15:10 INDUCTION EXTRACORPOREAL PHOTOPHERESIS STIMULATES BENEFICIAL IMMUNE MODULATION IN CYSTIC FIBROSIS PATIENTS UNDERGOING LUNG TRANSPLANTATION
Ilaria Righi – Paullo, Italy

BRIEF ORAL

Sunday, 17 September 2023

- 14:00 - 15:30
MC 2 **Safety and quality at the core of donation and transplantation**
*Chairs: Frederike Ambagtsheer - Rotterdam, The Netherlands
Régis Bronchard - Saint Denis, France*
- 14:00 SETTING EUROPEAN QUALITY AND SAFETY STANDARDS FOR ORGAN DONATION AND TRANSPLANTATION
Jaime Marco de Tena – Strasbourg, France
- 14:06 SAFETY OF ORGAN TRANSPLANTATION FROM DONORS WITH PRIMARY MALIGNANCY OF THE CENTRAL NERVOUS SYSTEM
Clara Manso Murcia – Murcia, Spain

- 14:12 DONOR-TRANSMITTED CANCER IN ORGAN DONATION AND SOLID ORGAN TRANSPLANTATION IN GERMANY FROM 2016-2022.
Axel Rahmel – Frankfurt, Germany
- 14:18 NO SURVIVAL BENEFIT IN KIDNEY TRANSPLANT RECIPIENTS IN THE EUROPEAN SENIOR PROGRAM
Marcel Naik – Berlin, Germany
- 14:24 DONATION AFTER MEDICAL ASSISTANCE IN DYING IN QUÉBEC – THE FIRST FIVE YEARS
Matthew Weiss – Montrea,l Canada
- 14:30 THE SCARCITY OF ORGAN DONORS IN CHILE IS NOT EXPLAINED BY FAMILIAL REFUSAL, BUT BY UNPREPARED ER AND ICU PROFESSIONALS
Francisca Gonzalez Cohens – Santiago, Chile
- 14:36 CITIZENSHIP STATUS AND KIDNEY FUNCTION OF LIVING KIDNEY DONORS IN THE UNITED STATES
Voramol Rochararoon – Rayong, Thailand
- 14:42 KIDNEY FUNCTION DECLINE PREDICTING FACTORS IN LIVING KIDNEY TRANSPLANTATION DONORS
Lada Trajceska – Skopje, North Macedonia
- 14:48 OUTCOMES FOR KIDNEY TRANSPLANT CANDIDATES WITH DECLINED DECEASED DONOR KIDNEY OFFERS: A RETROSPECTIVE SINGLE-CENTRE ANALYSIS
Anna Brotherton - Birmingham United Kingdom
- 14:54 CHARACTERISTICS OF PROSPECTIVE AND EFFECTIVE LIVING DONORS FOR RENAL TRANSPLANTATION: A CROSS-SECTIONAL STUDY.
Fernando Girón Luque - Bogotá Colombia
- 15:00 AI MEASURED PREOPERATIVE RENAL VOLUME AND RISK FACTORS ASSOCIATED WITH CHRONIC KIDNEY DISEASE POST DONOR NEPHRECTOMY IN THE ELDERLY
EunAh Jo - Seoul, Republic of South Korea
- 15:06 HIGHER ABDOMINAL FAT AREA ASSOCIATES WITH LOWER RENAL FUNCTION BEFORE AND AFTER LIVING KIDNEY DONATION
LB Lisa Westenberg - Groningen The Netherlands
- 15:12 BODY MASS INDEX (BMI), OBESITY AND URIC ACID: PRIOR TO DONOR NEPHRECTOMY AND OVER A 15-YEAR FOLLOW-UP PERIOD, EXPERIENCE OF OUR CENTER
Jelena Tadic - Belgrade Serbia
- 15:18 THE CRITICAL PATHWAY FOR DECEASED DONATION: AN ANALYSIS IN THREE REGIONS OF COLOMBIA
William Cruz Mususú – Bogota, Colombia

BRIEF ORAL

Sunday, 17 September 2023

14:00 - 15:30
Library

Progress and challenges in Pancreas and Islet transplantation

*Chairs: Paul Johnson – Oxford, United Kingdom
Hanne Scholz – Oslo, Norway*

- 14:00 ISLET TRANSPLANTATION VERSUS INSULIN ALONE IN TYPE 1 DIABETIC KIDNEY TRANSPLANT RECIPIENTS: A FRENCH NATIONWIDE STUDY ON BEHALF OF THE TREPID GROUP.
Mehdi Maanaoui – Lille, France
- 14:06 RELATION BETWEEN PRIMARY GRAFT FUNCTION AND 5-YEAR OUTCOMES OF ISLET TRANSPLANTATION: A RETROSPECTIVE STUDY IN 1210 PARTICIPANTS
Mikael Chetboun – Lille, France
- 14:12 SIMULTANEOUS ISLET KIDNEY TRANSPLANT – OUTCOMES FROM 2 UK TRANSPLANT CENTRES
Andrew Sutherland – Edinburgh, United Kingdom
- 14:18 EXPLORING PRESERVATION MODALITIES IN A SPLIT HUMAN PANCREAS MODEL TO INVESTIGATE THE EFFECT ON THE ISLET ISOLATION OUTCOMES.
Antoine Buemi – Brussels, Belgium
- 14:24 RE-ANIMATING PANCREATIC GRAFTS SUBJECTED TO PROLONGED COLD ISCHEMIA IN A PORCINE MODEL USING NORMOTHERMIC EX VIVO PERFUSION: A FEASIBILITY STUDY
Samrat Ray – Toronto, Canada
- 14:30 SINGLE-CENTER INITIAL EXPERIENCE OF DUODENODUODENOSTOMY FOR EXOCRINE DRAINAGE IN PANCREAS TRANSPLANTATION.
Joana Ferrer-Fàbrega – Barcelona, Spain
- 14:36 HEALTH RELATED QUALITY OF LIFE AFTER SIMULTANEOUS PANCREAS KIDNEY TRANSPLANTATION: HOW GOOD DOES IT GET?
Irene Mosca – Oxford, United Kingdom
- 14:42 HYPERTENSION IN THE DONOR IS ASSOCIATED WITH AN INCREASED RISK OF EARLY PANCREAS ALLOGRAFT FAILURE
Christophe Masset – Nantes, France
- 14:48 NORMOTHERMIC EX VIVO MACHINE PERFUSION OF THE PANCREAS IS SAFE AND FEASIBLE IN A PORCINE MODEL OF PANCREAS TRANSPLANTATION.
Catherine Parmentier – Toronto, Canada

- 14:54 ISLET ISOLATION AND TRANSPLANTATION OUTCOMES FOLLOWING DONATION AFTER CIRCULATORY DEATH - A COMPARISON WITH DONATION AFTER BRAIN DEATH
Paul Johnson – Oxford, United Kingdom
- 15:00 DIFFERENCES IN GLUCOSE HOMEOSTASIS BETWEEN TYPE 1 VS. TYPE 2 DIABETES AFTER PANCREAS TRANSPLANTATION
Richard Knight – Houston, United States
- 15:06 RISK FACTORS FOR GREATER THAN 10 YEARS PANCREAS GRAFT SURVIVAL IN THE UK; SHORT TERM RISK FACTORS ARE NOT ALWAYS THE BEST GUIDE FOR LONG TERM SURVIVAL
Argiris Asderakis – Cardiff, United Kingdom
- 15:12 OUTCOMES OF PANCREAS TRANSPLANTATION ALONE FROM DONATION AFTER CIRCULATORY DEATH
Irene Mosca – Oxford, United Kingdom
- 15:18 IMPACT OF NORMOTHERMIC REGIONAL PERFUSION ON OUTCOMES AFTER SPK TRANSPLANTATION – A UK ANALYSIS FROM THE NHSBT PANCREAS ADVISORY GROUP
Ruth Owen - Newcastle upon Tyne, United Kingdom

TV-STUDIO

Sunday, 17 September 2023

15:30 - 16:00
Muses Foyer

How registries will transform transplant data and care

Host: *Jacqui Thornton – Winchester, United Kingdom*

Guests: *Umberto Cillo – Padua, Italy*
Penilla Gunther – Stockholm, Sweden

PLENARY

Sunday, 17 September 2023

16:00 - 17:30
Lambrakis

Opening Plenary: Transplantation at crossroads

Chairs: *Gabriel Oniscu – Stockholm, Sweden*
John Boletis – Athens, Greece

During the Covid pandemic technology was a key asset for the delivery of care and collaboration was how we accelerated the implementation of change and achieved successful therapies. As we are emerging on the other side of the pandemic, we are witnessing a game-changing explosion of disruptive technologies such as AI, digitalization and virtual reality that hold immense potential but also bring new

challenges. This session will explore how transplant care could look in a technology-driven world. Is technology going to enhance the delivery of trusted transplant care? What is the impact for patients and how can they benefit from this technological revolution? We will then learn why we should sustain and expand the level of collaboration achieved during the pandemic to further accelerate the technological redesign of transplant care with examples from the world of Nobel prize winners.

- | | |
|-------|---|
| 16:00 | Introduction
<i>Pisana Ferrari – Udine, Italy; Vassilios Papalois, London, United Kingdom</i> |
| 16:20 | Digital transformation – make or break for transplant care
<i>John Nosta – Mendham, United States</i> |
| 16:40 | Realistic care and shared decision making – aspiration or reality?
<i>Donna Cryer – Washington, United States</i> |
| 17:00 | Deconstructing Creativity - Collaboration and it's contribution to success
<i>Tobias Degsell – Stockholm, Sweden</i> |
| 17:20 | Discussion & wrap-up |

JOINT SESSION

Sunday, 17 September 2023

- | | |
|-----------------------|---|
| 17:30 - 18:30
MC 2 | ESOT – ISOT joint session: Expanding living donor pool in kidney transplant
<i>Chairs: Sandeep Guleria – New Delhi, India
Hannah Maple – London, United Kingdom</i> |
| 17:30 | ABO Incompatible Kidney Transplant
<i>Deepak Shankar Ray - West Bengal, India</i> |
| 17:45 | Kidney Paired Exchange - India
<i>Vivek Kute – Ahmedabad, India</i> |
| 18:00 | Panel discussion
<i>Chloe Balleste - Barcelona, Spain; Shyam Bihari Bansal – Haryana, India; Sandeep Guleria – New Delhi, India; Hannah Maple - London, United Kingdom; Ashish Sharma - Chandigarh, India; Pukar Shrestha - Bhaktapur, Nepal</i> |

ASSEMBLY

Sunday, 17 September 2023

- | | |
|--------------------------|---|
| 17:45 - 18:45
Library | ELITA Assembly
<i>ELITA Assembly is reserved exclusively for ELITA affiliates in good standing.</i> |
|--------------------------|---|

TV-STUDIO

Sunday, 17 September 2023

17:45 - 18:15
Muses Foyer

President's focus: Accelerating Away from the Crossroads

Host: Jacqui Thornton – Winchester, United Kingdom

Guests: Gabriel Oniscu – Stockholm, Sweden

Monday, 18 September 2023

FULL ORAL

Monday, 18 September 2023

08:00 - 09:30

Lambrakis

Kidney allocation to improve outcomes

Chairs: *Nichon Jansen - Leiden, The Netherlands*
Rainer Oberbauer - Vienna, Austria

08:00

KIDNEY TRANSPLANTATION FROM UNCONTROLLED DONATION AFTER CARDIAC DEATH, AN OPTION WITH EXCELLENT RESULTS IN THE LONG TIME.

Maria Molina – Badalona, Spain

08:10

IS THERE A DIFFERENCE IN SURVIVAL OUTCOMES OF DUAL KIDNEY TRANSPLANTS OF DCD V/S DBD ALLOGRAFTS IN ABSENCE OF NATIONAL PATHOLOGY SERVICE?

Abdullah Khawaja – Liverpool, United Kingdom

08:20

ALL ECD KIDNEYS ARE EQUAL BUT ARE SOME MORE EQUAL THAN OTHERS? A POPULATION-COHORT ANALYSIS OF UK TRANSPLANT REGISTRY DATA

Kamlesh Patel – Morden, United Kingdom

08:30

IMPACT OF DECEASED DONOR ACUTE KIDNEY INJURY (AKI) ON RENAL TRANSPLANT OUTCOMES.

Mikhail Nozdrin – London, United Kingdom

08:40

DO WAITLISTED KIDNEY TRANSPLANT CANDIDATES AGED ≥ 70 YEARS HAVE A SURVIVAL BENEFIT POST-TRANSPLANTATION?

Benjamin Anderson – Birmingham, United Kingdom

08:50

GRAFT-RELATED OUTCOMES COMPARING LEFT VERSUS RIGHT KIDNEYS: A POPULATION COHORT ANALYSIS

Raja Rashid – Birmingham, United Kingdom

09:00

DECISION MAKING ABOUT LIVING DONOR KIDNEY TRANSPLANTATION: IN A MULTI-ETHNIC PATIENT POPULATION

Ahmed Ahmed – Leeds, United Kingdom

09:10

THE UK LIVING KIDNEY EXCHANGE PROGRAMME – PUSHING BOUNDARIES TO OPTIMISE TRANSPLANT POSSIBILITIES

L Matthew Robb – Bristol, United Kingdom

FULL ORAL

Monday, 18 September 2023

08:00 - 09:30

Trianti

AI & Digital Health: from donation to the outcome

Chairs: *Carmen Lefaucheur – Paris, France*
Michelle Willicombe – London, United Kingdom

08:00

INCREASING ORGAN DONORS AND TRANSPLANTS VIA INTEROPERABILITY

John Piano - Los Angeles, United States

08:10

THERMODYNAMIC CHARACTERIZATION OF ORGANS PRESERVED ON ICE – INVESTIGATING THE ASSUMPTION THAT ICE IS 4°C

Pratik Patel – Cambridge, United States

08:20

NEXT GENERATION SEQUENCING: FROM BANFF SCORE MOLECULAR SIGNATURES AND CLASSIFIERS TO HISTOLOGICAL ARCHETYPES OF KIDNEY BIOPSIES

Esteban Cortes Garcia – Paris, France

08:30

DEVELOPMENT, APPLICATION, AND VALIDATION OF A HISTOLOGICAL CLASSIFICATION AUTOMATION SYSTEM FOR KIDNEY ALLOGRAFT PRECISION DIAGNOSTICS

Valentin Goutaudier – Paris, France

08:40

DEVELOPMENT, VALIDATION, AND AUTOMATED REPORTING OF GENE EXPRESSION-BASED DIAGNOSIS OF RENAL ALLOGRAFT REJECTION BASED ON THE B-HOT GENE PANEL

Olivier Aubert – Paris, France

08:50

EXTENDED VALIDATION OF THE IBOX IN REAL LIFE SETTING, DIFFERENT TRANSPLANT SYSTEMS AND CLINICAL TRIALS: THE IBOX EXTENDED TRIAL

Olivier Aubert – Paris, France

09:00

A RANDOMIZED CONTROLLED TRIAL OF EHEALTH PROGRAM FOLLOW-UP BASED ON A 1-YEAR PREDICTION OF LONG-TERM GRAFT FAILURE (KTFS) IN KIDNEY TRANSPLANTATION

Magali Giral – Nantes, France

09:10

RISK CLASSIFICATION MODELS FOR KIDNEY GRAFT FAILURE FROM A LARGE GERMAN KIDNEY TRANSPLANT CENTRE

Marcel Naik – Berlin, Germany

FISHBOWL

Monday, 18 September 2023

08:00 - 09:30
Banquet Hall

AI & I

*Chairs: Marlies Reinders – Rotterdam, The Netherlands
Colin White – Balbriggan, Ireland*

Much has been said about the role of AI in the delivery of healthcare but is it really ready for prime time in transplantation? How will it improve and streamline care? Will it deliver personalised / precision care? Will it assist outpatient care? Will it be precision medicine for the organ or the patient or both? What should we expect from AI?

- 08:00 Introduction
Marlies Reinders – Rotterdam, The Netherlands
- 08:05 AI: From Option To Imperative
John Nosta – Mendham, United States
- 08:25 Your virtual doctor will see you now
Shafi Ahmed – London, United Kingdom
- 08:45 Training in the metaverse
Igor Sauer – Berlin, Germany
- 09:05 AI and I - round table discussion
John Nosta – Mendham, United States

SOLUTION ROOM

Monday, 18 September 2023

08:00 - 09:30
Mitropoulos

Let's talk about living donation: there's an app for that

*Chairs: Klemens Budde – Berlin, Germany
Hannah Maple – London, United Kingdom*

Physicians and patients may employ technology-based interventions to increase awareness of living kidney donation and also to link donors with transplant candidates. This session will provide a guide on how to use Mobile apps and/or Web pages to target the general population and ethnic minorities with the purpose of increasing knowledge on living donation, including donor suitability and pre-emptive transplantation, and also how to implement strategies to connect potential donors to transplant candidates. Should risk calculators be used in communicating the long-term risk of living donation? What are the ethical and legal challenges in the use of technology-based interventions?

- 08:00 From home education to web education
Emma Massey – Rotterdam, The Netherlands
- 08:20 www.i_need_a_donor
Frank Dor - London United Kingdom

- 08:40 Ethical and legal issues in using social media for identifying donors
Katrina Bramstedt - Queensland, Australia; Greg Moorlock - Warwick, United Kingdom
- 09:00 Risk calculators: friend or foe
Aisling Courtney – Belfast, United Kingdom
- 09:20 Discussion

BRIEF ORAL

Monday, 18 September 2023

- 08:00 - 09:30**
Skalkotas **Transplant Plus: Regenerative therapies and Xenotransplantation**
*Chairs: Jan Czogalla – Hamburg, Germany
Sandra Lindstedt – Lund, Sweden*
- 08:00 THE (PRO)RENIN RECEPTOR IS INVOLVED IN KIDNEY ORGANOID DEVELOPMENT
Martin Hoogduijn – Rotterdam, The Netherlands
- 08:06 ENGINEERING VASCULARIZED ENDOCRINE PANCREAS TO CURE TYPE 1 DIABETES
Kevin Bellofatto – Geneva, Switzerland
- 08:12 GENERATION OF VASCULARIZED ENDOCRINE CONSTRUCTS FOR TYPE 1 DIABETES
Laura Mar Fonseca – Geneva, Switzerland
- 08:18 ALLOGENEIC MESENCHYMAL STROMAL CELL THERAPY IN KIDNEY TRANSPLANTATION: SHOULD REPEATED HLA MISMATCHES BE AVOIDED?
Suzanne Bezstarosti – Leiden, The Netherlands
- 08:24 DEVELOPMENT OF AN ADVANCED PLATFORM FOR RAT LIVER NORMOTHERMIC MACHINE PERFUSION EQUIPPED WITH A BIOREACTOR SEEDING WITH MESENCHYMAL STEM CELLS
Caterina Lonati – Milan, Italy
- 08:30 THE CYTOPROTECTIVE EFFECTS OF EXTRACELLULAR VESICLES DERIVED FROM HUMAN AMNIOTIC EPITHELIAL CELLS ON PANCREATIC ISLETS
Reine Hanna – Geneva, Switzerland
- 08:36 INSULIN-INDEPENDENCE IN LARGE ANIMAL MODELS AFTER PANCRERATECTOMY AND AUTOTRANSPLANTATION OF 3D-BIOPRINTED BIONIC PANCREATIC PETALS.
Michal Wszola – Warsaw, Poland

- 08:42 A MICROFLUIDIC BILE-DUCT-ON-A-CHIP PLATFORM FOR STUDYING BILIARY EPITHELIUM IN A DISH
Jorke Willemse – Rotterdam, The Netherlands
- 08:48 THE EX VIVO REGENERATION OF ISCHEMICALLY DAMAGED HUMAN KIDNEY ALLOGRAFTS
Lauren Brasile – Albany, United States
- 08:54 TACROLIMUS-LOADED MIXED THERMOSENSITIVE HYDROGEL FOR IMPROVING THE OUTCOME OF SKIN AND VASCULARIZED COMPOSITE ALLOTRANSPLANTATION
Madonna Rica Anggelia – Taoyuan, Taiwan
- 09:00 SINGLE CELL RNA SEQUENCING ANALYSIS OF HUMAN AMNIOTIC EPITHELIAL CELLS TO DECIPHER THE MECHANISMS OF IMMUNOMODULATION CONFERED TO PANCREATIC ISLETS
Juliette Bignard – Geneva, Switzerland
- 09:06 FEASIBILITY OF MANUFACTURE OF CHIMERIC ANTIGEN RECEPTOR (CAR)-REGULATORY T CELLS (TREGS) FROM PATIENTS WITH END-STAGE RENAL DISEASE (ESRD)
Hervé Bastian – Valbonne, France
- 09:12 AUXILIARY LIVER XENOTRANSPLANTATION TECHNIQUE IN A TRANSGENIC PIG TO A NON-HUMAN PRIMATE MODEL
Kyo Won Lee - Seoul, Republic of South Korea
- 09:18 LONG-TERM (2 YEARS) SURVIVAL OF PORCINE TO NONHUMAN PRIMATE LIFE-SUSTAINING KIDNEY XENOTRANSPLANTATION
Ahmad Karadagi – Boston, United States

FULL ORAL

Monday, 18 September 2023

- 08:00 - 09:30**
MC 2 **Organ donation: clinical perspectives**
*Chairs: John Forsythe – Bristol, United Kingdom
Marco Sacchi – Milan, Italy*
- 08:00 PREDICTIVE RADIOLOGIC SIGNS TO EVOLVE TO BRAIN DEATH OR CIRCULATORY DEATH
Nuria Masnou Burralló – Girona, Spain
- 08:10 FACTORS DETERMINING CONSENT FOR ORGAN DONATION AFTER BRAIN DEATH IN FRANCE
Régis Bronchard - Saint Denis, France

- 08:20 MODULATORY EFFECT OF ALTEPLASE AND METHYLPREDNISOLONE ASSOCIATION ON BRAIN DEATH DONOR
Lucas Ferreira da Anuniação - São Paulo, Brazil
- 08:30 ACTIVATION OF THE COMPLEMENT SYSTEM EARLY ON DURING BRAIN DEATH MANAGEMENT
Laura Knijff – Leiden, The Netherlands
- 08:40 ANALYSIS OF RISK FACTORS FOR KIDNEY TRANSPLANTATION AFTER CONTROLLED CIRCULATORY DEATH AND SYSTEMATIC USE OF NORMOTHERMIC REGIONAL PERFUSION
Corinne Antoine - Paris, France
- 08:50 ‘SPREADING’ AGING WITH THE TRANSPLANTATION OF OLD ORGANS: AN EXPERIMENTAL REALITY
Maximilian Roesel – Boston, United States
- 09:00 LONG-TERM MORTALITY OF LIVING KIDNEY DONORS: A NATION-BASED COHORT STUDY
Jongman Kim - Seoul, Republic of South Korea
- 09:10 EXCELLENCE IN ORGAN UTILISATION – A QUANTITATIVE AND QUALITATIVE EVIDENCE BASE FOR A NEW APPROACHES IN THE UK
Claire Williment - London, United Kingdom

DARE TO ASK

Monday, 18 September 2023

08:00 - 09:30
Conference Suite 1

ESOT and IPTA joint session: Solutions to challenges in paediatric transplantation

Chairs: *Nicos Kessarlis – London, United Kingdom*
Jelena Stojanovic – London, United Kingdom

We discuss current dilemmas and hot topics in paediatric transplantation focusing on medical and surgical complexities. The session is delivered jointly by patients and healthcare professionals. Delegates can bring complex cases for discussion and get an expert opinion on them. The session is planned based on the feedback received for the paediatric session at ESOT 2021.

- 08:00 I had HLA incompatible kidney transplantation in childhood. Patient story
Megan Carter – Dublin, Ireland
- 08:05 Is antibody incompatible transplantation justifiable for children?
Nizam Mamode – London, United Kingdom
- 08:20 Combined liver and kidney transplantation in children with congenital metabolic abnormalities-is it worth doing?
Jelena Stojanovic – London, United Kingdom

- 08:35 Solutions for surgical challenges in liver transplantation
Carlos Esquivel – Stanford, United States
- 08:50 Solutions for surgical challenges in kidney transplantation
Nicos Kessaris – London, United Kingdom
- 09:05 Solutions for surgical challenges in heart transplantation
Martin Schweiger – Zurich, Switzerland
- 09:20 Panel Discussion

FOCUS GROUP

Monday, 18 September 2023

08:00 - 09:30
MC 3.2

Living donation revolutions

Chairs: Dieter Broering – Riyadh, Saudi Arabia
Mohamed Rela – Chennai, India

- 08:00 USEFULNESS OF LIVER VOLUMETRY BASED ON HEPATIC VENOUS TERRITORY AS PREOPERATIVE EVALUATION FOR LIVING DONOR LIVER TRANSPLANTATION
Woo Kyoung Jeong - Seoul, Republic of South Korea
- 08:10 RISK FACTORS ASSOCIATED WITH SURGICAL MORBIDITIES OF LAPAROSCOPIC LIVING LIVER DONORS
Jinsoo Rhu - Seoul, Republic of South Korea
- 08:20 DUAL GRAFT LDLT HAS A ROLE IN AVOIDING SMALL-FOR-SIZE SYNDROME
ChulSoo Ahn - Seoul, Republic of South Korea
- 08:50 REVOLUTIONIZING LIVER TRANSPLANT: THE JOURNEY FROM LAPAROSCOPIC LDLT TO ROBOTIC LDLT
KW Lee Kwang-Woong Lee - Seoul, Republic of South Korea
- 09:00 POST-LIVER TRANSPLANT LONG-TERM SURVIVAL IN PATIENTS WITH ACUTE-ON-CHRONIC LIVER FAILURE: LIVING-DONOR VERSUS DECEASED-DONOR LIVER TRANSPLANTATION
Sang-Bin Han - Seoul, Republic of South Korea
- 09:10 *EFFECTIVENESS OF A DESENSITIZATION PROTOCOL ON ANTIBODY-MEDIATED REJECTION IN LIVING DONOR LIVER TRANSPLANTATION: A RETROSPECTIVE COHORT STUDY
YoungRok Choi - Seoul, Republic of South Korea
- 09:20 INTERNATIONAL LIVING DONOR LIVER TRANSPLANT REGISTRY – LDLTREGISTRY.ORG
CHS Camila Hidalgo Salinas – Oxford, United Kingdom

FOCUS GROUP

Monday, 18 September 2023

08:00 - 09:30

MC 3.4

Kidney machine perfusion and ischemia reperfusion injury

*Chairs: Maria Kaisar - Oxford United Kingdom
Georgios Katsanos - Thessaloniki Greece*

08:00

TRANSPLANT OUTCOMES AFTER EXPOSURE OF DECEASED KIDNEY DONORS TO CONTRAST MEDIUM

Kinita Chotkan – Leiden, The Netherlands

08:10

THE SETUP USED FOR EX VIVO RENAL NORMOTHERMIC PERFUSION INFLUENCES A KIDNEY'S BEHAVIOR ON THE MACHINE

Veerle A. Lantinga – Groningen, The Netherlands

08:20

NORMOTHERMIC KIDNEY PERFUSION PHASE 1 – A CLINICAL TRIAL OF UP TO 24-HOUR NORMOTHERMIC MACHINE PERFUSION PRIOR TO TRANSPLANTATION

Richard Dumbill – Oxford, United Kingdom

08:30

MAGNETIC RESONANCE IMAGING ASSESSMENT OF FUNCTIONAL DIFFERENCES BETWEEN KIDNEYS IN VIVO AND DURING EX VIVO NORMOTHERMIC MACHINE PERFUSION

Tim L. Hamelink – Groningen, The Netherlands

08:40

KIDNEY TRANSCRIPTOME VARIES BETWEEN DONOR TYPES, WITH A DIFFERENTIAL RESPONSE TO ISCHEMIC PRECONDITIONING

Tiago Pinto Coelho – Liège, Belgium

08:50

FASTING PORCINE KIDNEYS DURING NORMOTHERMIC MACHINE PERFUSION DOES NOT AFFECT MITOCHONDRIAL FUNCTION

L. Annick van Furth – Groningen, The Netherlands

09:00

RENAL ARTERY FUNCTIONS IN KIDNEYS AFTER THREE MONTHS FOLLOWING RECONDITIONING IN PORCINE EXTENDED UDCD MODEL.

Galina Travnikova – Gothenburg, Sweden

09:10

REAL-TIME ASSESSMENT OF KIDNEY ALLOGRAFTS DURING HOPE USING FLAVIN MONONUCLEOTIDE (FMN) - A PRECLINICAL STUDY.

Richard Sousa Da Silva – Zürich, Switzerland

TV-STUDIO

Monday, 18 September 2023

09:30 - 10:00
Muses Foyer

Work-life balance: how to recruit and retain transplant professionals of the future

Host: Jacqui Thornton – Winchester, United Kingdom

*Guests: Pedro Miguel Baptista – Zaragoza, Spain
Emma Massey – Rotterdam, The Netherlands*

FULL ORAL

Monday, 18 September 2023

10:00 - 11:30
Lambrakis

Risk of transmission of infectious disease and prevention

*Chairs: Corinne Antoine - Paris, France
Marleen van Buren – Rotterdam, The Netherlands*

- 10:00 SHORT-TERM OUTCOME OF TRANSPLANT RECIPIENTS FROM SARS-COV-2-POSITIVE ORGAN DONORS IN GERMANY
Ana Paula Barreiros – Mainz, Germany
- 10:10 KIDNEY TRANSPLANT RECIPIENTS BECOME LESS ADHERENT TO PREVENTIVE MEASURES AFTER SARS-COV-2 VACCINATION AND AFTER AWARENESS OF ANTIBODY RESPONSE
Sophie Frölke – Amsterdam, The Netherlands
- 10:20 VIROLOGICAL & CLINICAL OUTCOMES IN ORGAN RECIPIENTS FROM SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) POSITIVE DECEASED ORGAN DONORS
Ines Ushiro-Lumb – London, United Kingdom
- 10:30 TWO-YEAR FOLLOW-UP OF LIVER GRAFTS FROM COVID-19 DONORS
Silvia Martini – Turin, Italy
- 10:40 CELLULAR HUMORAL MEMORY PROTECTS TRANSPLANT RECIPIENTS FROM EMERGING SARS-COV-2 VARIANTS OF CONCERN THAT RESIST CIRCULATING NEUTRALIZING ANTIBODIES
Olivier Thauvat – Lyon, France
- 10:50 THE HUMORAL RESPONSE TO COVID-19 VACCINATION OF KIDNEY TRANSPLANT RECIPIENTS IS PREDICTIVE OF SURVIVAL AFTER SARS-COV-2 INFECTION
Markus Hovd – Oslo, Norway
- 11:00 SARS-COV-2-SPECIFIC IMMUNOLOGICAL MEMORY PREDICTS SUCCESSFUL BOOSTER IMMUNIZATION AND SEVERE COVID-19 IN SOLID ORGAN TRANSPLANT PATIENTS
Laura Donadeu – Barcelona, Spain

11:10 HEPATITIS E VIRUS (HEV) INFECTION IN DECEASED ORGAN DONORS – OBSERVATIONS FROM THE FIRST 5 YEARS OF UNIVERSAL SCREENING
Ines Ushiro-Lumb – London, United Kingdom

SOLUTION ROOM

Monday, 18 September 2023

10:00 - 11:30
Trianti

Technology to support global transplantation

*Chairs: Muhammad Khurram – London, United Kingdom
Michelle Willicombe – London, United Kingdom*

How can technology can be utilised to support and develop organ transplantation in low and middle income countries?

This session explores the potential role of technology in supporting the development of organ transplantation programs in low and middle income countries. The use of technology to facilitate remote training opportunities and access to specialised expertise that may be unavailable in resource limited settings will be discussed. The potential benefits and challenges inherent in providing international support for program development and implementation will be considered, [[+/- including potential ethical concerns about international outreach activities]. Panelists and speakers from a range of settings will share their experiences and perspectives, and audience members will be strongly encouraged to share examples of effective practices and suggestions for future ESOT initiatives in this domain.

10:00 Introduction – what technology can do for global patient care
Raj Thuraisingham – London, United Kingdom

10:10 The global transplant multi-disciplinary meeting
*Chanaka Ruwan Abeyrathne – Colombo, Sri Lanka;
Chintana Galahitiyawa - Colombo, Sri Lanka; Abigail Lee London, United Kingdom; Smaragdi Marinaki - Athens, Greece; Mireia Musquera - Barcelona, Spain*

10:40 Remote transplant learning
Mohamad Zaimi Abdul Wahab - Kuala Lumpur, Malaysia

10:55 How do you make it work in real world?
Sunil Schroff – Chennai, India

11:10 *Discussion panel with audience*

SOLUTION ROOM

Monday, 18 September 2023

10:00 - 11:30
Banquet Hall

Consent for research in donation and transplantation during the end of life period

*Chairs: Jayme Locke – Birmingham, United States
Dominique Martin – Geelong, Australia*

This multidisciplinary session explores some of the common challenges associated with the conduct of transplant research involving potential deceased donors during the end-of-life period, particularly with regard to ethical and legal aspects of consent for participation in research. Each talk will comprise recommendations for good practice that should also help to address potential barriers to the approval of studies by research ethics committees. Attendees will have the opportunity to ask questions and discuss strategies to address common barriers, such as those that arise when seeking to conduct innovative trials or to involve the families of deceased donors in research.

- 10:00 Introduction
Jayme Locke – Birmingham, United States; Dominique Martin – Geelong, Australia
- 10:05 Consent for participation in research and deceased donation - untangling the legal frameworks
Shih-Ning Then – Brisbane, Australia
- 10:25 Making a decision about research in the context of donation - a family's perspective
Julie O'Hara – Alabama, United States
- 10:35 Qualitative research involving families of potential deceased donors - addressing the ethical concerns
Jessie Cooper - London United Kingdom; Zivarna Murphy - London United Kingdom
- 10:55 Discussion
Gabriel Oniscu - Stockholm Sweden; Matthew Weiss - Montreal, Canada

BRIEF ORAL

Monday, 18 September 2023

10:00 - 11:30
Mitropoulos

Looking through the glass – fresh perspectives on ethicolegal and psychosocial aspects of donation and transplantation

*Chairs: Frederike Ambagtsheer - Rotterdam, The Netherlands
Greg Moorlock – Warwick, United Kingdom*

10:00

CLINICAL TRANSLATION AND IMPLEMENTATION OF A BIO-ARTIFICIAL PANCREAS: A QUALITATIVE STUDY EXPLORING THE PERSPECTIVES OF PATIENTS WITH TYPE 1 DIABETES

Dide de Jongh – Rotterdam, The Netherlands

- 10:06 PSYCHOLOGICAL SCREENING AND FOLLOW-UP CARE FOR LIVING LIVER DONORS: 5-YEAR PROSPECTIVE COHORT DATA FROM A SINGLE ACADEMIC CENTRE
Leonieke Kranenburg – Rotterdam, The Netherlands
- 10:12 PSYCHOSOCIAL EVALUATION OF LIVING KIDNEY DONORS IN QATAR – PROCESS AND OUTCOMES OF THE COMMITTEE FOR OVERSIGHT OF LIVING DONATION
Riadh Fadhil – Doha, Qatar
- 10:18 TRANSPLANT EXPERIENCES AND QUALITY OF LIFE IN PATIENTS WHO UNDERWENT AN INCOMPATIBLE KIDNEY TRANSPLANT: A CROSS-SECTIONAL PILOT SURVEY
Emma Massey – Rotterdam, The Netherlands
- 10:24 ANXIETY AND DEPRESSIVE SYMPTOMS AMONG PATIENTS ON DIALYSIS, KIDNEY AND KIDNEY-PANCREAS TRANSPLANT RECIPIENTS
Istvan Mucsi – Toronto, Canada
- 10:30 LONG TERM OUTCOMES OF CHILDREN OF FEMALE KIDNEY TRANSPLANT RECIPIENTS – A RETROSPECTIVE REGISTRY STUDY
Goni Katz-Greenberg – Durham, United States
- 10:36 ANALYSIS OF HEALTH-RELATED QUALITY OF LIFE IN THE LIVER TRANSPLANT PATIENT CONDUCTED MORE THAN 10 YEARS AGO, STATEWIDE STUDY
Fernando García Perez – Madrid, Spain
- 10:42 QUALITATIVE AND QUANTITATIVE RESEARCH ON ASSESSING THE EXPERIENCE OF ONE'S BODY BY LIVING KIDNEY DONORS.
Mateusz Zatorski – Warsaw, Poland
- 10:48 DIFFERENCES BETWEEN PERCEIVED QUALITY OF LIFE AND MEDICAL OUTCOMES IN PATIENTS WITH ADVANCED HEART FAILURE
Marco Valente – Bologna, Italy
- 10:54 PROFESSIONALS' PERSPECTIVES ON REPORTING OF TRAVEL FOR ORGAN TRANSPLANTATION: AN INTERNATIONAL CROSS SECTIONAL STUDY.
Georgina Irish – Adelaide, Australia
- 11:00 THE ORGANIZATION OF THE HUMAN ORGAN TRADE: A COMPARATIVE SCRIPT ANALYSIS BETWEEN LEGAL AND ILLEGAL KIDNEY TRANSPLANTS
Frederike Ambagtsheer - Rotterdam, The Netherlands
- 11:06 IMPLEMENTING A VALUES-DRIVEN POLICY IN A COMPLEX SYSTEM: WHAT HAPPENED WHEN THE SOFT OPT-OUT SYSTEM OF ORGAN DONATION WAS IMPLEMENTED IN ENGLAND?
Leah Mc Laughlin – Cardiff, United Kingdom
- 11:12 ANALYSIS OF JUDICIAL LITIGATION CONCERNING ORGAN TRANSPLANTATION IN ONE OF THE LARGEST EUROPEAN UNIVERSITY HOSPITALS
Francois Cauchy – Geneva, Switzerland

11:18 NATIONAL HEALTH INSURANCE COVERAGE OF ORGAN PERFUSION MACHINES (PM) IMPROVES ACCESS TO TRANSPLANTATION.
Helene Logerot - Saint Denis, France

BRIEF ORAL

Monday, 18 September 2023

10:00 - 11:30

Skalkotas

Complications and infections after kidney transplant

*Chairs: Aisling Courtney - Belfast United, Kingdom
Evangelia Dounousi – Ioannina, Greece*

10:00 PREDICTION OF KIDNEY GRAFT SURVIVAL AMONG DECEASED TRANSPLANT RECIPIENTS IN THE UK: AN ARTIFICIAL INTELLIGENCE APPROACH
Hatem Ali – Coventry, United Kingdom

10:06 REAL-LIFE IMPLEMENTATION OF A STRATEGY BASED ON CMV-SPECIFIC CELL-MEDIATED IMMUNITY TO GUIDE CMV PREVENTIVE THERAPY IN SOLID ORGAN TRANSPLANTATION
Delphine Kervella – Barcelona, Spain

10:12 MACHINE LEARNING MODELS IN RENAL TRANSPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PREDICTIVE PERFORMANCE IN GRAFT SURVIVAL
Usman Haroon – London, United Kingdom

10:18 BURDEN OF REFRACTORY/RESISTANT CYTOMEGALOVIRUS OR CYTOMEGALOVIRUS DRUG INTOLERANCE IN SOLID ORGAN TRANSPLANT RECIPIENTS: EUROPEAN SUBGROUP ANALYSIS
Kimberly Davis – Lexington, United States

10:24 PREVALENCE OF CYTOMEGALOVIRUS ANTIVIRAL DRUG RESISTANCE IN TRANSPLANT RECIPIENTS
Steve Kleiboeker - Lee's Summit, United States

10:30 THE RISK OF VENOUS THROMBOEMBOLISM IS ENHANCED AFTER A CYTOMEGALOVIRUS INFECTION IN KIDNEY TRANSPLANT RECIPIENT
Christophe Masset – Nantes, France

10:36 IMPACT OF PROTON PUMP INHIBITORS IN KIDNEY TRANSPLANT RECIPIENTS
Christophe Masset – Nantes, France

- 10:42 HYPERCHOLESTEROLEMIA IMPAIRED CAPILLARY VEGF AND NITRIC OXIDE AND, IN TURN, DECREASED MICROVASCULAR DENSITY AND TUBULAR VILLIN IN RENAL ALLOGRAFTS.
Binnaz Handan Ozdemir – Ankara, Turkey
- 10:48 ADVERSE OUTCOMES AFTER ALEMTUZUMAB THERAPY FOR KIDNEY TRANSPLANT REJECTION
Lukas van Vugt – Rotterdam, The Netherlands
- 10:54 THE OUTCOME PREDICTION VALUE OF PROTEINURIA AND ALBUMINURIA BY DIFFERENT WAYS OF MEASUREMENT IN KIDNEY TRANSPLANTATION
Qiang Zhang – Guangzhou, China
- 11:00 TUBULORETICULAR INCLUSIONS: A NEW PROGNOSTIC BIOMARKER IN KIDNEY TRANSPLANTATION
Sarah Gleeson – London, United Kingdom
- 11:06 EARLY SURGICAL COMPLICATIONS IN EVEROLIMUS TREATED KIDNEY TRANSPLANT RECIPIENTS: A CLAVIEN-DINDO CLASSIFICATION ANALYSIS
Patrizia Silvestri – Rome, Italy
- 11:12 RISK OF BLEEDING AFTER PERCUTANEOUS GRAFT KIDNEY BIOPSY IN PATIENTS RECEIVING LOW DOSE ASPIRIN A SINGLE CENTER RETROSPECTIVE STUDY
Francesco Fontana – Modena, Italy
- 11:18 IMPACT OF ALLOGRAFT CELLULAR INFLAMMATION ON THE IGA NEPHROPATHY RECURRENCE AFTER KIDNEY TRANSPLANTATION.
Emilio Rodrigo – Santander, Spain

BRIEF ORAL

Monday, 18 September 2023

10:00 - 11:30
MC 3

Molecular transplant immunology

Chairs: Xavier Charmetant – Lyon, France
Maria Kaisar – Oxford, United Kingdom

- 10:06 SINGLE CELL RNA SEQUENCING OF DONOR-REACTIVE T CELLS REVEALS ROLE OF APOPTOSIS IN DONOR-SPECIFIC HYPORESPONSIVENESS OF KIDNEY TRANSPLANT RECIPIENTS
Nicolle Litjens – Rotterdam, The Netherlands
- 10:12 ELDERLY RENAL TRANSPLANT RECIPIENTS HAVE LESS POLYFUNCTIONAL ALLOREACTIVE CD4 T CELLS PRE TRANSPLANT AND LOWER IL-2 MEDIATED T CELL PROLIFERATION
Nicolle Litjens – Rotterdam, The Netherlands

- 10:24 RELEVANCE OF THE BANFF HUMAN ORGAN TRANSPLANT CONSENSUS GENE PANEL FOR DETECTING ANTIBODY AND T-CELL MEDIATED REJECTION OF KIDNEY ALLOGRAFTS
Alessia Giarraputo – Paris, France
- 10:30 DDPCR DETECTION OF MIRNAS FIBROSIS SIGNATURE IN URINE-EVS FROM KIDNEY TRANSPLANTED PATIENTS: A NON-INVASIVE APPROACH TO DETECT KIDNEY FIBROSIS
Marta Clos-Sansalvador – Badalona, Spain
- 10:36 MEK INHIBITION, A NEW THERAPEUTIC APPROACH IN ORGAN TRANSPLANTATION
Gilles Blanco – Nantes, France
- 10:42 DECONVOLUTION ANALYSIS REVEALS CHANGES IN IMMUNE CELL SUBSETS IN PERIPHERAL BLOOD FOR MULTIPLE REJECTION PHENOTYPES FOLLOWING KIDNEY TRANSPLANT
Thomas Whisenant - La Jolla, United States
- 10:48 PRESENCE OF KIR2DL2/S2, KIR2DL5, AND KIR3DL1 MOLECULES IN LIVER RECIPIENTS WITH ALCOHOLIC CIRRHOSIS COULD BE IMPLICATED IN DEATH BY GRAFT FAILURE
Manuel Muro – Murcia, Spain
- 10:54 A NOVEL URINE-BASED LIQUID BIOPSY BIOMARKER FOR RENAL FIBROSIS IN KIDNEY TRANSPLANT
Omar Enrique Taco Sánchez – Barcelona, Spain
- 11:00 NON-INVASIVE DETECTION OF REJECTION IN THE FIRST 2 WEEKS AFTER KIDNEY TRANSPLANTATION USING URINARY CHEMOKINES
Karin Boer – Rotterdam, The Netherlands
- 11:06 ACTIVE IMMUNOLOGICAL PARTICIPATION AND METABOLIC SHUTDOWN OF KIDNEY STRUCTURAL CELLS DURING KIDNEY TRANSPLANT REJECTION
Elisabet Van Loon – Leuven, Belgium
- 11:12 DIRECT IMMUNOPHENOTYPING OF REGULATORY B CELLS AT 3 MONTHS HAVE A PROGNOSTIC VALUE OF IMPROVED GRAFT OUTCOME AND REJECTION RISK IN KIDNEY TRANSPLANT
Inés Perezpayá – Badalona, Spain
- 11:18 Γ/Δ T CELLS IN ANTIBODY-MEDIATED REJECTION: RINGLEADER OR MERE EXECUTORS?
Xavier Charmetant – Lyon, France

JOINT SESSION

Monday, 18 September 2023

10:00 - 11:30 MC 2	Advances in CMV diagnosis and treatment
	<i>Chairs: Hannah Kaminski – Bordeaux, France Luciano Potena – Bologna, Italy</i>
10:00	Update on diagnosis of CMV infection in SOT and HSCT recipients in the era of new antivirals <i>Tiziana Lazzarotto – Bologna, Italy</i>
10:15	Immunological monitoring of CMV infection <i>Hannah Kaminski – Bordeaux, France</i>
10:30	CMV vaccine: have we reached the end? <i>Per Ljungman – Stockholm, Sweden</i>
10:45	Refractory/resistant CMV infection: new options <i>Paolo Grossi – Varese, Italy</i>
11:00	What is missing in the clinical applicability of CMV guidelines? <i>Hans Hirsch - Basel Switzerland</i>
11:15	Q&A

SOLUTION ROOM

Monday, 18 September 2023

10:00 - 11:30 Library	Let's talk about: the strongest people who win battles we know nothing about
	<i>Chairs: Fabienne Dobbels – Leuven, Belgium Ines Mega – Lisbon, Portugal</i>
10:00	Why has nobody told me this before? <i>Liz Schick – Bern, Switzerland</i>
10:20	You are not alone: Mental health challenges for HCP <i>Hannah Maple – London, United Kingdom</i>
10:40	How to address the unmet need? Solutions for patients and HCP <i>Martina de Zwaan – Hannover, Germany</i>
11:00	Discussion panel with audience <i>Fabienne Dobbels – Leuven, Belgium; Stephen Potts - Edinburgh, United Kingdom</i>

FISHBOWL

Monday, 18 September 2023

10:00 - 11:30	From the laparoscope to the robot
----------------------	--

Conference Suite 1

*Chairs: Silvio Nadalin – Tübingen, Germany
Khe Tran – Rotterdam, The Netherlands*

Surgical techniques in transplantation have been static for many years with the exception of laparoscopic approaches to donor-living donor surgery. Will the robot make a difference? How far have we progressed, or will we remain in the realm of open surgery?

- 10:00 Round one | Liver donor: laparoscopy
Ki-Hun Kim - Seoul, Republic of South Korea
- 10:10 Round one | Liver donor: robotic
Dieter Broering - Riyadh Saudi, Arabia
- 10:20 Round one | Rebuttal & Voting
- 10:30 Round two | Kidney donor: laparoscopy
Lucrezia Furian - Padua Italy
- 10:40 Round two | Kidney donor: robotic
Giuliano Testa – Dallas, United States
- 10:50 Round two | Rebuttal & Voting
- 11:00 Round three | Kidney recipient: robotic
Karel Decaestecker – Gent, Belgium
- 11:10 Round three | Liver recipient: robotic
Dieter Broering – Riyadh, Saudi Arabia
- 11:20 Round three | Discussion

SCIENTIFIC SYMPOSIUM

Monday, 18 September 2023

10:00 - 11:30
MC 3.2

Organised by the Vienna Comprehensive Transplant Center: Induction therapies in 2023 in SOT: Evidence and controversies

*Chairs: Rainer Oberbauer – Vienna, Austria
TBC -*

- 10:00 *Overview
Thomas Wekerle – Vienna, Austria*
- 10:10 *Kidney
Klemens Budde – Berlin, Germany; Rainer Oberbauer – Vienna, Austria*
- 10:20 *Liver
Jacques Pirenne – Leuven, Belgium; Thomas Soliman - Vienna, Austria*

- 10:30 *Heart*
Markus J. Barten – Hamburg, Germany; Andreas Zuckermann - Vienna, Austria
- 10:40 *Lung*
Andrew Fisher - Newcastle upon Tyne, United Kingdom; Peter Jaksch - Vienna, Austria
- 10:50 *Panel discussion with all speakers and Patrizia Burra (Padua) and AnnemarieWeißbacher (Innsbruck)*

Markus J. Barten - Hamburg, Germany; Patrizia Burra - Padua, Italy; Klemens Budde - Berlin, Germany; Andrew Fisher - Newcastle upon Tyne, United Kingdom; Peter Jaksch - Vienna, Austria; Jacques Pirenne - Leuven, Belgium; Thomas Soliman - Vienna, Austria; Annemarie Weissenbacher - Innsbruck, Austria; Andreas Zuckermann - Vienna, Austria

FOCUS GROUP

Monday, 18 September 2023

- 10:00 - 11:30**
MC 3.4 **Deceased donor kidney transplantation issues**
*Chairs: Emin Baris Akin – Istanbul, Turkey
Chloe Balleste – Barcelona, Spain*
- 10:00 FIVE-YEAR OUTCOMES OF KIDNEY TRANSPLANTATION FROM DONORS AFTER CIRCULATORY DEATH OLDER THAN 65 YEARS OLD
Maria Ovidia Lopez Oliva – Madrid, Spain
- 10:10 KIDNEY OUTCOMES FROM UNCONTROLLED DONATION AFTER CIRCULATORY DEATH: A LONGITUDINAL COHORT
Ana Pinho – Porto, Portugal
- 10:20 BIOLOGICAL INJURY ASSOCIATED WITH DECEASED DONOR PATHWAYS REFLECT DIFFERENCES IN THE DONOR KIDNEY PROTEOME AND CELLULAR STRESS RESPONSES
Rebecca Vaughan – Oxford, United Kingdom
- 10:30 RISK FACTORS OF ACUTE KIDNEY INJURY IN DECEASED KIDNEY DONORS
Katarina Timkova – Prague, Czech Republic
- 10:40 DONOR CHARACTERISTICS ASSOCIATED WITH EARLY THROMBOTIC MICROANGIOPATHY AFTER KIDNEY TRANSPLANTATION AND OUTCOMES: A SINGLE-CENTER EXPERIENCE.
Peenida Skulratanasak – Bangkok, Thailand
- 10:50 NON-IMMUNOLOGICAL RISK FACTORS AND CLINICAL OUTCOME OF SLOW GRAFT FUNCTION AFTER DECEASED DONOR KIDNEY TRANSPLANTATION.
Chang-Kwon Oh - Suwon, Republic of South Korea

- 11:00 KIDNEY TRANSPLANT SURVIVAL ANALYSIS AND PROGNOSTIC FACTORS AFTER 10 YEARS OF FOLLOW-UP.
Maria Ramos-Cebrián – Valencia, Spain
- 11:10 TRANSPLANT OUTCOME FROM OCTOGENARIAN DONORS: SINGLE KIDNEY TRANSPLANT VERSUS DUAL KIDNEY TRANSPLANT
Arianna Vittori – Padua, Italy

HANDS-ON COURSE

Monday, 18 September 2023

10:00 - 11:30
Ground floor foyer -
Hands on course

Machine Perfusion in my hands: Virtual and interactive LIVER (Group 1)

6 machines for organ perfusion will be available in the wet lab setting. Guided by tutors, participants will follow the steps of liver perfusion. Participants will rotate around the machines/stations every 15 minutes. Additional registration for this session is required. Please register via the Congress website

- 10:00 LifePort Liver Transporter - Organ Recovery Systems
Amelia Hessheimer – Madrid, Spain
- 10:15 VitaSmart - Bridge to life
Damiano Patrono – Turin, Italy
- 10:30 Metra - OrganOx
David Nasralla – London, United Kingdom
- 10:45 Aferetica
Vincent E. de Meijer – Groningen, The Netherlands
- 11:00 EBERS
Daniele Dondossola - Milan, Italy
- 11:15 Liver Assist - Xvivo
Davide Ghinolfi – Pisa, Italy

STATE OF THE ART

Monday, 18 September 2023

11:45 - 13:15
Lambrakis

We are always the same age inside? The role of ageing in organ transplantation

Chairs: *Menna Clatworthy – Cambridge, United Kingdom*
Diethard Monbaliu – Leuven, Belgium

In an effort to increase transplant numbers, we increasingly utilise organs from older donors. Some function well, whilst others have less good outcomes. In parallel, we are also considering older patients as transplant recipients, with varying levels of frailty that might lead to a more difficult post-transplant course. In this session, we will discuss the molecular features of organ ageing, and how organs and transplant recipients might be assessed to assist with decision-making on wait-listing and organ utilisation respectively. We will hear about how the negative effects of ageing can be influenced by the microbiome, and potentially reversed by targeting senescent cells within organs.

- 11:45 Organ-specific temporal changes in the molecular features of ageing
Menna Clatworthy – Cambridge, United Kingdom
- 12:05 The Gut microbiome and healthy ageing and longevity
Herbert Tilg – Innsbruck, Austria
- 12:25 Can we restore the regenerative capacity of old kidneys?
David Ferenbach – Edinburgh, United Kingdom
- 12:45 Age versus frailty in transplant recipients
Jasper Iske – Boston, United States
- 13:05 *Discussion & Summary*

STATE OF THE ART

Monday, 18 September 2023

11:45 - 13:15
Trianti

Lost in transplantation: Impact of digitalisation of care

Chairs: *Fabienne Dobbels – Leuven, Belgium*
Rainer Oberbauer – Vienna, Austria

The use of electronic devices and modern electronic technologies (eHealth) can undoubtedly improve clinical outcome of transplant recipients and reduce cost of health care. What are hurdles in implementing eHealth in clinical practice? What about patient preferences and required health care personnel technical skills to support patient needs? eHealth applications generate large amounts of data, which can be processed by methods of artificial intelligence (AI) to generate automatic algorithms to support patient decisions. What is ready for prime time? AI can provide automated analysis of digitalised slides of transplant pathology. Where do we stand with automated pathology readings in solid organ transplantation? Can AI overcome the problem of shortage of transplant pathologists? Implementation of large-scale clinical research is increasingly demanding nowadays, because of the logistic and financial burden. The recent mandatory requirement that future clinical studies collect patient reported outcomes (PROs) might make research a prohibitive task for Academia. How can digital technology fix the problem?

11:45 Introduction

- 11:50 Digital solutions to traditional problems: technology, software and policy
Klemens Budde – Berlin, Germany
- 12:10 Moving AI empowered algorithms into telemedicine clinical practice
Carmen Lefaucheur – Paris, France
- 12:30 Gamification of healthcare - a winning strategy?
Rundgren Olli – Jyväskylä, Finland
- 12:50 Large-scale clinical research and PROs: digital solutions to make it easy
Michelle Willicombe – London, United Kingdom

STATE OF THE ART

Monday, 18 September 2023

11:45 - 13:15
Library

Making a difference with shared decision-making

*Chairs: Pisana Ferrari – Udine, Italy
Raj Thuraiingham – London, United Kingdom*

This session provides attendees with an overview of current best practices in shared decision-making (SDM) and a series of talks exploring a range of ways in which SDM can have a powerful impact and improve equity in access to transplantation. Specifically, talks will explore the role of SDM and tools to support risk evaluation and decision-making in donation and transplantation; the role of SDM in empowering patient advocacy for transplant care; and the role of SDM in supporting decision-making and inclusion of persons with disabilities in transplantation.

- 11:45 Best practices in contemporary shared decision-making
Natalie Joseph-Williams - Cardiff, United Kingdom
- 12:05 Shared decision-making and risk evaluation - the role of decision-aids
Alessandra Grossi – Varese, Italy
- 12:25 Shared decision-making, empowerment and patient advocacy
Vivekanand Jha - New Delhi, India
- 12:45 Supported and shared decision-making in transplantation for people with disabilities
Keren Ladin – Boston, United States
- 13:05 Discussion & wrap-up

TV-STUDIO

Monday, 18 September 2023

13:15 - 13:45
Muses Foyer

X million Euros of EU investment – focus on four vital projects

Host: Jacqui Thornton - Winchester United Kingdom

*Guests: Ekaterine Berishvili – Geneva, Switzerland
Hannah Kaminski – Bordeaux, France
Luciano Potena – Bologna, Italy*

MODERATED EPOSTER SESSION

Monday, 18 September 2023

14:15 - 15:15
MEP-1

Moderated poster session on cardiac transplantation

Chair: Stephen Clark - Newcastle upon Tyne, United Kingdom

- 14:15 TRANSPLANT RECIPIENT OUTCOMES WITH EXTENDED CRITERIA DONORS: AN ANALYSIS OF THE GUARDIAN HEART REGISTRY
Andreas Zuckermann – Vienna, Austria
- 14:15 VALIDATION OF THE 2014 CONSENSUS PRIMARY GRAFT DYSFUNCTION DEFINITION USING THE GUARDIAN-HEART REGISTRY
Andrea Eixeres Esteve – Madrid, Spain
- 14:15 LOWER BASOPHIL COUNT AFTER ANTI-THYMOCYTE GLOBULIN INDUCTION IS ASSOCIATED WITH A LOWER INCIDENCE OF CARDIAC ALLOGRAFT REJECTION
Bosko Skoric – Zagreb, Croatia
- 14:15 HEART TRANSPLANTATION IN ADULTS WITH PERIPARTUM CARDIOMYOPATHY
Nadegda Koloskova – Moscow, Russian Federation
- 14:15 INFLAMMATION IN BRAIN DEATH DONORS PROTECTS TO PRIMARY GRAFT DYSFUNCTION IN HEART TRANSPLANTATION
Gabriel Moreno-Gonzalez – Barcelona, Spain
- 14:15 LOCAL LABORATORY-RUN DONOR-DERIVED CELL-FREE DNA TESTING IN STABLE HEART TRANSPLANTATION: TWO-CENTRE EUROPEAN FEASIBILITY STUDY
Tímea Teszák – Budapest, Hungary
- 14:15 CARDIORENAL PROTECTION WITH NEWER ANTIDIABETIC DRUGS IN HEART TRANSPLANTATION: A CASE REPORT.
Walter Baronti – Grosseto, Italy
- 14:15 LIVER AFTER HEART AND COMBINED HEART LIVER TRANSPLANTATION IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS: A CROATIAN EXPERIENCE
Maja Sremac – Zagreb, Croatia

- 14:15 LEFT VENTRICULAR ASSIST DEVICES AS BRIDGE-TO-TRANSPLANTATION IN A LOW ORGAN DONOR ENVIRONMENT
Dimitris Miliopoulos – Kallithea, Greece
- 14:15 INITIAL EXPERIENCE WITH LOCAL LABORATORY RUN ASSAY TO DETECT DONOR-DERIVED CELL FREE DNA FOR NONINVASIVE DIAGNOSIS OF ACUTE MYOCARDIAL REJECTION
Stefania Manno – Bologna, Italy

MODERATED EPOSTER SESSION

Monday, 18 September 2023

- 14:15 - 15:15**
MEP-2 **Moderated poster session on infections complications in kidney transplantation**
Chair: Raj Thuraisingham – London, United Kingdom
- 14:15 BKEVER STUDY: BKV CLEARANCE IN KIDNEY TRANSPLANT RECIPIENTS AFTER REPLACEMENT OF MMF BY EVEROLIMUS AND REDUCTION OF IMMUNOSUPPRESSION
Sophie Caillard – Strasbourg, France
- 14:15 OUTCOME OF KIDNEY TRANSPLANTS FROM VIREMIC AND NON-VIREMIC HEPATITIS C VIRUS POSITIVE DONORS INTO NEGATIVE RECIPIENTS: RESULTS OF THE SPANISH REGISTRY
Antonio Franco – Alicante, Spain
- 14:15 LATE OPPORTUNISTIC INFECTIONS AFTER KIDNEY TRANSPLANTATION IN THE ERA OF CONTEMPORARY IMMUNOSUPPRESSION: ROOM FOR IMPROVEMENT
Marie Matignon – Creteil, France
- 14:15 PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN KIDNEY TRANSPLANT RECIPIENTS : A RETROSPECTIVE MULTICENTER NATIONWIDE COHORT STUDY
Adelaide Sanson – Paris, France
- 14:15 LONG-TERM OUTCOMES OF LIVE KIDNEY DONORS WITH HEPATITIS B VIRUS INFECTION: A PROPENSITY SCORE-MATCHED COHORT STUDY
Saifu Yin – Chengdu, China
- 14:15 COMPASSIONATE USE PROGRAMME OF MARIBAVIR FOR ADULT PATIENTS WITH POST-TRANSPLANT REFRACTORY CMV INFECTION
Nassim Kamar – Toulouse, France
- 14:15 KIDNEY TRANSPLANTATION FROM DECEASED DONORS WITH BACTEREMIA
Maria Darema – Athens, Greece

- 14:15 ADVANTAGES OF MONITORING CELLULAR IMMUNE RESPONSE AGAINST CYTOMEGALOVIRUS IN RENAL TRANSPLANTATION.
Javier Arias-Alcalá – Cordoba, Spain
- 14:15 LONG-TERM IMMUNE DYSREGULATION AFTER RITUXIMAB INDUCTION IN ABO INCOMPATIBLE LIVING-DONOR RENAL TRANSPLANTATION – IMPACT ON CHRONIC BK VIRUS INFECTION
Rolf Weimer – Giessen, Germany

MODERATED EPOSTER SESSION

Monday, 18 September 2023

- 14:15 - 15:15** **Moderated poster session on COVID-19**
MEP-3 **Chair:** **Corinne Antoine – Paris, France**
- 14:15 SAFETY AND EFFICACY OF TIXAGEVIMAB/CILGAVIMAB FOR PRE-EXPOSURE PROPHYLAXIS IN KIDNEY TRANSPLANT RECIPIENTS: A MULTICENTER RETROSPECTIVE COHORT STUDY
Simona Simone – Bari, Italy
- 14:15 THE IMPACT OF MONOCLONAL ANTIBODY AGAINST SARS-COV2 AND VACCINATION ON OUTCOMES IN KIDNEY TRANSPLANT RECIPIENTS WITH COVID-19
Bruce Gelb - New York, United States
- 14:15 REPEATED COVID-19 VACCINATION OF IMMUNOCOMPROMISED KIDNEY TRANSPLANT RECIPIENTS LEADS TO THE INDUCTION OF A FUNCTIONAL T CELL SUBSET ASSOCIATED WITH ANTIBODY PRODUCTION
Yvette den Hartog – Rotterdam, The Netherlands
- 14:15 INCIDENCE AND SEVERITY OF COVID-19 IN RELATION TO ANTI-RBD IGG ANTIBODY LEVEL AFTER COVID-19 VACCINATION IN KIDNEY TRANSPLANT RECIPIENTS
Céline Imhof – Groningen, The Netherlands
- 14:15 TH1-DOMINANT CYTOKINE RESPONSES IN KIDNEY PATIENTS AFTER COVID-19 MRNA-1273 VACCINATION ARE ASSOCIATED WITH POOR HUMORAL RESPONSES
Yvette den Hartog – Rotterdam, The Netherlands
- 14:15 REPEATED COVID-19 VACCINATION ENHANCES MEMORY T-CELL IL-21 AND MEMORY B-CELL RESPONSES IN IMMUNOCOMPROMISED KIDNEY TRANSPLANT RECIPIENTS
S.R.K. Reshwan Malahe – Rotterdam, The Netherlands
- 14:15 REAL-WORD EXPERIENCE OF SOTROVIMAB TO PREVENT SEVERE COVID-19 IN KIDNEY TRANSPLANT RECIPIENTS: RESULTS FROM A NATIONAL STUDY
Marie Matignon – CRETEIL, France

- 14:15 THE IMPACT OF EARLY THERAPIES FOR COVID IN A GROUP OF KIDNEY TRANSPLANT PATIENTS
Elena Conto – Verona, Italy
- 14:15 SERONEGATIVE TRANSPLANT PATIENTS REMAIN AT SIGNIFICANT RISK OF SARS-COV-2 INFECTION AND COMPLICATIONS; WE ARE NOT OUT OF THE WOODS YET
Laszlo Szabo – Cardiff, United Kingdom
- 14:15 SARS-COV-2 ANTIBODIES RESPONSE AFTER VACCINATIONS IN KOREAN KIDNEY TRANSPLANT RECIPIENTS
Kina Kim - Seoul, Republic of South Korea

PLENARY

Monday, 18 September 2023

15:00 - 16:30
Lambrakis

Overcoming the organ shortage: Thinking outside the box

Chairs: *Beatriz Dominguez-Gil – Madrid, Spain*
Stefan Schneeberger – Innsbruck, Austria

This plenary session will address innovative strategies to fight organ shortage in countries with developed organ donation programs from a multidisciplinary perspective. The speakers will give insight into the role of algorithms and artificial intelligence aiming to enhance the equitable answer to the patients urgently waiting for an organ as well as the new solutions coming from regenerative medicine and bioengineering promising to revolutionize the transplant field

- 15:00 Introduction: setting the scene for the session – current strategies
Stefan Schneeberger – Innsbruck, Austria
- 15:10 Can AI better address the gap between supply and demand?
Dorry Segev - New York, United States
- 15:30 Can bioengineering be a solution?
Pedro Miguel Baptista – Zaragoza, Spain
- 15:50 Reprogramming the blood group?
Sarah Hosgood – Cambridge, United Kingdom
- 16:10 Reconsidering the demand – one organ for life?
Marlies Reinders – Rotterdam, The Netherlands

PLENARY

Monday, 18. September 2023

17:00 - 18:30

Leonardo Da Vinci

Lambrakis

Chairs: Ekaterine Berishvili – Geneva, Switzerland
Oriol Bestard – Barcelona, Spain
Menna Clatworthy – Cambridge, United Kingdom
Marta Crespo – Barcelona, Spain
Ina Jochmans – Leuven, Belgium
Jayme Locke – Birmingham, United States
Umberto Maggiore – Parma, Italy
Gabriel Oniscu – Stockholm, Sweden
Luciano Potena – Bologna, Italy

- 17:00 BCL-6 INHIBITORS POTENTLY INHIBIT ALLOGENEIC T CELL ACTIVATION - A NOVEL MECHANISM OF IMMUNOSUPPRESSION?
Louisa Steines – Regensburg, Germany
Challenged by Jury member Oriol Bestard - Barcelona, Spain
- 17:10 ENGINEERED T CELLS OVERCOMING REJECTION BY ANTIBODIES (CORAT CELLS): SELECTIVE TARGETING OF ALLOREACTIVE B CELLS IN SOLID ORGAN TRANSPLANTATION
Anna Christina Dragon – Hannover, Germany
Challenged by Jury member Ekaterine Berishvili - Geneva, Switzerland
- 17:20 COMBINATION OF TCR-DEFICIENT CAR-TREGS AND ANTI-CD3 MONOCLONAL ANTIBODIES TO PROMOTE TRANSPLANT TOLERANCE
Julien Zuber – Paris, France
Challenged by Jury member Menna Clatworthy - Cambridge, United Kingdom
- 17:30 RECIPIENT FCGR3A POLYMORPHISM INFLUENCES THE PROGNOSIS OF AMR AND THE RESPONSE TO IVIG IN RENAL TRANSPLANTATION
Alice Koenig – Lyon, France
Challenged by Jury member Umberto Maggiore - Parma, Italy
- 17:40 CLINICAL VALIDATION OF AUTOMATED URINARY CHEMOKINE ASSAYS FOR NON-INVASIVE DETECTION OF KIDNEY TRANSPLANT REJECTION: A PROSPECTIVE COHORT STUDY
Elisabet Van Loon – Leuven, Belgium
Challenged by Jury member Jayme Locke - Birmingham, United States
- 17:50 RACE-FREE EGFR EQUATION IN KIDNEY RECIPIENTS: A DEVELOPMENT AND VALIDATION STUDY
Marc Raynaud – Paris, France
Challenged by Jury member Marta Crespo - Barcelona, Spain
- 18:00 DONOR-DERIVED CELL FREE DNA AS A SURVEILLANCE TOOL FOR ACUTE CELLULAR REJECTION IN HEART TRANSPLANTATION: RESULTS FROM THE FREE-DNA CAR STUDY
Marta Jimenez-Blanco – Madrid, Spain
Challenged by Jury member Luciano Potena - Bologna, Italy

- 18:10 LONG-TERM OUTCOMES AFTER HYPOTHERMIC OXYGENATED MACHINE PERFUSION (HOPE) AND TRANSPLANTATION OF 1291 DONOR LIVERS USING REAL-WORLD DATA
Janina Eden – Zürich, Switzerland
- Challenged by Jury member Ina Jochmans -Leuven, Belgium*

BRIEF ORAL

Monday, 18 September 2023

- 17:00 - 18:30**
Trianti **Kidney allograft immunopathology**
*Chairs: Olivier Aubert – Paris, France
Candice Roufosse – London, United Kingdom*
- 17:00 HUMAN LEUKOCYTE ANTIGEN MISMATCHES AND GRAFT OUTCOMES IN THE CONTEMPORARY ERA OF IMMUNOSUPPRESSION: A UK REGISTRY ANALYSIS
Raja Rashid – Birmingham, United Kingdom
- 17:06 PATTERNS OF MAJOR-HISTOCOMPATIBILITY-COMPLEX (MHC) CLASS I-RELATED CHAIN A (MICA) ALLOIMMUNE RESPONSES REVEALED BY MACHINE LEARNING ALGORITHMS
Angeliki Vittoraki – ATHENS, Greece
- 17:12 EARLY SYSTEMIC SUBCLINICAL INFLAMMATION SCORES ARE ASSOCIATED WITH SIGNIFICANT RISK FOR LONG-TERM KIDNEY GRAFT FAILURE
Torbjørn Heldal – Oslo, Norway
- 17:18 EARLY SYSTEMIC VASCULAR INFLAMMATION SCORE IS ASSOCIATED WITH I-IFTA IN BIOPSIES 6-WEEKS AND 1-YEAR AFTER KIDNEY TRANSPLANTATION
Torbjørn Heldal – Oslo, Norway
- 17:24 CLINICAL AND MOLECULAR SPECTRUM OF V-LESION
Anna Buxeda – Barcelona, Spain
- 17:30 PRECISE COMPOSITION AND LOCALIZATION OF THE INFLAMMATORY BURDEN OF 125 KIDNEY TRANSPLANT REJECTIONS: DETERMINANTS AND PROGNOSIS IMPACT
Marion Rabant – Paris, France
- 17:36 HIGH REJECTION RATES WITH NO INDUCTION+RAPID STEROID WITHDRAWAL IN WELL MATCHED LIVING DONOR KIDNEY TRANSPLANTS WITH PREFORMED TCELL ALLOREACTIVITY
Maria Meneghini – Barcelona, Spain

- 17:42 EUROPEAN SURVEY ON CLINICAL PRACTICE OF DETECTING AND TREATING T-CELL MEDIATED KIDNEY TRANSPLANT REJECTION
Priyanka Koshy – Leuven, Belgium
- 17:48 PROFILING THE IMMUNE CELL INFILTRATE OF KIDNEY ALLOGRAFTS IN RELATION TO THE EXISTING BANFF HISTOLOGY
Thibaut Vaulet – Leuven, Belgium
- 17:54 OUTCOMES OF STANDARD VERSUS DELAYED INITIATION OF TACROLIMUS IN RECIPIENTS OF DONATION AFTER CARDIOCIRCULATORY DEATH KIDNEY
Lan Zhu – Wuhan, China
- 18:00 REAL-LIFE ASSESSMENT OF NON-INVASIVE MOLECULAR BIOMARKERS FOR PREDICTING CLINICAL AND SUBCLINICAL HISTOLOGICAL LESIONS IN KIDNEY TRANSPLANT RECIPIENTS
Joana Sellares – Barcelona, Spain
- 18:06 INHIBITION OF MTOR PATHWAY PREVENTS MISSING SELF-INDUCED NK CELLS-MEDIATED REJECTION
Olivier Thauvat – Lyon, France
- 18:12 THE INFLUENCE OF MYCOPHENOLATE MOFETIL ON TOP OF TACROLIMUS ON BLOOD PRESSURE IN A RANDOMIZED COHORT OF KIDNEY TRANSPLANT RECIPIENTS.
Zainab Al Fatly – Rotterdam, The Netherlands
- 18:18 A COMPREHENSIVE MONITORING OF MEDICATION ADHERENCE OVER THE FIRST TWO YEARS AFTER RENAL TRANSPLANTATION - A PROSPECTIVE, NON-INTERVENTIONAL STUDY.
Frederik Haupenthal – Vienna, Austria

DARE TO ASK

Monday, 18 September 2023

17:00 - 18:30
Mitropoulos

When the tension gets too intense- ethical and clinical challenges in the ICU in donation and transplantation.

*Chairs: Željka Gavranović - Zagreb, Croatia
Eduardo Sousa - Coimbra Portugal*

The aim of this session is to go in-depth into the role of ICU professionals in organ donation. Major ethical and clinical challenges in the ICU context will be treated, including their role in brain death donors DBD, Donors after cardiac death DCD, pediatric DCD donors and donations included in end-of-life care ICOD. Thus it will cover both ICU, donation and pediatric aspects. The session will point out the need to bring the multi-professional team to the table to widen the perspective on realistic care. DCD in the context of end-of-life care, with an emphasis on potential perspectives/attitudes of HCP and families about decision-making

15:00	Introduction <i>Željka Gavranović Zagreb, Croatia; Eduardo Sousa – Coimbra, Portugal</i>
15:05	Implementation of intensive care oriented to organ donation <i>Sara Alcántara Carmona – Madrid, Spain</i>
15:20	Role and perceptions of ICU professionals on DCD <i>Matthieu Le Dorze – Paris, France</i>
15:35	Paediatric perspective on DCD <i>Janet Mattsson – Stockholm, Sweden</i>
15:50	Maximization of deceased donor detection in ICU through innovative digital tools <i>Marco Sacchi – Milan, Italy</i>
16:05	Discussion Panel

FULL ORAL

Monday, 18 September 2023

17:00 - 18:30 Library	Pediatric Transplantation around the world <i>Chairs: Silvio Nadalin – Tübingen, Germany Jelena Stojanovic – London, United Kingdom</i>
17:00	BELATACEPT OUTCOMES IN PEDIATRIC KIDNEY TRANSPLANTATION: AN INTERNATIONAL MULTICENTER STUDY <i>Julien Hogan – Paris, France</i>
17:10	LONGITUDINAL DYNAMICS OF SOLUBLE IMMUNE MEDIATORS IN PAEDIATRIC LIVER TRANSPLANTATION IDENTIFIED SIGNATURES ASSOCIATED WITH A FREEDOM OF REJECTION <i>Evgeny Chichelnitskiy – Hannover, Germany</i>
17:20	MOLECULAR HLA MISMATCHING FOR PREDICTION OF PRIMARY HUMORAL ALLOIMMUNITY AND GRAFT FUNCTION DETERIORATION IN PAEDIATRIC KIDNEY TRANSPLANTATION. <i>Jon Jin Kim – Nottingham, United Kingdom</i>
17:30	CAN HOPE MITIGATE ISCHEMIA-REPERFUSION INJURY IN EX-SITU SPLIT GRAFTS? A COMPARATIVE STUDY WITH LIVING DONATION IN PEDIATRIC LIVER TRANSPLANTATION <i>Guillaume Rossignol – Lyon, France</i>
17:40	‘UNIQUE’ STUDY - A 20 YEAR UK NATIONAL STUDY ON CLINICAL OUTCOMES AND QUALITY OF LIFE IN CHILDREN WITH MULTI-ORGAN TRANSPLANTS <i>Alicia Paessler – London, United Kingdom</i>

- 17:50 MONITORING OF TORQUE-TENO VIRUS LOADS IN PEDIATRIC KIDNEY TRANSPLANT RECIPIENTS MAY PREDICT OPPORTUNISTIC VIRAL INFECTIONS DURING FOLLOW-UP
Fabian Eibensteiner – Vienna, Austria
- 18:00 NATIONAL LIVER ALLOCATION POLICIES FOR PEDIATRIC LIVER TRANSPLANTATION ACHIEVE OPTIMAL OUTCOMES: INTENTION-TO-TREAT ANALYSIS OF ITALIAN WAITING LIST
Silvia Trapani – Rome, Italy
- 18:10 PEDIATRIC KIDNEY TRANSPLANT PROGRAM IN WAR CONDITIONS
Oleg Godik – Kyiv, Ukraine

STORYTELLING

Monday, 18 September 2023

17:00 - 18:30
Conference Suite 1

Patient storytelling

Chairs: *John Boletis – Athens, Greece*
Penilla Gunther – Stockholm, Sweden

This session will give the stage to organ recipients (lung, heart, kidney and liver) to tell their stories. A panel discussion with members of the medical profession will follow including a surgeon, specialist nurse, social worker and psychologist.

- 15:00 Introduction
John Boletis – Athens, Greece
- 15:05 My transplant life journey
Guðmundur Felix Grétarsson – Lyon, France
- 15:20 Dealing with unknown
TBC
- 15:35 Getting my life back
Pisana Ferrari – Udine, Italy
- 15:50 What it meant to save lives
Lisa Wilson – Hornchurch, United Kingdom
- 16:05 Panel discussion on patient experience, with moderator
Jacqui Thornton – Winchester, United Kingdom

BRIEF ORAL

Monday, 18 September 2023

- 17:00 - 18:30**
MC 3.2
- Contemporary heart transplantation: scores, pumps, cells and much more**
*Chairs: Marco Masetti – Bologna, Italy
Martin Schweiger – Zurich, Switzerland*
- 17:00 IMAGING AND FUNCTIONAL EVALUATION OF THE EFFECT OF TRANSPLANTATION OF MESENCHYMAL STEM CELLS IN EXPERIMENTAL MODEL OF MYOCARDIAL INFARCTION.
Antonella Koutela – Athens, Greece
- 17:06 TRANSPLANTING PATIENTS WITH AMYLOIDOTIC CARDIOMYOPATHY: A DREAM FOR FEW
Alessio Aloisio - Bologna Italy
- 17:12 *THE FIRST IMPLANT OF A BIOARTIFICIAL TOTAL ARTIFICIAL HEART IMPLANTATION IN A PATIENT WITH SEVERE PULMONARY HYPERTENSION.*
Lucrezia Palmieri – Naples, Italy
- 17:18 MULTIDRUG-RESISTANT ORGANISMS IN CRITICAL CARE AND 30-DAY OUTCOMES OF HEART TRANSPLANT PATIENTS
Sophia Hatzianastasiou – Athens, Greece
- 17:24 OUTCOME OF HEART TRANSPLANT BRIDGED WITH VENO-ARTERIAL EXTRACORPOREAL MEMBRANE OXYGENATION: A SINGLE CENTER EXPERIENCE
Giacomo Ruzzenenti – Milan, Italy
- 17:30 HEART TRANSPLANT AFTER VENO-ARTERIAL EXTRACORPOREAL MEMBRANE OXYGENATION SUPPORT: MID-TO LONG TERM OUTCOMES FROM A THREE-CENTERS REGISTRY
Alessandra Francica – Verona, Italy
- 17:36 HEART TRANSPLANT SURVIVAL OUTCOMES: ROLE OF DONOR-TRANSMITTED ATHEROSCLEROSIS
Stepan Sakhovskiy – Moscow, Russian Federation
- 17:42 POST-OPERATIVE INFECTIONS AND KIDNEY DYSFUNCTION IN HEART TRANSPLANT RECIPIENTS: A DEADLY BOND
Maria Francesca Scuppa – Bologna, Italy
- 17:48 VALIDATION OF THE CLINICAL UTILITY OF MICRORNA AS NON-INVASIVE BIOMARKERS OF CARDIAC REJECTION: A PROSPECTIVE LONGITUDINAL MULTICENTER STUDY.
Guillaume Coutance – Paris, France
- 17:54 THE DIAGNOSTIC VALUE OF MIR-339 FOR CORONARY STENOSIS OF CARDIAC ALLOGRAFT
Sofya Sharapchenko – Moscow, Russian Federation
- 18:00 THE IMPACT OF EXERCISE TRAININGS ON PHYSICAL CAPACITY AND QUALITY OF LIFE AFTER HEART TRANSPLANTATION
Maria Simonenko - Saint-Petersburg, Russian Federation

- 18:06 MICRORNA-101 PLASMA LEVEL: DIAGNOSTIC AND PROGNOSTIC VALUE FOR CARDIAC GRAFT ACUTE CELLULAR REJECTION
Sofya Sharapchenko – Moscow, Russian Federation
- 18:12 DEVELOPMENT AND VALIDATION OF SPECIFIC POST-TRANSPLANT RISK SCORES ACCORDING TO THE TRANSPLANT ERA: A UNOS COHORT ANALYSIS.
Guillaume Coutance – Paris, France
- 18:18 GRAFT REMODELING AFTER THORACIC TRANSPLANTATION: MIR-339 AND GALECTIN-3 IN THE DIAGNOSIS OF STRUCTURAL CHANGES
Sofya Sharapchenko - Moscow, Russian Federation

FOCUS GROUP

Monday, 18 September 2023

- 17:00 - 18:30**
MC 3.4 **Access to transplantation & donation: is luck involved?**
*Chairs: Fabienne Dobbels – Leuven, Belgium
Nichon Jansen – Leiden, The Netherlands*
- 17:00 THE KIDNEY DISTRIBUTION SYSTEM FOR TRANSPLANTATION IN CHILE EXPLAINED ACCORDING TO GAME THEORY: HOW THEORETICAL GENEROSITY TRANSFORMS INTO SELFISHNESS
Francisca Gonzalez Cohens – Santiago, Chile
- 17:10 IMPROVING THE ACCESS TO HEART TRANSPLANTATION FOR FOREIGN PATIENTS OVER 10 YEAR PERIOD
Giada Giovannelli – Bologna, Italy
- 17:20 APOL1 GENETIC RISK FACTORS ELIMINATES POTENTIAL LIVING KIDNEY DONORS
Bruce Gelb - New York, United States
- 17:30 GENDER DISPARITY TO ACCESS TO KIDNEY TRANSPLANTATION IN TURKEY: 10-YEARS EVALUATION
Yaprak Sarıgöl Ordın - Izmir Turkey
- 17:40 LOW FEMALE ACCESS TO KIDNEY TRANSPLANTATION AND POST-TRANSPLANT PREGNANCY
Patrizia Silvestri – Rome, Italy
- 17:50 EXCELLENCE IN ORGAN TRANSPLANTATION – A QUALITATIVE STUDY OF GENDER SPECIFIC CARE NEEDS IN TRANSPLANTATION
Claire Williment – London, United Kingdom

- 18:00 LANGUAGE BARRIER AND LUNG TRANSPLANTATION: A DIFFICULT-TO-TREAT CASE
Marco Valente – Bologna, Italy
- 18:10THE THE GRAPHIC NOVEL “THE NEW US” TO SUPPORT DOCTOR-PATIENTS RELATIONSHIP IN TRANSPLANT PATIENT CARE-PATHWAY
Enrica Baraldi - Parma, Italy

HANDS-ON COURSE

Monday, 18 September 2023

17:00 - 18:30
Ground floor foyer -
Hands on course

Machine Perfusion in my hands: Virtual and interactive LIVER (Group 2)

6 machines for organ perfusion will be available in the wet lab setting. Guided by tutors, participants will follow the steps of liver perfusion. Participants will rotate around the machines/stations every 15 minutes.

Additional registration for this session is required. Please register via the Congress website

- 17:00 LifePort Liver Transporter - Organ Recovery Systems
Amelia Hessheimer – Madrid, Spain
- 17:15 VitaSmart - Bridge to life
Damiano Patrono – Turin, Italy
- 17:30 Metra - OrganOx
David Nasralla – London, United Kingdom
- 17:45 EBERS
Thamara Perera – Birmingham, United Kingdom
- 18:00 Aferetica
Daniele Dondossola - Milan, Italy
- 18:15 Liver Assist - Xvivo
Davide Ghinolfi – Pisa, Italy

Tuesday, 19. September 2023

FULL ORAL

Tuesday, 19 September 2023

08:00 - 09:30

Lambrakis

Kidney immunology and HLA mismatch analysis

Chairs: *Sebastiaan Heidt – Leiden, The Netherlands*
Alice Koenig – Lyon, France

08:00

ASSOCIATION OF PIRCHE-II SCORES WITH KIDNEY ALLOGRAFT ANTIBODY-MEDIATED REJECTION: A POPULATION-BASED STUDY
Zeynep Demir – Paris, France

08:10

NON-HLA RECIPIENT GENOTYPES ASSOCIATE WITH INCREASED RISK OF ANTIBODY-MEDIATED KIDNEY GRAFT REJECTION
Sophie Limou – Nantes, France

08:20

IMPACT OF HLA EVOLUTIONARY DIVERGENCE AND EPLET MISMATCHES ON KIDNEY ALLOGRAFT REJECTION AND OUTCOME: A POPULATION-BASED STUDY
Zeynep Demir – Paris, France

08:30

ALLOIMMUNE RISK STRATIFICATION IN KIDNEY TRANSPLANTATION - DEVELOPMENT AND VALIDATION OF A NOVEL HLA MOLECULAR MISMATCH ALGORITHM
Hannah Charlotte Copley – Cambridge, United Kingdom

08:40

NON-A1/NON-A1B TO B BLOOD GROUP DECEASED DONOR KIDNEY TRANSPLANT: A LARGE AND SUCCESSFUL SINGLE CENTER EXPERIENCE
Hasan Khamash – Phoenix, United States

08:50

ANTI-HLA I IGG FC AGALACTOSYLATION DRIVES DIRECT ENDOTHELIAL CELL ACTIVATION VIA IFNA PATHWAY
Anaïs BEYZE – Montpellier, France

09:00

MULTIPARAMETER MASS SPECTROMETRY DECIPHERS SPECIFIC CIRCULATING NATURAL KILLER TCELL SUBSETS PROTECTING KIDNEY TRANSPLANT PATIENTS FROM CMV INFECTION
Laura Donadeu – Barcelona, Spain

09:10

SPATIAL PROFILING OF THE KIDNEY ALLOGRAFT UNRAVELS A CENTRAL ROLE OF FCYRIII+ INNATE IMMUNE CELLS IN REJECTION
Baptiste Lamarthée – Leuven, Belgium

FULL ORAL

Tuesday, 19 September 2023

08:00 - 09:30

Trianti

Transplant Plus: Regenerative therapies and Xenotransplantation

Chairs: Nuria Montserrat – Barcelona, Spain

Fotios Sampaziotis – Cambridge, United Kingdom

08:00

AUTOMATED DETECTION AND QUANTIFICATION OF IMMUNE CELL INFILTRATES IN THE TWO FIRST SUCCESSFUL PIG-TO-HUMAN KIDNEY XENOTRANSPLANTS

Erwan Morgand – Paris, France

08:10

MULTIMODAL DEEP PHENOTYPING OF GENETICALLY MODIFIED PIG KIDNEY XENOGRAFTS TRANSPLANTED TO HUMAN RECIPIENTS REVEALS ANTIBODY-MEDIATED REJECTION

Valentin Goutaudier – Paris, France

08:20

HYDROGEL-BASED, PREVASCULARIZED, RETRIEVABLE ENDOCRINE CONSTRUCT TO TREAT TYPE 1 DIABETES

Fanny Lebreton – Geneva, Switzerland

08:30

BIOENGINEERING OF VASCULARIZED INSULIN-SECRETING ORGANOID FOR TYPE 1 DIABETES CELL THERAPY

Laura Mar Fonseca – Geneva, Switzerland

08:40

EXTRAHEPATIC BILE DUCT ORGANOID AS A MODEL TO STUDY ISCHEMIA/REPERFUSION INJURY DURING LIVER TRANSPLANTATION

Henrik Junger – Regensburg, Germany

08:50

GENERATION OF 'UNIVERSAL' LOW-IMMUNOGENIC HUMAN PRIMARY CHOLANGIOCYTE ORGANOID FOR TREATMENT OF BILE DUCT DISORDERS

Sandra Petrus-Reurer – Cambridge, United Kingdom

09:00

MODELING KIDNEY FIBROSIS AND EXPLORING THE ANTI-FIBROTIC ACTIVITY OF MEMBRANE PARTICLES GENERATED FROM MESENCHYMAL STROMAL CELLS IN KIDNEY ORGANOID

Shengbing Li – Rotterdam, The Netherlands

09:10

HLA-DQ EPLET MISMATCH LOAD MAY IDENTIFY KIDNEY TRANSPLANT PATIENTS ELIGIBLE FOR TACROLIMUS WITHDRAWAL WITHOUT DSA FORMATION AFTER MSC THERAPY

Suzanne Bezstarosti – Leiden, The Netherlands

FOCUS GROUP

Tuesday, 19 September 2023

08:00 - 09:30
Banquet Hall

Oncology - it's time for wider access

*Chairs: Umberto Cillo – Padua, Italy
Pal-Dag Line – Asker, Norway*

- 08:00 ONCOLOGIC RESULTS AFTER TEN YEARS OF SYSTEMATIC APPLICATION OF LOCO REGIONAL THERAPIES FOR HEPATOCELLULAR CARCINOMA
Enrico Prosperi – Bologna, Italy
- 08:10 LAPAROSCOPIC ABLATION AND SALVAGE TRANSPLANTATION FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA
Nicola Canitano – Padua, Italy
- 08:20 THE CLOUDED ZONE BEHIND THE SELECTION PROCESS FOR LIVER TRANSPLANTATION IN COLORECTAL LIVER METASTASES PATIENTS: A PROSPECTIVE ANALYSIS
Alessandra Bertacco – Padua, Italy
- 08:30 LIVER TRANSPLANTATION FOR HCC BEYOND MILAN CRITERIA AFTER DOWN-STAGING WITH STEREOTACTIC RADIOTHERAPY OR TRANSARTERIAL RADIOEMBOLIZATION
Alberto Calleri – Turin, Italy
- 08:40 EVALUATION OF A DELAYED LIVER TRANSPLANT STRATEGY FOR PATIENTS LISTED FOR HCC TREATED WITH RESECTION OR THERMOABLATION AS A BRIDGE TO LT
Catherine Lamarque – Créteil, France
- 08:50 LIVER TRANSPLANTATION SURVIVAL BENEFIT OVER RESECTION FOR COLORECTAL METASTASIS IN PATIENTS WITH HIGH TUMOR LOAD: MULTICENTER RETROSPECTIVE ANALYSIS
Jacopo Lanari – Padua, Italy
- 09:00 VON WILLEBRAND FACTOR ANTIGEN ALLOWS IMPROVED DECISION MAKING IN HCC PATIENTS SUBJECTED TO SURGICAL TREATMENT OPTIONS
David Pereyra – Vienna, Austria
- 09:10 DE NOVO CANCERS AFTER LIVER TRANSPLANTATION: A FRENCH NATIONWIDE COHORT.
Ilias Kounis – Paris, France

SOLUTION ROOM

Tuesday, 19 September 2023

08:00 - 09:30
Mitropoulos

Let's talk about DCD hearts – rewriting the rules of donation?

*Chairs: Nichon Jansen – Leiden, The Netherlands
Arezu Aliabadi-Zuckermann – Vienna, Austria*

- This session will focus on how to set up a DCD heart donation program, the different types of DCD heart preservation, ethical issues concerning death declaration and the effect of DCD heart donation on lung donation.
- 08:00 Heart preservation in DCD donation. The UK experience.
Marius Berman – Cambridge, United Kingdom
- 08:15 How to setup a DCD heart donation program in The The Netherlands TA NRP or direct procurement ?
Niels van der Kaaij – Utrecht, The Netherlands
- 08:30 Ethical issues in DCD heart donation when faced with NRP programs
Antonio Rubino – Cambridge, United Kingdom
- 08:45 The US View
Jordan Hoffman – Denver, United States
- 09:00 Discussion

FULL ORAL

Tuesday, 19 September 2023

- 08:00 - 09:30**
Skalkotas **Managing myself after transplantatin- a fulltime job**
*Chairs: Martijn van den Hoogen – Rotterdam, The Netherlands
Michelle Willicombe – London, United Kingdom*
- 08:00 SYMPTOM BURDEN IN KIDNEY TRANSPLANT RECIPIENTS: A CROSS-SECTIONAL STUDY
Niels Riemersma – Groningen, The Netherlands
- 08:10 THE LONGITUDINAL DEVELOPMENT OF TRANSPLANT SPECIFIC WELL-BEING AND PROMINENT SYMPTOMS FROM PRE-TRANSPLANT TO FIVE YEARS AFTER HEART TRANSPLANTATION.
Marita Dalvindt – Lund, Sweden
- 08:20 QUANTITATIVE FINDINGS FROM THE COMPASSIONATE MINDFUL RESILIENCE PROGRAMME IN ADULT PATIENTS WITH CHRONIC KIDNEY DISEASE (THE COSMIC STUDY)
Anna Wilson – Belfast, United Kingdom
- 08:30 MEDITERRANEAN DIET AND METABOLIC SYNDROME: A DIETARY INTERVENTION STUDY TO REDUCE METABOLIC SYNDROME RISK AFTER HEART TRANSPLANTATION.
Sandro Sponga – Udine, Italy
- 08:40 THE EFFECT OF SYSTEMCHANGE™ ON MEDICATION ADHERENCE IN KIDNEY TRANSPLANT RECIPIENTS: A RANDOMIZED CLINICAL TRIAL
Yaprak Sarıgöl Ordin – Izmir, Turkey

- 08:50 NURSE-LED SELF-MANAGEMENT SUPPORT AFTER ORGAN TRANSPLANTATION – A MULTICENTER, MULTI-ORGAN STEPPED WEDGE RANDOMIZED CONTROLLED TRIAL
Emma Massey – Rotterdam, The Netherlands
- 09:00 A RANDOMIZED CONTROLLED STUDY OF TELEMONITORING IN KIDNEY TRANSPLANT RECIPIENTS : INTERIM RESULTS OF THE AP'TX TRIAL
Christophe Mariat - St. Priest en Jercy, France
- 09:10 UPTAKE OF HOME-MONITORING AFTER KIDNEY TRANSPLANTATION: A RETROSPECTIVE ANALYSIS
Bartu Hezer – Rotterdam, The Netherlands

BRIEF ORAL

Tuesday, 19 September 2023

- 08:00 - 09:30**
MC 3 **Transplantation outcomes and complications**
*Chairs: Marina Berenguer – Valencia, Spain
Giacomo Germani – Padua, Italy*
- 08:00 SPLIT-LIVER TRANSPLANTATION FOR PRIMARY SCLEROSING CHOLANGITIS IS ASSOCIATED WITH REDUCED GRAFT SURVIVAL DUE TO HEPATIC ARTERY THROMBOSIS
Daniel Cox – Melbourne, Australia
- 08:06 IDENTIFICATION OF NOVEL LIVER TRANSPLANT BIOPSIES PHENOTYPES ASSOCIATED WITH DISTINCT BIOLOGICAL PROFILES AND ALLOGRAFT SURVIVAL
Zeynep Demir – Paris, France
- 08:12 MACHINE PERFUSION TECHNIQUES FOR LIVER TRANSPLANTATION - A META-ANALYSIS OF THE FIRST SEVEN RANDOMIZED CONTROLLED TRIALS
Janina Eden – Zürich, Switzerland
- 08:18 ABSORBABLE SELF-EXPANDABLE BILIARY STENT AS APREVENTIVE TREATMENT OF BILIARY COMPLICATIONS IN LIVER TRANSPLANT
Victor López-López – Murcia, Spain
- 08:24 THE ITALIAN EXPERIENCE ON LIVER TRANSPLANTATION FOR UNRESECTABLE PERI-HILAR CHOLANGIOCARCINOMA: A NATIONAL SURVEY AND FUTURE PERSPECTIVES
Alessandro Furlanetto – Padua, Italy
- 08:30 EARLY DIAGNOSIS OF LIVER GRAFT FIBROSIS AND STEATOSIS: ARE NON-INVASIVE TESTS THE ANSWER?
Colin Dumont – Brussels, Belgium
- 08:36 IMPROVEMENT OF THE OUTCOMES OF LIVER TRANSPLANTATION AFTER THE COVID-19 ERA: THE POSITIVE PROACTIVE EFFECT OF SARS-COV-2
Marco Pascale – Rome, Italy

- 08:42 **RADIOLOGICAL CLASSIFICATION OF ISCHEMIC CHOLANGIOPATHY AFTER DECEASED-DONOR LIVER TRANSPLANTATION**
Midas van den Tweel – Rotterdam, The Netherlands
- 08:48 **ADD-ON CONTRAST-ENHANCED US WITH DOPPLER US ON POD#1 CAN REDUCE FALSE POSITIVES OF VASCULAR COMPLICATION AFTER LIVER TRANSPLANTATION**
Woo Kyoung Jeong - Seoul, Republic of South Korea
- 08:54 **SURVIVAL OUTCOMES OF SALVAGE VS PRIMARY LIVER TRANSPLANTATION FOR EARLY-STAGE HEPATOCELLULAR CANCERS: SYSTEMATIC REVIEW AND META-ANALYSIS**
Ahmed E Sherif – Edinburgh, United Kingdom
- 09:00 **LIVER TRANSPLANTATION VERSUS LIVER RESECTION AND HEPATOCELLULAR CARCINOMA: A SURVIVAL META-ANALYSIS OF META-ANALYSIS**
Francesca Cardella – Naples, Italy
- 09:06 **SALVAGE LIVER TRANSPLANTATION FOLLOWING RESECTION OF COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA**
Enrico Prosperi – Bologna, Italy
- 09:12 **SAFETY AND EFFICACY OF GLP1-RAS AND ISGLT-2- COMPARED WITH THE STANDARD OF CARE IN A COHORT OF LIVER TRANSPLANTED PATIENTS: A RETROSPECTIVE STUDY**
Aida Rebiha – Paris, France
- 09:18 **MODIFYING TACROLIMUS RELATED TOXICITY AFTER LIVER TRANSPLANTATION COMPARING ENVARSUS® AND ADVAGRAF®: A MULTICENTER RANDOMIZED, CONTROLLED TRIAL**
Midas Mulder – Rotterdam, The Netherlands

BRIEF ORAL

Tuesday, 19 September 2023

- 08:00 - 09:30**
MC 2 **Innovations in surgical techniques**
Chairs: Hannah Maple – London, United Kingdom
Raj Prasad - Leeds, United Kingdom
- 08:00 **TRANSITION FROM OPEN- TO ROBOT-ASSISTED DONOR RIGHT HEPATECTOMY PROGRAM FOR ADULT TO ADULT LIVING LIVER DONATION: EARLY OUTCOMES AND LESSONS LEARNED**
Michele Finotti – Padua, Italy
- 08:06 **REFINING AUXILIARY PARTIAL ORTHOTOPIC LIVER TRANSPLANTATION (APOLT) FOR ACUTE LIVER FAILURE IN 48 ADULT PATIENTS**
Riccardo Pravisani – Udine, Italy

- 08:12 **ROBOTIC KIDNEY TRANSPLANTATION : A SINGLE INSTITUTIONAL EXPERIENCE**
Hyun-jeong Kim - Seoul, Republic of South Korea
- 08:18 **IPSILATERAL SIMULTANEOUS NEPHRECTOMY WITH URETERO-URETERAL ANASTOMOSIS IN KIDNEY TRANSPLANTATION FOR POLYCYSTIC KIDNEY DISEASE**
Silvio Nadalin – Tübingen, Germany
- 08:24 **LAPDOCTOR: TELL ME HOW DIFFICULT WILL BE MY DONOR. MULTICENTRIC VALIDATION OF A NEW SCORING SYSTEM THAT ANTICIPATES DIFFICULTY OF LDN.**
Gionata Spagnoletti – Rome, Italy
- 08:30 **HAND ASSISTED RETROPERITONEOSCOPIC DONOR NEPHRECTOMY (HARP-DN); LESSONS LEARNED FROM 1001 CASES**
Emin Baris Akin – Istanbul, Turkey
- 08:36 **MINIMALLY INVASIVE APPROACH FOR RAPID LIVER TRANSPLANTATION: ARE WE READY FOR PRIME TIME? EXPERIENCE WITH LAPAROSCOPIC SECOND STEP APPROACH.**
Alessandra Bertacco – Padua, Italy
- 08:42 **FULL-LEFT/FULL-RIGHT LIVER SPLITTING WITH MIDDLE HEPATIC VEIN AND CAVAL PARTITION DURING DUAL HYPOTHERMIC OXYGENATED MACHINE PERFUSION**
Alessandro Furlanetto – Padua, Italy
- 08:48 **CLAMSHELL VERSUS BILATERAL ANTEROLATERAL THORACOTOMY FOR DOUBLE LUNG TRANSPLANTATION: IMPACT ON FUNCTIONAL AND CLINICAL OUTCOMES**
Alessandro Palleschi – Milan, Italy
- 08:54 **A SINGLE CELL AND SPATIAL TRANSCRIPTOMICS APPROACH TO ELUCIDATING CD8 T CELLS IN VASCULARIZED COMPOSITE ALLOTRANSPLANTATION REJECTION**
Bruce Gelb - New York, United States
- 09:00 **HAND TRANSPLANTATION AT A TERTIARY CARE CENTRE IN INDIA**
George Kurian – Kochi, India
- 09:06 **DISCORDANT HISTOLOGICAL FINDINGS DURING ACUTE REJECTION IN A COMBINED FACE AND HAND TRANSPLANT RECIPIENT**
Bruce Gelb - New York, United States
- 09:12 **DEVELOPMENT OF A SHARED DECISION MAKING CONVERSATION AID FOR VCA**
Sheila Jowsey-Gregoire – Rochester, United States
- 09:18 **MULTI-LEVEL ANALYSIS OF THE NEOVASCULARIZATION AND INTEGRATION PROCESS OF A NON-VASCULARIZED RECTUS FASCIA FOLLOWING INTESTINAL TRANSPLANTATION**
Laurens J. Ceulemans – Leuven, Belgium

SOLUTION ROOM

Tuesday, 19 September 2023

08:00 - 09:30
Library

Health democracy in organ transplantation

*Chairs: George Papatheodoridis – Athens, Greece
Marleen van Buren – Rotterdam, The Netherlands*

The session will explore the concept of shared decision-making (SDM) from a range of perspectives, engaging with misconceptions and assumptions about the role of SDM in donation and transplantation. Participants will learn about potential barriers - both real and imagined- to meaningful SDM and discuss examples of effective strategies to address common barriers. Following three talks featuring patient, clinician and organizational perspectives, a multidisciplinary panel will draw on their personal and professional experiences to discuss the culture(s) of SDM in a range of settings.

08:00

Introduction
Marleen van Buren – Rotterdam, The Netherlands

08:06

How can patients shape delivery of transplantation?
Penilla Gunther – Stockholm, Sweden

08:24

Implementing patient centricity in clinics
Caroline Whitworth – Edinburgh, United Kingdom

08:42

Going patient-centric in clinical trial design and endpoints (early involvement of patients)
Aimee Sundberg – Lexington, United States

09:00

Discussion Panel with audience
Keren Ladin – Boston, United States; Georgios Tsoulfas - Thessaloniki, Greece

FISHBOWL

Tuesday, 19 September 2023

08:00 - 09:30
Conference Suite 1

Orchestrating clinical translation of regenerative therapies

*Chairs: Patrizia Burra – Padua, Italy
John Forsythe – Bristol, United Kingdom*

The transition from pre-clinical to clinical studies is a unique process that is impacted by the developed therapy product and the complexity of the manufacturing process. This session will discuss the potential challenges and tips for preparing a smooth translation of RM product.

08:00

Introduction
Patrizia Burra - Padua, Italy; John Forsythe - Bristol United Kingdom

08:10

The scientist's view
Ying Kai Chan – Boston, United States

- 08:25 The clinician's view
Eelco de Koning – Leiden, The Netherlands
- 08:40 The commercial view
Panos Kefalas – London, United Kingdom
- 08:55 The patient view
Liz Schick – Bern, Switzerland
- 09:10 Audience debate and discussion
Patrizia Burra - Padua, Italy; John Forsythe - Bristol United Kingdom

FOCUS GROUP

Tuesday, 19 September 2023

- 08:00 - 09:30**
MC 3.2 **Biomarkers and monitoring kidney health**
*Chairs: Asimina Fylaktou – Thessaloniki, Greece
Claire Tinel – Paris, France*
- 08:00 EVOLUTION OF DDCFDNA DURING THE FIRST WEEK AFTER SURGERY PREDICTS MEDIUM TO LONG-TERM RENAL OUTCOMES
David Cucchiari – Barcelona, Spain
- 08:10 MAGNETIC RESONANCE IMAGING TEXTURE ANALYSIS TO ASSESS GRAFT INTERSTITIAL FIBROSIS AND TUBULAR ATROPHY IN PATIENTS WITH TRANSPLANTED KIDNEYS
Francesco Fontana – Modena, Italy
- 08:20 VALIDATION OF THE INTERNATIONAL IGA NEPHROPATHY PREDICTION TOOL IN KIDNEY TRANSPLANT RECIPIENTS WITH IGA NEPHROPATHY RECURRENCE
Emilio Rodrigo – Santander, Spain
- 08:30 CORTICAL IRON DEPOSITION ASSESSED BY MAGNETIC RESONANCE IMAGE IS ASSOCIATED WITH FIBROSIS
Anna Manonelles – Barcelona, Spain
- 08:40 INTRA-GRAFT TEMRA CD8+ T CELLS: AN INDEPENDENT PREDICTOR OF KIDNEY ALLOGRAFT FAILURE INDEPENDENT OF REJECTION CATEGORIES
Thibaut Vaulet – Leuven, Belgium
- 08:50 LONGITUDINAL MONITORING OF TORQUE TENO VIRUS DNAEMIA IN RENAL TRANSPLANT RECIPIENTS PREDICTS LONG-TERM COMPLICATIONS OF INADEQUATE IMMUNOSUPPRESSION
Olivier Thaunat – Lyon, France

- 09:00 TORQUE TENO VIRUS PLASMA CONCENTRATION TRENDS IN KIDNEY TRANSPLANT RECIPIENTS BEFORE PATHOGENIC INFECTIONS AND ALLOGRAFT REJECTION
Steve Kleiboeker - Lee's Summit, United States
- 09:10 TORQUE TENO VIRUS VIRAL LOAD PREDICTS SARS-COV-2 VACCINE RESPONSE IN KIDNEY TRANSPLANT RECIPIENTS
Morgane Solis – Strasbourg, France

FOCUS GROUP

Tuesday, 19 September 2023

- 08:00 - 09:30**
MC 3.4 **Insights on IRI and PGD in cardiothoracic transplantation**
*Chairs: Irene Bello – Barcelona, Spain
Stephan Ensminger – Lübeck, Germany*
- 08:00 POSITIVE LONG-TERM EFFECTS OF 17B-ESTRADIOL AND METHYLPREDNISOLONE ASSOCIATION ON LUNG INFLAMMATION TRIGGERED BY BRAIN DEATH IN FEMALE RATS
Marina Vidal-dos-Santos - São Paulo, Brazil
- 08:10 MITOCHONDRIAL DAMAGE COMPARISON BETWEEN BRAIN DEATH DONORS AND DONORS AFTER CIRCULATORY DEATH IN LUNG TRANSPLANTATION: PROSPECTIVE MULTICENTER STUDY
Irene Bello – Barcelona, Spain
- 08:20 A NOVEL WHOLE-BODY COOLING SYSTEM PROTECTS DONOR LUNGS FROM ISCHEMIA REPERFUSION INJURY: TARGETING UNCONTROLLED DONATION AFTER CIRCULATORY DEATH DONORS
Hiromichi Niikawa – Sendai, Japan
- 08:30 NOT TOO WARM, NOT TOO COLD: REAL-WORLD MULTI-CENTER OUTCOMES WITH ELEVATED HYPOTHERMIC PRESERVATION OF DONOR LUNGS
John Haney – Durham, United States
- 08:40 SINGLE-CENTER SHORT TO INTERMEDIATE TERM OUTCOMES AFTER 100 DONOR HEART PROCUREMENTS WITH A NON-PERFUSING HYPOTHERMIC STORAGE SYSTEM
Iuliana Coti – Vienna, Austria
- 08:50 CUSTODIOL-N VERSUS CUSTODIOL: RESULTS FROM A PROSPECTIVE RANDOMISED SINGLE BLIND MULTICENTER PHASE III TRIAL IN PATIENTS UNDERGOING HEART TRANSPLANTATION
Andreas Zuckermann – Vienna, Austria
- 09:00 EFFECTS OF TRIIODOTHYRONINE AND PRECONDITIONING ON EX VIVO RAT HEARTS SUBJECTED TO NORMOTHERMIC PERFUSION. IMPLICATIONS FOR DONOR HEART PRESERVATION
Iordanis Mourouzis – Athens, Greece

09:10 EARLY ECMO OVERCOMES PRIMARY GRAFT DYSFUNCTION AFTER HEART TRANSPLANT.
ANGELIKI GKOUZIOUTA – Kallithea, Greece

TV-STUDIO

Tuesday, 19 September 2023

09:30 - 10:00
Muses Foyer

Spotlight on ESOT Congress 2025
Chairs: Jacqui Thornton – Winchester, United Kingdom
Guest: Olivier Thauinat – Lyon, France

BRIEF ORAL

Tuesday, 19 September 2023

10:00 - 11:30
Lambrakis

Management and selection of kidney transplant candidates
Chairs: Maria Darema – Athens, Greece
Umberto Maggiore – Parma, Italy

10:00 REPEAT HLA CLASS 2 MISMATCHES REMAIN ASSOCIATED WITH GRAFT LOSS OF THE SECOND KIDNEY TRANSPLANT : A COLLABORATIVE TRANSPLANT STUDY REGISTRY ANALYSIS
Lissa Pipeleers – Brussels, Belgium

10:06 SENSITIVE HLA ANTIBODY DETECTION AND THE RISK OF ANTIBODY-MEDIATED REJECTION AND GRAFT FAILURE
Jasper Callemeyn - Korbeek-Lo, Belgium

10:12 DEVELOPMENT AND VALIDATION OF A MULTIDIMENSIONAL PROGNOSTICATION SYSTEM FOR KIDNEY TRANSPLANT PATIENT SURVIVAL: THE MORTALITY MBOX
Charlotte Debiais-Deschamps – Paris, France

10:18 OUTCOMES OF RENAL TRANSPLANTATION USING DONOR AFTER CARDIOCIRCULATORY DEATH FOR HIGHLY SENSITIZED PATIENTS IN SPANISH AND CATALAN PROGRAMS
Edoardo Melilli – Barcelona, Spain

10:24 DIETARY OXALIC ACID INTAKE AND PLASMA OXALIC ACID CONCENTRATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE
Joke Roodnat – Rotterdam, The Netherlands

- 10:30 CIRCULATING TNF-A LEVELS IN DECEASED DONORS ASSOCIATE WITH POSTTRANSPLANT FUNCTION IN KIDNEY TRANSPLANTATION
Sarah Fawaz – Oxford, United Kingdom
- 10:36 UTILITY OF RAMP TEST TIME IN PATIENTS UNDERGOING ASSESSMENT FOR RENAL TRANSPLANTATION
Rebecca Smith – London, United Kingdom
- 10:42 ASSOCIATION BETWEEN ABDOMINAL CT MEASUREMENTS OF BODY COMPOSITION AND WAITLIST MORTALITY IN KIDNEY TRANSPLANT CANDIDATES
Evelien Quint – Groningen, The Netherlands
- 10:48 EMPLOYMENT BEFORE, AT OR AFTER KIDNEY TRANSPLANTATION IN DENMARK – A NATIONAL CASE-CONTROL STUDY
Rasmus Carlsen – Oslo, Norway
- 10:54 DOES TYPE OF DIALYSIS MODALITY INFLUENCE POST-TRANSPLANTATION OUTCOMES? A POPULATION-COHORT ANALYSIS USING REGISTRY DATA
Asra Karim – Birmingham, United Kingdom
- 11:00 CHARACTERISTICS OF PRE-TRANSPLANT HOSPITALIZATIONS ARE ASSOCIATED WITH ELDERLY PATIENT SURVIVAL AFTER KIDNEY TRANSPLANTATION
Renaud Snanoudj - Le Kremlin-Bicêtre, France
- 11:06 SARCOPENIA OF KIDNEY TRANSPLANT RECIPIENTS AS A PREDICTIVE MARKER FOR REDUCED GRAFT FUNCTION AND GRAFT SURVIVAL AFTER KIDNEY TRANSPLANTATION
Hristos Karakizlis – Giessen, Germany
- 11:12 EFFECTS OF SOCIAL DEPRIVATION ON REGISTRATION ON THE RENAL TRANSPLANTATION WAITING-LIST THROUGH MARKERS OF NEPHROLOGICAL CARE: A MEDIATION ANALYSIS.
Eve Calvar – Caen, France
- 11:18 THE PATIENT'S WISH IS A MAJOR REASON FOR REMOVAL FROM THE EUROPEAN SENIOR PROGRAMME WAITING LIST
Marcel Naik – Berlin, Germany

SOLUTION ROOM

Tuesday, 19 September 2023

10:00 - 11:30
Trianti

Personalization starts before transplantation: choosing the best organ for long-term success

Chairs: *Carmen Lefaucheur – Paris, France*
Maarten Naesens – Leuven, Belgium

In this session, we will discuss the recent advancements in the immunologic risk stratification, as well as insights into the role of donor characteristics (e.g. Older DCD kidneys), and how the immunological risks add to the organ quality risks. We can also discuss which algorithms and tools exist to improve this risk stratification, and how this could be implemented into realistic allocation systems, better than it is done currently.

- 10:00 Optimising patient selection (risk stratification)
Sebastiaan Heidt – Voorburg, The Netherlands
- 10:20 Combining donor and recipient characteristics for optimal risk stratifications at the time of transplantation in different solid organ transplantation
Olivier Aubert – Paris, France
- 10:40 Survey on practices on dealing with highly sensitized patients
Lionel Rostaing – Grenoble, France
- 11:00 Engage 1, 2, 3
Lucrezia Furian – Padua, Italy
- 11:20 Discussion panel

BRIEF ORAL

Tuesday, 19 September 2023

- 10:00 - 11:30**
Banquet Hall
- Organ preservation and ischemia reperfusion**
*Chairs: Amelia Hessheimer – Madrid, Spain
Diethard Monbaliu – Leuven, Belgium*
- 10:00 REMOVAL OF CHROMATIN-ASSOCIATED-MOLECULAR-PATTERNS (CAMPS) REDUCES EX-SITU REPERFUSION INJURY IN PORCINE DCD LIVERS PRESERVED WITH NMP.
Fungai Dengu – Oxford, United Kingdom
- 10:06 IN SITU AND EX SITU DYNAMIC PRESERVATION VERSUS COLD STORAGE IN LIVER TRANSPLANTATION FROM OLDER DONATION AFTER CIRCULATORY DEATH DONORS
Ivo Schurink – Rotterdam, The Netherlands
- 10:12 MAXIMUM LIVER FUNCTION CAPACITY TEST (LIMAX) DURING ABDOMINAL NORMOTHERMIC REGIONAL PERFUSION AS PREDICTOR OF GRAFT FUNCTION AFTER TRANSPLANTATION
Femke de Goeij – Rotterdam, The Netherlands
- 10:18 MITOCHONDRIAL INTEGRITY AND FUNCTION PARTIALLY RECOVER DURING LONG-TERM NORMOTHERMIC PERFUSION OF THE LIVER
Christina Bogensperger – Innsbruck, Austria

- 10:24 OUTCOMES OF LIVERS WITH PROLONGED DURATION OF EX SITU NORMOTHERMIC PERFUSION: CAN LIVER TRANSPLANTATION BE A DAYTIME ACTIVITY?
Harry Spiers – Cambridge, United Kingdom
- 10:30 GRAFT VIABILITY AND LIVER TRANSPLANT RECOVERY ASSESSMENT USING INDOCYANINE GREEN CLEARANCE TEST: PRELIMINARY ANALYSIS OF A PROSPECTIVE STUDY.
Gabriele Spoletini – Rome, Italy
- 10:36 OBSERVATIONS DURING IMPLEMENTATION OF AN EX-SITU NORMOTHERMIC LIVER MACHINE PERFUSION PROGRAMME
Gabriel Oniscu – Stockholm, Sweden
- 10:42 MARKERS OF COAGULATION AND FIBRINOLYSIS DURING NORMOTHERMIC LIVER PERFUSION MIGHT REFLECT ON VASCULAR INTEGRITY AND PRESERVATION INJURY
Jule Dingfelder – Vienna, Austria
- 10:48 PILOT, RANDOMIZED TRIAL FOR THE COMPARISON OF HYPOTHERMIC VERSUS NORMOTHERMIC EX-SITU LIVER PRESERVATION IN DCD LIVER TRANSPLANTATION (DCDNET TRIAL)
Davide Ghinolfi – Pisa, Italy
- 10:54 NORMOTHERMIC MECHANICAL PERFUSION (NMP) REDUCES THE RISK OF ISCHEMIC CHOLANGIOPATHY IN RECIPIENTS OF DCD LIVER TRANSPLANTS
Kunam Reddy – Phoenix, United States
- 11:00 THE ROLE OF COLD ISCHEMIA TIME AND HYPOTHERMIC PERFUSION IN PREDICTING EARLY HEPATOCELLULAR CARCINOMA RECURRENCES AFTER LIVER TRANSPLANTATION
Gerti Dajti – Bologna, Italy
- 11:06 THE EFFECT OF CONTINUOUS LIVER NORMOTHERMIC MACHINE PERFUSION ON THE SEVERITY OF HISTOLOGICAL BILE DUCT INJURY.
Nicholas Gilbo – Leuven, Belgium
- 11:12 THE IMPACT OF DONOR TIME TO DEATH AND FUNCTIONAL WARM ISCHAEMIA TIME ON RECIPIENT OUTCOME FOLLOWING DCD LIVER TRANSPLANTATION
Abdullah Malik - Newcastle upon Tyne, United Kingdom
- 11:18 HOPE REDUCES DURATION OF GLYCOCALYX SHEDDING – ITS DAMAGE MARKER SYNDECAN-1 CAN PREDICT EARLY ALLOGRAFT DYSFUNCTION
Laurin Rauter – Vienna, Austria

FULL ORAL

Tuesday, 19 September 2023

10:00 - 11:30

Improving outcomes of end-stage heart failure: from MCS to the long-term

Mitropoulos	<i>Chairs: Cristiano Amarelli – Naples, Italy Stephen Clark - Newcastle upon Tyne, United Kingdom</i>
10:00	5-YEAR OUTCOME AFTER CONTINUOUS FLOW LVAD WITH FULL-MAGNETIC VS HYBRID LEVITATION SYSTEM: RESULTS OF AN ALL-COMERS MULTICENTER REGISTRY <i>Alessandra Francica – Verona, Italy</i>
10:10	IMPACT OF THE 2018 FRENCH ALLOCATION SCHEME ON THE PROFILE OF HEART TRANSPLANTATION CANDIDATES AND RECIPIENTS: INSIGHTS FROM A HIGH-VOLUME CENTER. <i>Guillaume Coutance – Paris, France</i>
10:20	RESULTS FROM OVER 800 TRANSPLANT RECIPIENTS ENROLLED IN THE GUARDIAN-HEART REGISTRY: CHALLENGING THE STANDARD OF CARE <i>Andreas Zuckermann – Vienna, Austria</i>
10:30	HEART TRANSPLANTATION FROM CONTROLLED DONATION AFTER THE CIRCULATORY DETERMINATION OF DEATH: OUR EXPERIENCE. <i>María del Mar Martín Magán - El Palmar, Spain</i>
10:40	MOLECULAR DIAGNOSTIC CLASSIFICATION OF HEART ALLOGRAFT REJECTION BASED ON THE TARGETED BANFF HUMAN ORGAN TRANSPLANT GENE EXPRESSION PANEL <i>Alessia Giarraputo – Paris, France</i>
10:50	BANFF HUMAN ORGAN TRANSPLANT CONSENSUS GENE PANEL FOR DETECTING ANTIBODY MEDIATED REJECTION IN HEART ALLOGRAFT BIOPSIES <i>Alessia Giarraputo – Paris, France</i>
11:00	PREGNANCY AFTER HEART TRANSPLANT <i>Lisa Coscia – Philadelphia, United States</i>
11:10	LONG-TERM OUTCOMES OF COMPLEMENT INHIBITION FOR PREVENTION OF ANTIBODY-MEDIATED REJECTION IN IMMUNOLOGICALLY HIGH-RISK HEART TRANSPLANTATION <i>Guillaume Coutance – Paris, France</i>

SOLUTION ROOM

10:00 - 11:30
Skalkotas

What if HCP listen to patients? Non-adherence after transplantation

*Chairs: Anna Brantmark – Gothenburg, Sweden
Keren Ladin – Boston, United States*

Various aspects of non-adherence will be discussed from the perspectives of health care professionals and more importantly patients. This session will challenge the conventional thinking around this topic and suggest a more person-focused approach to addressing this issue. It will address the link between health care beliefs and adherence and also how the side effect burden affects this

- issue. The session will end with a brainstorming segment with patients, panel members and the audience looking for solutions to this complex issue
- 10:00 The realities of post-transplant medication - the patient perspective
Emma Dalman – Stockholm, Sweden
- 10:10 Clinicians' approach to fixing the problem
Janette Ribaut – Basel, Switzerland
- 10:20 The impact of health care beliefs on adherence
Rob Horne – London, United Kingdom
- 10:40 How strong is the link between symptom burden and adherence
Anna Forsberg – Lund, Sweden
- 11:00 Panel Discussion and debate with the audience - the way forward
Anna Brantmark - Gothenburg, Sweden; Emma Dalman - Stockholm, Sweden; Anna Forsberg - Lund Sweden; Rob Horne - London, United Kingdom; Keren Ladin - Boston, United States

BRIEF ORAL

Tuesday, 19 September 2023

- 10:00 - 11:30**
MC 3 **Translational transplant immunology**
*Chairs: Marta Crespo – Barcelona, Spain
Thomas Resch – Innsbruck, Austria*
- 10:00 CLINICAL AND IMMUNOLOGICAL FACTORS ASSOCIATED WITH THYMIC FUNCTION AT THE TIME OF KIDNEY TRANSPLANTATION.
Ioannis Katerinis – Paris, France
- 10:06 DOES RECEPTOR-MEDIATED INTERNALISATION OF HYALURONAN (HA) MATRIX IN THE RENAL CORTEX EXPLAIN THE PROTECTION CONFERRED BY ISCHAEMIC PRE-CONDITIONING?
Aeliya Zaidi – Cardiff, United Kingdom
- 10:12 DIFFERENTIAL KINETICS OF HLA CLASS II ANTIGENS EXPRESSION ON PRIMARY HUMAN GLOMERULAR ENDOTHELIAL CELLS
Maria Meneghini – Barcelona, Spain
- 10:18 A PRO-INFLAMMATORY IMMUNE STATE IS INFLUENCED BY PERTURBATIONS OF MICROBIAL METABOLITES IN RENAL TRANSPLANTATION
Fernando Yuen Chang – London, United Kingdom
- 10:24 UNREPRESENTED HUMAN LEUKOCYTE ANTIGEN ALLELES ON SINGLE ANTIGEN BEAD ASSAYS: A COMPARISON AMONGST DIFFERENT TEST KITS
Shan-Yeu Carolyn Tien – Singapore, Singapore

- 10:30 EVALUATION OF METHODS FOR THE TISSUE-OF-ORIGIN DECONVOLUTION OF PLASMA AND URINARY CELL-FREE DNA IN ALLOGRAFT RECIPIENTS AND HEALTHY VOLUNTEERS
Nicholas Kueng – Bern, Switzerland
- 10:36 HUMAN REGULATORY B CELLS PREVENT EFFECTOR CD4+CD25- T CELL PROLIFERATION THROUGH A MECHANISM DEPENDENT FROM GRANZYME B AND LYMPHOTOXIN ALPHA.
Nicolas Sailliet – Nantes, France
- 10:42 THE INFLUENCE OF VIRUS-SPECIFIC IMMUNOGLOBULINES AS MODULATORS OF ANTIGEN-SPECIFIC T-CELL EXPANSION
Amina Abu-Omar – Homburg, Germany
- 10:48 GAMMA-DELTA T CELL THERAPY FOR POST-TRANSPLANT CYTOMEGALOVIRUS INFECTION: PROOF OF CONCEPT
Lionel Couzi – Bordeaux, France
- 10:54 THE DISTINCT INNATE IMMUNE RESPONSE OF DONATION AFTER CIRCULATORY DEATH LIVERS DURING NORMOTHERMIC MACHINE PERFUSION
Joris Blondeel – Leuven, Belgium
- 11:00 EX SITU PORCINE LIVER MACHINE PERFUSION ACTIVATES THE COMPLEMENT SYSTEM AND INCREASES CYTOKINES INDEPENDENT OF PRE-INDUCED LIVER INJURY
Ida Færden – Oslo, Norway
- 11:06 TETRAHYDRO-BENZOTHIOPHENE ROR GAMMA T INVERSE AGONISTS TO TARGET TH17 IN SENSITIZED SKIN ALLOGRAFT MOUSE MODEL
Ahmed Fouda - Montreal Canada
- 11:12 CD8+CD3- CELLS ARE CRITICAL FOR TREG MEDIATED HUMORAL TOLERANCE
Romy Steiner – Vienna, Austria
- 11:18 RESEARCH FOR NOVEL MECHANISM OF IMMUNOSUPPRESSION THROUGH PD-1/PD-L1 PATHWAY
Sunghyo An - Seoul, Republic of South Korea

FOCUS GROUP

Tuesday, 19 September 2023

10:00 - 11:30
MC 2

Digital Health for personalised care

Chairs: *Klemens Budde – Berlin, Germany*
Oriol Bestard – Barcelona, Spain

- 10:00 DEVELOPMENT AND VALIDATION OF ANTIBODY-MEDIATED REJECTION PREDICTION MODEL ON AUGMENTED DATA USING GENERATIVE MODEL IN KIDNEY TRANSPLANT PATIENTS
Daniel Yoo – Paris, France
- 10:10 DEEP LEARNING MODELS OF REAL-TIME NON-INVASIVE IMAGING DURING WARM PERFUSION OF EXPANDED CRITERIA DONOR KIDNEYS POTENTIALLY PREDICT ACUTE REJECTION
Iacopo Cristoferi – Rotterdam, The Netherlands
- 10:20 PANCREATIC STEATOSIS AND TRANSPLANT SUITABILITY ASSESSMENT WITH IMAGE BASED MACHINE LEARNING MODELS
Georgios Kourounis - Newcastle upon Tyne, United Kingdom
- 10:30 THE IMPACT OF DEATH IN PREDICTING KIDNEY-ALLOGRAFT FAILURE: A COMPETING RISK ANALYSIS STUDY (NCT03474003)
Agathe Truchot – Paris, France
- 10:40 PREDICTORS OF OUTCOMES OF DCD VERSUS DBD KIDNEY TRANSPLANTATION FROM SUPRA MARGINAL DONORS (D4). A MACHINE LEARNING ANALYSIS OF NHSBT REGISTRY DATA
Sanjay Mehra – Liverpool, United Kingdom
- 10:50 MEASUREMENT FREQUENCY OF BLOOD PRESSURE IN NEWLY KIDNEY TRANSPLANTED PATIENTS DROPS OVER TIME IN REGULAR TELEMEDICINE SURVEILLANCE
Verena Graf – Berlin, Germany
- 11:00 EXPECTATIONS, CONCERNS, AND WILLINGNESS TOWARD THE USE OF MHEALTH TOOLS IN LIVER AND KIDNEY TRANSPLANT RECIPIENTS: A PILOT SURVEY STUDY.
Justyna Gołębiewska – Gdańsk, Poland
- 11:10 BLOOD PRESSURE MEASUREMENTS IN A REGULAR TELEMEDICINE SERVICE AFTER RENAL TRANSPLANTATION IN DIFFERENT AGE GROUPS
Matthias Pfefferkorn – Berlin, Germany

SOLUTION ROOM

Tuesday, 19 September 2023

10:00 - 11:30
Library

Let's talk about transition: can we ever get it right?

Chairs: *Jelena Stojanovic – London, United Kingdom*
Stella Stabouli – Thessaloniki, Greece

Based on ESOT 2021 delegate feedback that more discussions are needed on transition, this session addresses systems where the transition process is poor flagging its challenges, followed by a summary of a very successful transition

- programme. Session is opened by a patient who had heart and kidney transplant as a child and shares her experiences on good and bad transition process and effects it had on her lives. We expand on the role of MDT in transition and close the session with an open discussion between delegates and panellists on future collaborations on guideline setting.
- 10:00 Patient story- off to a flying start
Cecilia Adamou - Cobham, United Kingdom
- 10:10 Challenges in setting up a transition programme
Fernanda Ortiz – Helsinki, Finland
- 10:30 Multidisciplinary team and its role in transition
Claire Gaymer - London, United Kingdom; Nicos Kessarlis – London, United Kingdom
- 10:55 Successful transition - one way to do it
Paul Harden – Oxford, United Kingdom
- 11:10 Guideline proposal discussion
Paul Harden - Oxford, United Kingdom; Jelena Stojanovic – London, United Kingdom; Nicos Kessarlis - London, United Kingdom; Fernanda Ortiz - Helsinki, Finland

FISHBOWL

Tuesday, 19 September 2023

10:00 - 11:30
Conference Suite 1

Digital interface with patients – outpatients in the 22nd century

Chairs: *Marita Dalvindt – Lund, Sweden*
Colin White – Balbriggan, Ireland

The move to increased digitalisation offers huge advantages but also warrants major changes in the way health systems function for both patients, their families and healthcare workers. Successful implementation requires investment and overcoming change resistance. This session will focus on how to do this successfully and the potential cost savings along with a discussion on how such technology reduces the carbon footprint of healthcare.

- 10:00 Telemedicine 2.0: Outpatient telemedicine clinics - implementation, advantages and pitfalls
Conor Byrne – London, United Kingdom
- 10:20 Measuring Return of investment in digital healthcare interventions
John Nosta – Mendham, United States
- 10:40 The environmental impact of telemedicine
Dorry Segev - New York, United States
- 11:00 Audience debate and discussion
John Nosta – Mendham, United States; Raj Thuraisingham - London, United Kingdom

FOCUS GROUP

Tuesday, 19 September 2023

10:00 - 11:30

MC 3.2

The clinical spectrum of kidney transplant rejection

*Chairs: Caroline Dudreuilh – London, United Kingdom
Alice Koenig – Lyon, France*

10:00

MICROVASCULAR INJURY, EITHER IN DSA POSITIVE OR NEGATIVE ANTIBODY-MEDIATED REJECTION (ABMR), DETERMINES THE PROGNOSIS IN RENAL ALLOGRAFTS

Binnaz Handan Ozdemir – Ankara, Turkey

10:10

NEXT GENERATION SEQUENCING: ANTIBODY-MEDIATED REJECTION MOLECULAR SIGNATURE AND MACHINE LEARNING CLASSIFIER

Esteban Cortes Garcia – Paris, France

10:20

PROTOCOL BIOPSIES IN PATIENTS WITH SUBCLINICAL DE NOVO DSA AFTER KIDNEY TRANSPLANTATION: LONG TERM DEATH CENSORED GRAFT SURVIVAL.

Dominique Bertrand – Rouen, France

10:30

IMPACT OF PREFORMED DONOR-SPECIFIC HLA-CW AND HLA-DP ANTIBODIES ON ACUTE ANTIBODY MEDIATED REJECTION IN KIDNEY TRANSPLANTATION.

Mehdi Maanaoui – Lille, France

10:40

CLINICAL UTILITY ASSESSMENT OF ANNUAL SYSTEMATIC SCREENING OF POST KIDNEY TRANSPLANT DE NOVO DONOR SPECIFIC ANTIBODIES

Sofiane Salhi – Toulouse, France

10:50

DEVELOPMENT OF DE NOVO DONOR-SPECIFIC HLA ANTIBODIES AND ABMR IN RENAL TRANSPLANT PATIENTS DEPENDS ON CYP3A5 GENOTYPE

Justa Friebus-Kardash – Essen, Germany

11:00

DISTINCT EFFECTOR CD28-CD8 T CELL POPULATIONS DIFFERENTIALLY CONTRIBUTE TO KIDNEY ALLOGRAFT REJECTION

Kevin Louis – Paris, France

11:10

SUBCLINICAL REJECTION-FREE DIAGNOSTIC AFTER KIDNEY TRANSPLANTATION USING BLOOD GENE EXPRESSION

Richard Danger – Nantes, France

BRIEF ORAL

Tuesday, 19 September 2023

- 10:00 - 11:30**
MC 3.4
- Treatable traits lead the way towards better outcomes in lung transplantation**
*Chairs: Antoine Roux —Paris, France
Andrea Zajacova – Prague, Czech Republic*
- 10:54 EVALUATION OF LONG-LASTING LUNG INFLAMMATION IN CIRCULATORY DEATH RAT DONORS USING TISSUE CULTURE AND NORMOTHERMIC REGIONAL PERFUSION
Mayara Munhoz de Assis Ramos - Sao Paulo, Brazil
- 11:18 EVEROLIMUS IN LUNG TRANSPLANT RECIPIENTS FOR CLAD PREVENTION: A REAL LIFE EXPERIENCE
Letizia Corinna Morlacchi – Milan, Italy
- 10:42 FUNGAL INFECTION WITHIN THE FIRST YEAR AFTER LUNG TRANSPLANTATION DOES NOT AFFECT LONG TERM SURVIVAL
Embla Bodén – Lund, Sweden
- 10:30 DIAGNOSTIC YIELD AND SAFETY OF CRYOBIOPSY VERSUS FORCEPS BIOPSY IN LUNG ALLOGRAFT RECIPIENTS: A SINGLE-CENTER RETROSPECTIVE ANALYSIS
Alessandro Palleschi – Milan, Italy
- 11:06 IDENTIFYING TREATABLE TRAITS IN RESTRICTIVE ALLOGRAFT SYNDROME: A NESTED CASE-CONTROL STUDY
Hanne Beeckmans – Leuven, Belgium
- 10:18 CLINICAL RELEVANCE OF CELL-FREE DNA QUANTIFICATION AND QUALIFICATION DURING THE FIRST MONTH AFTER LUNG TRANSPLANTATION
Silvia Casas – Brisbane, United States
- 10:36 INFLUENCE OF THE RESPIRATORY TRACT'S MICROBIOLOGICAL SPECTRUM ON THE OUTCOME AFTER LUNG TRANSPLANTATION
Maximilian Vorstandlechner – Munich, Germany
- 10:24 COMPARISON OF PLASMA DONOR-DERIVED CELL-FREE DNA WITH LASHA SCORING SYSTEM IN LUNG TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE
Federica Pezzuto – Padua, Italy
- 11:12 EXTRACORPOREAL PHOTOPHORESIS IN CHRONIC LUNG ALLOGRAFT DYSFUNCTION. SINGLE CENTER EXPERIENCE
Juan Pablo Reig Mezquida – Valencia, Spain
- 10:48 POLIOMAVIRUS BK REPLICATION IN URINE DETERMINES A RAPID DECLINE IN KIDNEY FUNCTION AFTER LUNG TRANSPLANTATION.
Javier Arias-Alcalá – Cordoba, Spain
- 11:00 EFFECT OF DONOR AGE ON LUNG TRANSPLANT SURVIVAL: A MULTICENTER RETROSPECTIVE STUDY FROM THE COLT DATABASE.
Berenice Reucherand – Nantes, France

- 10:12 INCREASED TOTAL CELL-FREE DNA EARLY AFTER LUNG TRANSPLANTATION IS ASSOCIATED WITH BASELINE LUNG ALLOGRAFT DYSFUNCTION
Andrea Zajacova – Prague, Czech Republic

HANDS-ON COURSE

Tuesday, 19 September 2023

- 10:00 - 11:30**
Ground floor foyer -
Hands on course **Machine Perfusion in my hands: Virtual and interactive KIDNEY (Group 1)**

6 machines for organ perfusion will be available in the wet lab setting. Guided by tutors, participants will follow the steps of kidney perfusion. Participants will rotate around the machines/stations every 15 minutes.

Additional registration for this session is required. Please register via the Congress website

- 10:00 LifePort Kidney Transporter - Organ Recovery Systems
Sarah Hosgood – Cambridge, United Kingdom
- 10:15 VitaSmart - Bridge to life
Colin Wilson - Newcastle upon Tyne, United Kingdom
- 10:30 Kidney Assist Transport - Xvivo
Henri Leuvenink – Groningen, The Netherlands
- 10:45 Kidney Assist - Xvivo
Cyril Moers – Groningen, The Netherlands
- 11:00 EBERS
Annemarie Weissenbacher – Innsbruck, Austria
- 11:00 Aferetica
Lionel Badet - Lyon, France

STATE OF THE ART

Tuesday, 19 September 2023

- 11:45 - 13:15**
Lambrakis **Charting the Future - Bioartificial Organs Approaching the Bedside?!**
Chairs: Cristiano Amarelli – Naples, Italy
Nina Pilat – Vienna, Austria

Regenerative medicine requires orchestrated interdisciplinary approach to achieve an overarching goal - repair, replace, and regenerate damaged organs and tissues. This session will address the state of the art, and key lessons from, organ

- decellularization, organoids generation technology, 3D printing and artificial organ creation, proposing a path forward towards safe translation.
- 11:45 Advancements towards artificial organs
Cecile Legallais – Paris, France
- 12:05 Small organs large aspirations: Next generation organoids
Nuria Montserrat – Barcelona, Spain
- 12:25 Lung bioengineering and regeneration
Sandra Lindstedt – Lund, Sweden
- 12:45 Bioprinting
Burcin Ekser – Indianapolis, United States
- 13:05 *Panel discussion*

STATE OF THE ART

Tuesday, 19 September 2023

11:45 - 13:15
Trianti

Caring in times of crisis

*Chairs: Luciano Potena – Bologna, Italy
Jelena Stojanovic – London, United Kingdom*

This state-of-the-art session addresses the practical and ethical implications of providing transplant and donation care in times of crisis. Three speakers will provide a current overview of factors that may disrupt healthcare systems and undermine standards of care in a range of settings as well as recommendations to minimise disruptions to care and protect potential and actual organ donors and transplant recipients. They will explore the provision of care to refugees fleeing conflict who are transplant candidates and recipients; migrants' vulnerabilities to organ trafficking; and maintenance of donation and transplantation programs in the setting of pandemics.

- 11:45 Are we prepared for the next crisis?
Matthew Weiss – Montreal, Canada
- 12:05 Transplant care in times of conflict
Mehmet Sever – Istanbul, Turkey
- 12:25 Migration and organ trade: kidney sales as a gateway to Europe
Frederike Ambagtsheer – Rotterdam, The Netherlands
- 12:45 Is there enough Resilience in the system?
Raymond Vanholder – Ghent, Belgium
- 13:05 Discussion & wrap-up
Luciano Potena – Bologna, Italy

STATE OF THE ART

Tuesday, 19 September 2023

11:45 - 13:15
Library

From meaning to measurement- how to value what matters in transplantation care

*Chairs: Micaela Hamrin – Stockholm, Sweden
Nichon Jansen – Leiden, The Netherlands*

Patient-reported outcome measures (PROMs) and Patient Reported Experience Measures (PREMs) are necessary to determine if health services also lead to better health from patients' perspectives. There is a demand for increased use of such instruments in clinical routines as well as in national quality registers for transplantation. There are inherent challenges when using PREMs as satisfaction with care might be influenced by expectations, personality traits and previous care experiences. One way to minimize the impact of these factors is to ask about specific experiences, e.g., the care in relation to transplantation. It has been shown that systematic use of patient-reported measures improves and facilitates the communication and relationship between patients and health care professionals. Health problems are identified and dealt with in a more proactive way. PREMs focus on aspects of the humanity of care, such as being treated with dignity or not kept waiting while PROMs focus more on outcomes of importance e.g. HRQoL, functional status, and symptom distress. This session will outline, what to measure, why and how. Why is it increasingly important to evaluate the patients' perspective of the transplantation process and care?

- 11:45 What matters to me
Micaela Hamrin – Stockholm, Sweden
- 11:50 Measuring what matters for patients
K.M. Karin Vermeulen – Groningen, The Netherlands
- 12:10 Will PROMS and PREMs drive change in transplant practice?
Fabienne Dobbels – Leuven, Belgium
- 12:30 Measuring cost-effectiveness in transplant care
Lorenzo Mantovani – Milan, Italy
- 12:50 Striving to become patient centric in life sciences research
Claudio Procaccianti – Milan, Italy
- 13:10 Time to measure together
Micaela Hamrin – Stockholm, Sweden

TV-STUDIO

Tuesday, 19 September 2023

13:30 - 14:00
Muses Foyer

Diversity, collaboration and equity – the TI way.

Host: Jacqui Thornton - Winchester United Kingdom

*Guests: Saskia Bos - Newcastle upon Tyne, United Kingdom
Nazia Selzner – Toronto, Canada
Thierry Berney – Geneva, Switzerland*

MODERATED EPOSTER SESSION

Tuesday, 19 September 2023

14:15 - 15:15
MEP-1

Moderated poster session on pancreas and islet transplantation

Chair: Ekaterine Berishvili – Geneva, Switzerland

14:15

CONTINUOUS VS DISCONTINUOUS HUMAN ISLET PURIFICATION: A MATCHED DONOR COMPARISON.

Antoine Buemi – Brussels, Belgium

14:15

NORMOTHERMIC EX SITU PANCREAS PERFUSION FOR THE PRESERVATION OF PORCINE PANCREAS GRAFTS

Laura Mazilescu – Essen, Germany

14:15

EFFECT OF RECIPIENT BODY MASS INDEX ON OUTCOME OF PANCREAS TRANSPLANTATION: A SINGLE-CENTER 20-YEAR EXPERIENCE

Samrat Ray – Toronto, Canada

14:15

USING DIABETES TECHNOLOGY TO MANAGE HYPERGLYCAEMIA IN PEOPLE WITH TYPE 1 DIABETES AND FAILING PANCREAS TRANSPLANT

Thomas Johnston – London, United Kingdom

14:15

EARLY RELAPAROTOMY NEED AND RISK FACTORS AFTER SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION

Bruno Fraga Dias – Porto, Portugal

14:15

40TH ANNIVERSARY OF PANCREAS TRANSPLANTATION IN SPAIN. LESSONS LEARNED AFTER MORE THAN 650 CASES IN A SINGLE CENTER

Joana Ferrer-Fàbrega – Barcelona, Spain

14:15

RETRANSPLANTATION AFTER PANCREAS GRAFT FAILURE IS IT A VIABLE OPTION FOR SELECTED CANDIDATES?

Barbara Franchin – Padua, Italy

14:15

EVALUATION OF THE EFFICACY OF ANTI-INFLAMMATORY PULMONARY ENTERAL FORMULA IN THE TREATMENT OF PANCREATIC AND LUNG INJURY DUE TO OBSTRUCTIVE JAUNDICE

Sanem Cimen – Ankara, Turkey

- 14:15 ISLET ISOLATION AFTER NORMOTHERMIC MACHINE PERFUSION OF DISCARDED HUMAN PANCREAS. A PROOF OF CONCEPT STUDY.
Catherine Parmentier – Toronto, Canada
- 14:15 SHORT-TERM RESULTS OF ALEMTUZUMAB INDUCTION PROTOCOL CHANGE IN SIMULTANEOUS PANCREAS KIDNEY TRANSPLANTATION FOLLOWING THE COVID-19 PANDEMIC
Vikrant Thakur – Manchester, United Kingdom

MODERATED EPOSTER SESSION

Tuesday, 19 September 2023

- 14:15 - 15:15**
MEP-2 **Moderated poster session on liver transplantation**
Chair: Hermien Hartog – Groningen, The Netherlands
- 14:15 LIVER TRANSPLANTATION DURING COVID-19 PANDEMIC WITH INFECTED DONOR: A RISK WORTH TAKING
Davide Chiappori - L'Aquila, Italy
- 14:15 INDIVIDUALIZED HBIG WITHDRAWAL IN AN HISTORICAL COHORT OF LIVER TRANSPLANT RECIPIENTS IN ITALY.
Raffaella Viganò – Milan, Italy
- 14:15 DO DONOR LIVER BLOOD TESTS PREDICT LIVER TRANSPLANT OUTCOMES? UK NATIONAL COHORT STUDY
Colin Wilson - Newcastle upon Tyne, United Kingdom
- 14:15 OUTCOMES OF RE-REFERRALS FOR PATIENTS WITH ALCOHOL-RELATED LIVER DISEASE WHO WERE PREVIOUSLY DECLINED FOR LIVER TRANSPLANTATION
Benjamin Cox – Toronto, Canada
- 14:15 THE MORBIDITY BURDEN AFTER LIVER TRANSPLANTATION – A TREATMENT-BASED ANALYSIS
Joris Couillerot – Lyon, France
- 14:15 EVALUATION THE SIX MONTH ABSTINENCE RULE PRIOR TO LIVER TRANSPLANT: A CLINICAL PRACTICE GUIDELINE
C Joanna Dionne – Hamilton, Canada
- 14:15 IMPACT OF DUAL HYPOTHERMIC OXYGENATED MACHINE PERFUSION (D-HOPE) ON HEPATOCELLULAR CARCINOMA RECURRENCE AFTER LIVER TRANSPLANTATION
Damiano Patrono – Turin, Italy

- 14:15 LIVER TRANSPLANT RECIPIENTS WITH AUTOIMMUNE HEPATITIS IN THE SWISS TRANSPLANT COHORT STUDY HAVE A HIGHER RISK OF GRAFT LOSS AND VASCULAR COMPLICATIONS
Julien Vionnet – Lausanne, Switzerland
- 14:15 GOOD OUTCOMES AFTER PEDIATRIC LIVER-RETRANSPLANTATIONS: THE ETHICAL DISCUSSION SHOULD BE ENDED
Markus Götz – Regensburg, Germany
- 14:15 IS REMNANT LIVER VOLUME RATIO LESS THAN 30% STILL CONTRAINDICATION TO RIGHT HEPATECTOMY FOR LIVING LIVER DONORS?
Joodong Kim - Daegu, Republic of South Korea

MODERATED EPOSTER SESSION

Tuesday, 19 September 2023

- 14:15 - 15:15**
MEP-3 **Moderated poster session on kidney transplants in children and young people**
Chair: Miriam Cortes Cerisuelo – London, United Kingdom
- 14:15 DONOR-DERIVED CELL-FREE DNA (DD-CFDNA) AS A NON-INVASIVE BIOMARKER OF KIDNEY ALLOGRAFT REJECTION IN PEDIATRIC KIDNEY TRANSPLANTATION.
Julien Hogan – Paris, France
- 14:15 RENAL ALLOGRAFT SURVIVAL FOR (RE)TRANSPLANTED CHILDREN IN ADULTHOOD; AN ERA REGISTRY STUDY FROM 1978 TO 2019.
Evgenia Preka – London, United Kingdom
- 14:15 REGIONAL OUTCOMES OF PAEDIATRIC RENAL TRANSPLANTATION IN THE UK. A MACHINE LEARNING ANALYSIS
Georgios Koufopoulos – Liverpool, United Kingdom
- 14:15 KIDNEY TRANSPLANTATION IN CHILDREN WEIGHING 10 KG OR LESS: IS IT A CHALLENGE?
Ozlem Unlugedik – Istanbul, Turkey
- 14:15 THE EFFECT OF HLA MISMATCHES ON POST-TRANSPLANT OUTCOMES IN PAEDIATRIC RENAL TRANSPLANTATION
Angela Benson – London, United Kingdom
- 14:15 BASILIXIMAB VS ANTI-THYMOCYTE/ANTI-LYMPHOCYTE GLOBULINS IN PEDIATRIC KIDNEY TRANSPLANTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Mikhail Nozdrin – London, United Kingdom

- 14:15 EFFECT OF DONOR TYPE ON GRAFT AND PATIENT SURVIVAL IN PAEDIATRIC RECIPIENTS OF KIDNEY AND LIVER TRANSPLANTATION.
Maria Selyanina – London, United Kingdom
- 14:15 STEROID-BASED VS STEROID-FREE IMMUNOSUPPRESSION IN PAEDIATRIC KIDNEY TRANSPLANTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Kavyesh Vivek - London, United Kingdom
- 14:15 COMPARISON OF OUTCOMES BETWEEN BASILIXIMAB AND THYMOGLOBULIN IN LOW-RISK PEDIATRIC KIDNEY TRANSPLANT RECIPIENTS FROM PEDIATRIC DECEASED DONORS
Qiang Zhang – Guangzhou, China
- 14:15 SYSTEMATIC DIGITAL ASSESSMENT OF PATIENT-REPORTED OUTCOMES IN CLINICAL FOLLOW-UP OF PEDIATRIC KIDNEY TRANSPLANTATION PATIENTS: A PILOT STUDY.
Fabian Eibensteiner – Vienna, Austria

TV-STUDIO

Tuesday, 19 September 2023

14:30 - 15:00
Muses Foyer

Xenotransplantation – are we ready for clinical trials in humans?

Host: Jacqui Thornton – Winchester, United Kingdom

*Guests: Frederike Ambagtsheer – Rotterdam, The Netherlands
Jayme Locke – Birmingham, United States*

PLENARY

Tuesday, 19 September 2023

15:15 - 16:45
Lambrakis

Resolving the Shumway Paradox: Xenotransplantation in the spotlight

*Chairs: Umberto Cillo – Padua, Italy
Ekaterine Berishvili – Geneva, Switzerland*

The session will review the scientific advances that laid the first pig-to-human heart transplant, one of the most exciting breakthroughs in transplantation medicine of the century. Featured experts will discuss the future for xenotransplantation including clinical potential, challenges, ethical considerations.

15:15 Introduction & Opening

- 15:20 Xenotransplantation: From zero to hero?
Where do we come from? Where are we going?
Jayne Locke – Birmingham, United States
- 15:40 CRISPR then nature – Generation of the genetically modified pigs: techniques and choice of the target genes
David Ayares – Blacksburg, United States
- 16:00 Building the bridge to clinic
Main challenges on the path to success, international standards and regulatory issues for xenotransplantation
Eckhard Wolf – Munich, Germany
- 16:20 Panel discussion

FULL ORAL

Tuesday, 19 September 2023

17:00 - 18:30
Lambrakis

Innovations in kidney immunosuppression

Chairs: *Georg Böhmig – Vienna, Austria*
Marlies Reinders – Rotterdam, The Netherlands

- 17:00 IMPACT OF DESENSITIZATION THERAPY WITH ISATUXIMAB ON HLA-SPECIFIC MEMORY B CELLS AND PLASMA CELLS IN HIGHLY SENSITIZED PATIENTS
Alba Torija - Hospitalet de Llobregat, Spain
- 17:10 DARATUMUMAB DESENSITIZATION BEFORE KIDNEY TRANSPLANTATION – A PILOT STUDY
Marie Matignon – Creteil, France
- 17:20 EARLY RESULTS OF ATTAIN (ITN090ST): DARATUMUMAB & BELATACEPT FOR HLA DESENSITIZATION IN KIDNEY TRANSPLANT CANDIDATES WITH 100% CPRA
Flavio Vincenti - San Francisco, United States
- 17:30 A PILOT STUDY EVALUATING DUAL CO-STIMULATION BLOCKADE WITH DAZODALIBEP (HZN4920) AND BELATACEPT FOR PROPHYLAXIS OF KIDNEY ALLOGRAFT REJECTION
Flavio Vincenti - San Francisco, United States
- 17:40 A PHASE I/IIA TRIAL OF AUTOLOGOUS REGULATORY T CELL THERAPY TOGETHER WITH DONOR BONE MARROW INFUSION IN KIDNEY TRANSPLANTATION
Thomas Wekerle – Vienna, Austria

- 17:50 LONG-TERM OUTCOMES AFTER CONVERSION TO A BELATACEPT-BASED IMMUNOSUPPRESSION IN KIDNEY TRANSPLANT: A MATCHED COHORT STUDY
Gillian Divard – Paris, France
- 18:00 EFFECTIVENESS OF THE TREATMENT OF ANTIBODY MEDIATED REJECTION: A REAL-WORLD EVIDENCE STUDY
Gillian Divard – Paris, France
- 18:10 RESULTS OF THE TRIBUTE RANDOMIZED TRIAL: TREATMENT WITH BORTEZOMIB OF LATE ANTIBODY-MEDIATED REJECTION DUE TO DE NOVO DSA
Renaud Snanoudj - Le Kremlin-Bicêtre, France

FULL ORAL

Tuesday, 19 September 2023

17:00 - 18:30
Trianti

Basic science immunology

*Chairs: Martin Hoogduijn – Rotterdam, The Netherlands
Nina Pilat – Vienna, Austria*

- 17:00 A NOVEL BI-SPECIFIC FUSION PROTEIN WITH CTLA4IG/PDL2 AS A NOVEL IMMUNOSUPPRESSANT MOLECULE MODULATING ALLOIMMUNE RESPONSES
Delphine Kervella – Barcelona, Spain
- 17:10 VISUALIZING THE EFFECT OF BCL6 INHIBITION ON B AND T LYMPHOCYTES BY THE SMALL MOLECULE COMPOUND 79-6 BY MEANS OF IMAGING FLOW CYTOMETRY
Rens Kraaijeveld – Rotterdam, The Netherlands
- 17:20 PROTECTIVE EFFECT OF RECOMBINANT THROMBOMODULIN ALPHA AGAINST LONG COLD ISCHEMIA REPERFUSION INJURY IN A RAT KIDNEY TRANSPLANT MODEL
Kazunobu Shinoda – Kawasaki, Japan
- 17:30 NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITION AS A NOVEL TREATMENT TARGET IN ALLOGRAFT REJECTION
Bernhard Texler – Innsbruck, Austria
- 17:40 NK-MEDIATED INNATE ALLORECOGNITION CONTROLS THE EARLY PRODUCTION OF DONOR SPECIFIC ANTIBODIES BY THE INVERTED DIRECT PATHWAY
Xavier Charmetant – Lyon, France

- 17:50 ALLOREACTIVE T CELL REPERTOIRES DISPLAY BIASED VARIABLE SEGMENT USAGE AND FINE-TUNING OF PEPTIDE SPECIFICITY BY COMPLEMENTARITY-DETERMINING REGION 3B.
Alexandra Sharland – Sydney, Australia
- 18:00 MAPPING THE CELLULAR AND MOLECULAR LANDSCAPE OF ADAPTIVE IMMUNE RESPONSES IN KIDNEY ALLOGRAFT REJECTION
Kevin Louis – Paris, France
- 18:10 SINGLE CELL TRANSCRIPTOME OF ALLOREACTIVE CD8 T CELLS SUPPORTS ROLES FOR BOTH DELETION AND EXHAUSTION IN TOLERANCE INDUCTION.
Alexandra Sharland – Sydney, Australia

STORYTELLING

Tuesday, 19 September 2023

17:00 - 18:30
Mitropoulos

I did it my way. How did I get here?

Chairs: *Hannah Esser – Innsbruck, Austria*
Hannah Valantine – Stanford, United States

This motivational session will highlight the highs and lows of the career => motivation for the young generation.

- 17:00 Aspirations and inspirations
Camillo Ricordi – Miami, United States
- 17:15 How do you turn obstacles into opportunities/ challenges
Hannah Valantine – Stanford, United States
- 17:30 Changing the preservation paradigm
Peter Friend – Oxford, United Kingdom
- 17:45 Breaking down barriers
Elmi Müller - Cape Town, South Africa
- 18:00 Panel Discussion
Hannah Esser – Innsbruck, Austria; Hannah Valantine - Stanford, United States

BRIEF ORAL

Tuesday, 19 September 2023

17:00 - 18:30
Library

Cardiovascular and metabolic complications after kidney transplant - old challenges, new solutions

*Chairs: Maria Koukoulaki - Athens, Greece
Adnan Sharif – Birmingham, United Kingdom*

- 17:00 IS A BLOOD PRESSURE BELOW 130/80 MM HG A UNIVERSAL GOAL FOR ALL RENAL TRANSPLANT RECIPIENTS? AN ANALYSIS OF THE COLLABORATIVE TRANSPLANT STUDY
Thuong Hien Tran – Heidelberg, Germany
- 17:06 COMPARISON OF OFFICE, HOME AND AMBULATORY BLOOD PRESSURE IN KIDNEY TRANSPLANT RECIPIENTS WITH AND WITHOUT TELEMEDICINE MONITORING
Georgios Eleftheriadis – Berlin, Germany
- 17:12 PREDICTION OF MACE AND MORTALITY AMONG KIDNEY TRANSPLANT CANDIDATES USING RISK FACTORS, CORONARY ARTERY CALCIUM SCORE AND CORONARY CT ANGIOGRAPHY
Marie Nielsen – Aarhus, Denmark
- 17:18 INFLUENCE OF LOW- AND HIGH-DENSITY LIPOPROTEIN CHOLESTEROL ON GRAFT FUNCTION IN RENAL TRANSPLANT RECIPIENTS - A COLLABORATIVE TRANSPLANT STUDY REPORT
Thuong Hien Tran – Heidelberg, Germany
- 17:24 GLIFLOZIN IN RENAL TRANSPLANTATION: A MULTICENTER OBSERVATIONAL STUDY (GREAT-ASTRE)
Lucie Maigret – Tours, France
- 17:30 RISK FACTORS OF DE NOVO POST TRANSPLANTATION DIABETES MELLITUS MORE THAN 8 WEEKS AFTER KIDNEY TRANSPLANTATION - A NATIONAL COHORT STUDY
Rasmus Carlsen – Oslo, Norway
- 17:36 POST-TRANSPLANT DIABETES MELLITUS IN DIFFERENT IMMUNOSUPPRESSION TREATMENTS: A META-ANALYSIS
Laia Oliveras - L'Hospitalet de Llobregat, Spain
- 17:42 DEVELOPMENT AND VALIDATION OF A NEW SCORE TO ASSESS THE RISK OF POST-TRANSPLANTATION DIABETES MELLITUS IN KIDNEY TRANSPLANT RECIPIENTS
Maria Carolina Isaza-Lopez – Medellin, Colombia
- 17:48 A PROSPECTIVE COHORT STUDY OF SODIUM/GLUCOSE COTRANSPORTER 2 INHIBITOR-TREATED DIABETIC KIDNEY TRANSPLANT PATIENTS
Jin min Kong - Busan, Republic of South Korea
- 17:54 FIRST USE OF DEEP LONG SHORT-TERM MEMORY NEURAL NETWORK IN PREDICTING KIDNEY GRAFT FUNCTION
Vesna Furic Cunko – Zagreb, Croatia
- 18:00 IMPACT OF FULL CORRECTION OF HEMOGLOBIN AMONG POST-TRANSPLANT ANEMIC KIDNEY TRANSPLANT RECIPIENTS: PROSPECTIVE RANDOMIZED CONTROLLED TRIAL
Hasaneen Aboatya – Kuwait, Kuwait

- 18:06 ERECTILE DYSFUNCTION AFTER KIDNEY TRANSPLANTATION IN MALES WITH END-STAGE KIDNEY DISEASE: A META-ANALYSIS
Adelina Miron – Iasi, Romania
- 18:12 OUTCOMES FOLLOWING ARTERIO-VEINUS FISTULA LIGATION FOLLOWING KIDNEY TRANSPLANTATION
Michelle Willicombe – London, United Kingdom
- 18:18 PROSPECTIVE RANDOMIZED CONTROLLED TRIAL ANALYZING THE EFFECTS OF DENOSUMAB ON BONE MINERAL DENSITY AND BONE METABOLISM IN RENAL ALLOGRAFT TRANSPLANTS.
Amit Sharma – Chandigarh, India

FOCUS GROUP

Tuesday, 19 September 2023

- 17:00 - 18:30**
Conference Suite 1 **Public perception in organ donation : multi-stakeholder vision and work team**
Chairs: Corinne Antoine – Paris, France
Chloe Balleste – Barcelona, Spain
- 17:00 ORGAN DONATION AFTER BRAIN-DEATH - FAMILY DYNAMICS, FACTORS FOR CONSENT AND ATTACHMENT OF MEANING AS A WAY TO PROCESS LOSS
Isidora Skourli – Athens, Greece
- 17:10 RELATIVES' DECISION PROCESSES AND PERCEPTIONS IN THE CONTEXT OF INTENSIVE CARE FOR ORGAN DONATION: RESULTS OF A QUALITATIVE STUDY
Rubén García-Sánchez – Madrid, Spain
- 17:20 OUTCOME TO DEVELOPING EDUCATION PROGRAMS TO ADVANCE ORGAN DONATION ACTIVITY IN THE ORGAN PROCUREMENT ORGANIZATION: A SIX YEAR DATA
Maria Theresa Bad-Ang - Davao City, Philippines
- 17:30 ICU STAFF'S SELF-REPORTED NEED FOR SUPPORT AND EDUCATION IN ORGAN DONATION
Kathe Meyer – Oslo, Norway
- 17:40 IMPROVING DECEASED DONATION THROUGH AN INTERNATIONAL COOPERATION TRAINING FOR HEALTH PROFESSIONALS
Chloe Balleste – Barcelona, Spain
- 17:50 MASS MEDIA CAMPAIGNS SENSITIZE BUT FAIL TO INCREASE ACTUAL ORGAN DONATION RATE
Francisca Gonzalez Cohens – Santiago, Chile

- 18:00 BARRIERS AND FACILITATORS TOWARD THE MAKING OF DECEASED ORGAN DONATION AMONG STAKEHOLDERS FROM TWO DIVERSE REGIONS IN INDIA.
Britzer Paul Vincent – Luton, United Kingdom
- 18:10 OLDER LIVING LIVER DONORS CAN ENLARGE THE DONOR POOL: A SYSTEMATIC REVIEW AND META-ANALYSIS
Hayo ter Burg – Rotterdam, The Netherlands

BRIEF ORAL

Tuesday, 19 September 2023

- 17:00 - 18:30**
MC 3.2 **Pediatric Transplantation - Stronger Together**
*Chairs: Miriam Cortes Cerisuelo – London, United Kingdom
Nicos Kessarlis – London, United Kingdom*
- 17:00 LANDSCAPE OF SUBCLINICAL REJECTION IN A LARGE INTERNATIONAL COHORT OF PEDIATRIC KIDNEY TRANSPLANT (KTX) RECIPIENTS.
Julien HOGAN – Paris, France
- 17:06 DETERMINATION OF SHORT AND LONG TERM RESULTS OF LIVER TRANSPLANTED PATIENTS WITH THE DIAGNOSIS OF INBORN ERRORS OF METABOLISM
Figen Ozcay – Ankara, Turkey
- 17:12 THE UK KIDNEY DONOR RISK INDEX POORLY PREDICTS LONG-TERM TRANSPLANT SURVIVAL IN PAEDIATRIC KIDNEY TRANSPLANT RECIPIENTS.
Jon Jin Kim – Nottingham, United Kingdom
- 17:18 IMPACT OF ANTI-ENDOTHELIN-1 RECEPTOR TYPE A ANTIBODIES IN PEDIATRIC RENAL TRANSPLANTATION
Emanuele Cozzi – Padua, Italy
- 17:24 SIMULTANEOUS TOTAL INTERNAL BILIARY DIVERSION IN LIVER TRANSPLANTATION FOR PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TYPE 1: A STANDARD OF CARE?
Jagadeesh Menon – Chennai, India
- 17:30 HYPOTHERMIC OXYGENATED MACHINE PERFUSION IN PEDIATRIC KIDNEY TRANSPLANTATION: A PRELIMINARY SINGLE CENTER EXPERIENCE.
Gionata Spagnoletti – Rome, Italy
- 17:36 LIVER RETRANSPLANTATION IN CHILDREN.
Agnieszka Kwiecińska – Warsaw, Poland

- 17:42 KIDNEY TRANSPLANTATION IN PEDIATRIC PATIENTS WITH SEVERE LOWER URINARY TRACT DYSFUNCTION. IS ILEAL CONDUIT M.BRICKER AS GOOD AS NORMAL BLADDER?
Dorota Broniszczak-Czyszczek – Warsaw, Poland
- 17:54 KIDNEY GRAFT OUTCOMES FOLLOWING KIDNEY VERSUS SIMULTANEOUS LIVER-KIDNEY TRANSPLANTATION IN CHILDREN – ANALYSIS OF THE UNOS DATABASE
Ioannis D. Kostakis – London, United Kingdom
- 18:00 KIDNEY GRAFT OUTCOMES FOLLOWING PAEDIATRIC BLOOD GROUP INCOMPATIBLE TRANSPLANTATION – ANALYSIS OF THE UNOS DATABASE
Ioannis D. Kostakis – London, United Kingdom
- 18:06 VALIDATION OF A PREDICTION SYSTEM FOR RISK OF ALLOGRAFT LOSS (IBOX) IN PEDIATRIC KIDNEY TRANSPLANT RECIPIENTS
Julien Hogan – Paris, France
- 18:12 BRIDGING THE RENAL TRANSPLANT GAP IN PEDIATRIC PATIENTS IN GREECE: A 3-YEAR EXPERIENCE OF A PEDIATRIC TRANSPLANT PROGRAM IN AN ADULT TRANSPLANT CENTER
Eleni Kapsia – Athens, Greece
- 18:18 FIRST REPORT ON THE USE OF A TRANSPLANTED RECTUS SHEATH FASCIA FOR A COMBINED LIVER AND KIDNEY TRANSPLANT IN A PAEDIATRIC PATIENT WITH MMA
Alicia Paessler – London, United Kingdom

FULL ORAL

Tuesday, 19 September 2023

17:00 - 18:30
MC 3.4

Defining risk and optimizing selection

Chairs: *Luca Belli – Milan, Italy*
Nazia Selzner – Toronto, Canada

- 17:00 WHERE TO DRAW THE LINE IN EX-SITU SPLIT LIVER TRANSPLANTATION FOR ADULT RECIPIENTS? A BENCHMARKING ANALYSIS
Xavier Muller – Lyon, France
- 17:10 LIVER TRANSPLANTATION IN THE ELDERLY: PROPOSAL FOR AN INNOVATIVE PATIENT SELECTION PROTOCOL
Nicola Canitano – Padua, Italy
- 17:20 AGE AND LIVER GRAFT: A SYSTEMATIC REVIEW WITH METAREGRESSION
Ilaria Neri – Rome, Italy

- 17:30 DEVELOPMENT OF A 'LIVER ATLAS' USING OVER 1,000 CONSECUTIVE DECEASED DONOR LIVERS TO IDENTIFY HEPATIC STEATOSIS PRIOR TO RETRIEVAL
Hussain Abbas – Oxford, United Kingdom
- 17:40 PREDICTING POST-TREATMENT (SURGICAL, ABLATIVE, LIVER TRANSPLANT) RECURRENCE IN EARLY-STAGE HEPATOCELLULAR CARCINOMA USING DEEP MACHINE LEARNING
Ramesh Batra - New Haven, United States
- 17:50 DOES NATIVE HEPATECTOMY TECHNIQUE HAVE ANY IMPACT ON ONCOLOGIC OUTCOMES OF LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA?
Riccardo Pravisani – Udine, Italy
- 18:00 PREDICTION AND DIAGNOSIS OF REJECTION IN LIVER TRANSPLANTATION USING A BIOMARKER MODEL BASED ON CXCL-10 AND MICRORNAS 155-5P AND 181A-5P
Pablo Ruiz – Barcelona, Spain
- 18:10 WORLDWIDE DATA FROM THE IMPROVEMENT LIVER TRANSPLANT STUDY: AN INTERIM ANALYSIS OF DONOR AND RECIPIENT PROFILES.
Alfonso Avolio – Rome, Italy

HANDS-ON COURSE

Tuesday, 19 September 2023

17:00 - 18:30
Ground floor foyer -
Hands on course

Machine Perfusion in my hands: Virtual and interactive KIDNEY (Group 2)

6 machines for organ perfusion will be available in the wet lab setting. Guided by tutors, participants will follow the steps of kidney perfusion. Participants will rotate around the machines/stations every 15 minutes.

Additional registration for this session is required. Please register via the Congress website

- 17:00 LifePort Kidney Transporter - Organ Recovery Systems
Sarah Hosgood – Cambridge, United Kingdom
- 17:15 VitaSmart - Bridge to life
Colin Wilson - Newcastle upon Tyne, United Kingdom
- 17:30 Kidney Assist Transport - Xvivo
Henri Leuvenink – Groningen, The Netherlands
- 17:45 Kidney Assist - Xvivo
Cyril Moers – Groningen, The Netherlands

- 18:00 **EBERS**
Annemarie Weissenbacher – Innsbruck, Austria
- 18:15 **Aferetica**
Lionel Badet – Lyon, France

HANDS-ON COURSE

Tuesday, 19 September 2023

17:00 - 18:00
Ground floor foyer -
Hands on course

Machine Perfusion in my hands: Virtual and interactive LUNG/HEART

2 machines for organ perfusion will be available in the wet lab setting. Guided by tutors, participants will follow the steps of heart and lung perfusion. Participants will rotate around the machines/stations every 25 minutes.

Additional registration for this session is required. Please register via the Congress website

- 17:00 **XPS - Xvivo**
Sandra Lindstedt – Lund, Sweden
- 17:25 **Heart technology - Xvivo**
Cristiano Amarelli – Naples, Italy

STATE OF THE ART

Tuesday, 19 September 2023

20:00 - 21:00
Atrium

Xenotransplantation: Navigating Ethical Frontiers and Societal Impact

Chair: Jacqui Thornton - Winchester United Kingdom

20:00 Discussion Panel

David Ayares - Blacksburg, United States; Efstratios Chatzixiros - Geneva, Switzerland; Penilla Gunther - Stockholm, Sweden; Matthias Kaiser - Bergen, Norway; Jayme Locke - Birmingham, United States; Eckhard Wolf - Munich, Germany;

Wednesday, 20 September 2023

STATE OF THE ART

Wednesday, 20 September 2023

08:00 - 09:30
Lambrakis

ABMR across organs

*Chairs: Marlies Reinders – Rotterdam, The Netherlands
Robin Vos – Leuven, Belgium*

Antibody-mediated rejection is recognised as a major threat to transplant success, for all solid organs. Although the existence of antibody-mediated rejection is widely recognised, the phenotypic diversity of the disease presents clinical dilemmas in its classification, with implications for the outcome. In this session, new insights into the pathobiology of antibody-mediated rejection and phenotypes of microvascular inflammation will be discussed, as well as their relation to clinical diagnostics and therapeutic options. Finally, guidelines for monitoring and prevention of antibody-mediated rejection will be critically evaluated.

08:00

New picture of ABMR: The phenotype and importance of ABMR
Candice Roufosse – London, United Kingdom

08:20

Monitoring ABMR in organ transplantation
Marta Crespo – Barcelona, Spain

08:40

Prevention and treatment of ABMR
Carmen Lefaucheur – Paris, France

09:00

ABMR without anti-HLA Donor specific antibodies: New targets and activation mechanisms
Olivier Thauvat – Lyon, France

09:20

Q&A

STATE OF THE ART

Wednesday, 20 September 2023

08:00 - 09:30
Trianti

Machine Perfusion - what next?

*Chairs: Ina Jochmans – Leuven, Belgium
Stefan Schneeberger – Innsbruck, Austria*

As Machine Perfusion is making a significant impact on the delivery of transplantation, a new set of questions is being asked: what next after organ perfusion? How do we blend Machine Perfusion with regenerative medicine? How

	do we deliver this service and make it available without introducing new barriers to access?
08:00	Introduction <i>Ina Jochmans – Leuven, Belgium</i>
08:05	In-situ, ex-situ or both? <i>Gabriel Oniscu – Stockholm, Sweden</i>
08:25	Treat & Repair is the new aim <i>Paulo Martins - Boston, United States</i>
08:45	From Preservation to Organ banking <i>Marcelo Cypel – Toronto, Canada</i>
09:05	Make or break: achieving sustainability <i>Annemarie Weissenbacher – Innsbruck, Austria</i>
09:25	Session wrap-up

STATE OF THE ART

Wednesday, 20 September 2023

08:00 - 09:30
Banquet Hall

Policy making, driving change in Europe

Chairs: *Efstratios Chatzixiros – Geneva, Switzerland*
Pisana Ferrari – Udine, Italy

This state-of-the-art session aims to share the initiatives driven in policy-making to homogenise clinical practices ensuring legal and ethical framework in Europe. Different stakeholders involved in organ donation and transplantation activities, (public/international institutions, patients, and professionals) will present projects driven in this regard. The main topics and challenges that will be discussed are the risk of overlapping initiatives; the role of the stakeholders shaping policies in the EU; the possibility to extend the EU experience to other territories; and the policy implementation.

08:00	Transplant Eurovision <i>Emanuele Cozzi – Padua, Italy</i>
08:20	From aspiration to implementation <i>Stefaan van der Spiegel – Brussels, Belgium</i>
08:40	Can patients' associations shape policy in the EU? <i>Penilla Gunther – Stockholm, Sweden</i>
09:00	Making donation usual in Europe <i>Chloe Balleste – Barcelona, Spain</i>
09:20	Discussion

TV-STUDIO

Wednesday, 20 September 2023

09:30 - 10:00
Muses Foyer

Transplantation- a public health issue? Ensuring equal access.

Host: Jacqui Thornton – Winchester, United Kingdom

*Guests: Chloe Balleste – Barcelona, Spain
Umberto Cillo – Padua, Italy
Luciano Potena – Bologna, Italy*

SOLUTION ROOM

Wednesday, 20 September 2023

10:00 - 11:30
Lambrakis

A new dawn? Molecular microscope for real time patient care

*Chairs: Menna Clatworthy - Cambridge United Kingdom
Michael Mengel - Alberta Canada*

This solution room session will present novel insight into molecular diagnosis for real-time patient care. The Banff point of view, the medical point of view and the next steps into moving to real-time molecular diagnosis in solid organ transplantation will be discussed. Is histology old fashion?

- | | |
|-------|---|
| 10:00 | Molecular Diagnosis: Building the molecular diagnosis system (why?)
<i>Alexandre Loupy – Paris, France</i> |
| 10:15 | Molecular Diagnosis: moving to real time diagnosis (how do we move?)
<i>Olivier Aubert – Paris, France</i> |
| 10:30 | Is histology really overrated?
<i>Candice Roufosse – London, United Kingdom</i> |
| 10:45 | Rejection in liver transplantation
<i>Chris Bellamy – Edinburgh, United Kingdom</i> |
| 10:55 | Rejection in lung transplantation
<i>Antoine Roux – Paris, France</i> |
| 11:05 | Meet the experts, Histology vs molecular diagnosis. Is histology old fashion these days?
<i>Olivier Aubert - Paris, France; Chris Bellamy - Edinburgh, United Kingdom; Alexandre Loupy - Paris France; Michael Mengel - Alberta, Canada; Candice Roufosse - London, United Kingdom; Antoine Roux - Paris, France</i> |

DARE TO ASK

Wednesday, 20 September 2023

10:00 - 11:30
Trianti

How can I bring machine perfusion into my clinical practice?

*Chairs: Cristiano Amarelli – Naples, Italy
Sarah Hosgood – Cambridge, United Kingdom*

How to implement technology in routine clinical practice?
How does machine perfusion change KPIs in transplants?
How to get MP reimbursed?

10:00

Introduction
Cristiano Amarelli - Naples, Italy; Sarah Hosgood – Cambridge, United Kingdom

10:05

Do I need a liver perfusion programme?
Damiano Patrono – Turin, Italy

10:20

Lung programme establishment
Sandra Lindstedt – Lund, Sweden

10:35

More hearts but at what cost?
Arezu Aliabadi-Zuckermann – Vienna, Austria

10:50

Where to go with kidney perfusion?
Cyril Moers – Groningen, The Netherlands

11:05

Q&As from audience: Building a sustainable perfusion programme?

FULL ORAL

Wednesday, 20 September 2023

10:00 - 11:30
Banquet Hall

Kidney biomarkers to the rescue

*Chairs: Umberto Maggiore – Parma, Italy
Elisabet Van Loon – Leuven, Belgium*

10:00

ASSESSMENT OF DONOR-DERIVED CELL-FREE DNA (DD-CFDNA) IN KIDNEY TRANSPLANT RECIPIENTS WITH INDICATION BIOPSY
Louise Benning – Heidelberg, Germany

10:10

MULTIDIMENSIONAL RISK ASSESSMENT OF KIDNEY ALLOGRAFT REJECTION USING DONOR DERIVED CELL-FREE DNA
Cindy Ursule-Dufait – Paris, France

- 10:20 DETECTION OF KIDNEY ALLOGRAFT REJECTION USING BLOOD BIOMARKERS: RESULTS OF THE EUROPEAN MULTICENTER PROSPECTIVE EU-TRAIN TRIAL (NCT03652402)
Valentin Goutaudier – Paris, France
- 10:30 DSA-NEGATIVE MICROVASCULAR INFLAMMATION IN KIDNEY TRANSPLANT BIOPSIES: GENE EXPRESSION COMPARISON WITH NATIVE AND TRANSPLANT KIDNEY CONTROLS
Anna Buxeda – Barcelona, Spain
- 10:40 AGE-MODULATED PROTEOMIC SIGNATURES OF DONOR KIDNEY BIOPSIES ASSOCIATE WITH BELOW-MEDIAN 12 MONTH OUTCOMES
Philip Charles – Oxford, United Kingdom
- 10:50 OVERALL ACTIVITY AND CHRONICITY INDICES OF KIDNEY TRANSPLANT BIOPSIES: VALIDATION ON NEW DATA.
Thibaut Vaulet – Leuven, Belgium
- 11:00 ASSESSING REJECTION WITH MACHINE LEARNING BASED ON BIOPSY ELEMENTARY LESIONS AND CLINICAL INFORMATION
Marc Labriffe – Limoges, France
- 11:10 KIDNEY COLOR: ARTIFICIAL INTELLIGENCE IMAGE PROCESSING TO IMPROVE KIDNEY TRANSPLANT OUTCOMES PREDICTION
Enric Miret Alomar – Barcelona, Spain

FULL ORAL

Wednesday, 20 September 2023

- 10:00 - 11:30**
Mitropoulos **Organ preservation and ischemia reperfusion**
*Chairs: Umberto Cillo – Padua, Italy
Thamara Perera – Birmingham, United Kingdom*
- 10:00 PROLONGED HYPOTHERMIC MACHINE PERFUSION TO ENABLE DAYTIME LIVER TRANSPLANTATION – A RANDOMIZED CLINICAL TRIAL
Vincent E. de Meijer – Groningen, The Netherlands
- 10:10 WHAT IS THE OPTIMAL PRESERVATION STRATEGY FOR MARGINAL LIVER GRAFTS USING HYPOTHERMIC OXYGENATED PERFUSION? A PRECLINICAL STUDY
Xavier Muller – Lyon, France
- 10:20 HYPOTHERMIC OXYGENATED PERFUSION AFTER NORMOTHERMIC REGIONAL PERFUSION TO EXTEND SELECTION CRITERIA IN CDCD LIVER TRANSPLANTATION
Xavier Muller – Lyon, France

- 10:30 DUAL HYPOTHERMIC OXYGENATED MACHINE PERFUSION IS ASSOCIATED WITH IMPROVED RECOVERY OF ACUTE KIDNEY INJURY AFTER DCD LIVER TRANSPLANTATION
Femke de Goeij – Rotterdam, The Netherlands
- 10:40 LACTATE DYNAMICS DURING THE FIRST 6 HOURS OF LIVER NORMOTHERMIC MACHINE PERFUSION PREDICTS CLINICAL OUTCOME – A MULTICENTER STUDY
Julia Hofmann – Innsbruck, Austria
- 10:50 BLOCKADE OF REGULATED CELL DEATH ABROGATES EFFECTOR T-CELL INFILTRATION AND MINIMIZES HEPATIC ISCHEMIA REPERFUSION DAMAGE
Elke Eggenhofer – Regensburg, Germany
- 11:00 THE USE OF A CYTOKINES ADSORPTION CARTRIDGE DURING EX-SITU HYPO AND NORMOTHERMIC MACHINE PERFUSION IN LIVER TRANSPLANTATION: A PILOT RANDOMIZED STUDY
Davide Ghinolfi – Pisa, Italy
- 11:10 HYPOXIA INDUCIBLE FACTOR MODULATION DURING NORMOTHERMIC MACHINE PERFUSION (NMP) ACCELERATES REDUCTION IN HEPATIC STEATOSIS
Hussain Abbas – Oxford, United Kingdom

BRIEF ORAL

Wednesday, 20 September 2023

- 10:00 - 11:30**
Skalkotas **Kidney rejection, function and survival**
*Chairs: Muhammad Khurram – London, United Kingdom
Stathis Tsiakas – Athens, Greece*
- 10:00 LANDSCAPE OF T-CELL MEDIATED REJECTION RESPONSE TO TREATMENT AFTER KIDNEY TRANSPLANTATION.
Gillian Divard – Paris, France
- 10:06V OPERABILITY OF THE BANFF “V” LESION SCORE IN DSA POSITIVE MIXED REJECTION
Karolien Wellekens – Leuven, Belgium
- 10:12 CALLING INTO QUESTION THE ADDED VALUE OF THE ‘PTC RULE’ IN CLASSIFYING KIDNEY TRANSPLANT REJECTION
Karolien Wellekens – Leuven, Belgium
- 10:18 COMPARISON OF CLINICAL AND PATHOLOGICAL FEATURES OF REJECTION IN ABO-IMCOMPATIBLE AND ABO-COMPATIBLE KIDNEY TRANSPLANTATION
Hyun-jeong Kim – Seoul, Republic of South Korea

- 10:24 ACUTE REJECTION AFTER CONVERSION TO BELATACEPT IN KIDNEY TRANSPLANTATION
Dominique Bertrand – Rouen, France
- 10:32 SUBCLINICAL ANTIBODY-MEDIATED REJECTION DETECTED BY EARLY (TWO WEEKS) PROTOCOL BIOPSIES IN HIGHLY IMMUNIZED TRANSPLANT RECIPIENTS
Carolt Arana – Barcelona, Spain
- 10:38 A NOVEL TWO STAGE REJECTION PREDICTION MODEL IN KIDNEY ALLOGRAFT USING SERIAL GENE EXPRESSION PROFILE AND DONOR-DERIVED CELL-FREE DNA
Sook Park – Chicago, United States
- 10:44 SURVIVAL OUTCOMES COMPARING OLDER LIVING DONOR VERSUS STANDARD CRITERIA DONOR KIDNEY TRANSPLANTATION VERSUS NOT BEING TRANSPLANTED
Kamlesh Patel – Morden, United Kingdom
- 10:50 PREDICTION OF GRAFT SURVIVAL PRIOR TO ACCEPTING AN OFFER FOR LIVING DONOR KIDNEY TRANSPLANT: AN ARTIFICIAL INTELLIGENCE APPROACH
Hatem Ali – Coventry, United Kingdom
- 10:56 PREDICTION OF KIDNEY FAILURE AND DEVELOPMENT OF HYPERTENSION AMONG POTENTIAL LIVING DONORS: AN ARTIFICIAL INTELLIGENCE APPROACH
Hatem Ali – Coventry, United Kingdom
- 11:02 DECEASED DONOR KIDNEY TRANSPLANTATION IN PRESENSITIZED RECIPIENTS WITHOUT PRIOR DESENSITIZATION THERAPY: A SINGLE-CENTER EXPERIENCE
Lan Zhu – Wuhan, China
- 11:08 IMPACT OF INDIVIDUAL EPLETS TO ACUTE REJECTION STUDIED BY MACHINE LEARNING METHOD: ANALYSIS OF KOREAN ORGAN TRANSPLANTATION REGISTRY
Jong Cheol Jeong - Seongnam, Republic of South Korea
- 11:14 CLINICAL EVOLUTION OF PATIENTS WITH DE NOVO DONOR-SPECIFIC HLA ANTIBODIES AFTER KIDNEY TRANSPLANTATION
Covadonga López del Moral – Berlin, Germany
- 11:20 USE OF TOCILIZUMAB IN CHRONIC ACTIVE ANTIBODY-MEDIATED REJECTION IN PEDIATRIC KIDNEY TRANSPLANT RECIPIENTS
Maria Sangermano – Padua, Italy

STORYTELLING

Wednesday, 20 September 2023

10:00 - 11:30
Library

Equality, diversity and inclusion: where do we go from here?

*Chairs: Dominique Martin – Geelong, Australia
David Paredes-Zapata – Barcelona, Spain*

This session will focus on equality, diversity, and inclusion within ESOT and in the wider context of scientific research and clinical practice. The first part of the session will include a presentation of the results of the ESOT survey on equality, diversity, and inclusion, covering the community's thoughts about the present status of the Society and the field of transplantation as well as their proposals to improve such status. Potential areas of intervention will be presented to the audience for a discussion of practical actions to be taken in different contexts to take ESOT into a more inclusive future. The second part of the session will provide the audience with insights on implicit bias, one of the key factors at the basis of human beings' perceptions about social groups, which affects our knowledge and behaviours.

- 10:00 Welcome and introduction
Dominique Martin - Geelong, Australia; David Paredes-Zapata – Barcelona, Spain
- 10:05 ESOT Survey on Equality, Diversity, and Inclusion: Results overview
Anna Forsberg - Lund Sweden; Liset Pengel - Rotterdam, The Netherlands
- 10:25 Implicit bias
Simona Capisani – Durham, United Kingdom
- 10:45 Discussion
- 10:45 Taking ESOT into the future
Anna Forsberg - Lund Sweden; Liset Pengel - Rotterdam, The Netherlands
- 11:15 Wrap up and conclusion
Dominique Martin - Geelong, Australia; David Paredes-Zapata – Barcelona, Spain

PLENARY

Wednesday, 20 September 2023

11:45 - 13:45
Lambrakis

Closing Plenary: The future of transplant health and healthcare

*Chairs: Fiona Loud – Alton, United Kingdom
Luciano Potena – Bologna, Italy*

With an extraordinary array of exciting developments in transplantation, we are looking at an exciting future. However, there is still much to do in enhancing life after transplantation, defining, and improving the outcomes that matter to patients and placing transplantation at the top of political agendas and at the core of European healthcare. In this session we will explore solutions to improve the future of transplant health, taking a moonshot towards a unified transplant healthcare in Europe to reduce variation in care and improve access to innovative therapies. We will also explore how we should shape transplant care so that patients, professionals and policy makers are equal partners willing to embrace this evolution and redefine the vision for the future of our field.

11:45	<i>Introduction</i>
12:10	Moon shot to a unified transplant healthcare <i>Efstratios Chatzixiros – Geneva, Switzerland</i>
11:50	The future of transplant health - Enhancing life after transplantation <i>Maarten Naesens – Leuven, Belgium</i>
12:30	One + one = three <i>Fiona Loud – Alton, United Kingdom</i>
12:50	LDV winners presentation and award ceremony <i>Luciano Potena – Bologna, Italy</i>
13:10	Legacy Award Ceremony in honour of Maria Rosa Costanzo and Michael Nicholson <i>Vassilios Papalois – London, United Kingdom</i>
13:20	Discussion & wrap-up <i>Luciano Potena – Bologna, Italy</i>
13:30	Presidential Address <i>Gabriel Oniscu – Stockholm, Sweden</i>